0001022079-24-000099.txt : 20240424 0001022079-24-000099.hdr.sgml : 20240424 20240424161222 ACCESSION NUMBER: 0001022079-24-000099 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240424 DATE AS OF CHANGE: 20240424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 24870711 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 10-Q 1 dgx-20240331.htm 10-Q dgx-20240331
000102207912/312024Q1FALSE00010220792024-01-012024-03-3100010220792024-04-15xbrli:sharesiso4217:USD00010220792023-01-012023-03-31iso4217:USDxbrli:shares00010220792024-03-3100010220792023-12-3100010220792022-12-3100010220792023-03-310001022079us-gaap:CommonStockMember2023-12-310001022079us-gaap:AdditionalPaidInCapitalMember2023-12-310001022079us-gaap:RetainedEarningsMember2023-12-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001022079us-gaap:TreasuryStockCommonMember2023-12-310001022079us-gaap:NoncontrollingInterestMember2023-12-310001022079us-gaap:RetainedEarningsMember2024-01-012024-03-310001022079us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001022079us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001022079us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001022079us-gaap:CommonStockMember2024-03-310001022079us-gaap:AdditionalPaidInCapitalMember2024-03-310001022079us-gaap:RetainedEarningsMember2024-03-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001022079us-gaap:TreasuryStockCommonMember2024-03-310001022079us-gaap:NoncontrollingInterestMember2024-03-310001022079us-gaap:CommonStockMember2022-12-310001022079us-gaap:AdditionalPaidInCapitalMember2022-12-310001022079us-gaap:RetainedEarningsMember2022-12-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001022079us-gaap:TreasuryStockCommonMember2022-12-310001022079us-gaap:NoncontrollingInterestMember2022-12-310001022079us-gaap:RetainedEarningsMember2023-01-012023-03-310001022079us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001022079us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001022079us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001022079us-gaap:CommonStockMember2023-03-310001022079us-gaap:AdditionalPaidInCapitalMember2023-03-310001022079us-gaap:RetainedEarningsMember2023-03-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001022079us-gaap:TreasuryStockCommonMember2023-03-310001022079us-gaap:NoncontrollingInterestMember2023-03-310001022079dgx:InvigorateProgramMember2024-03-31xbrli:pure0001022079dgx:InvigorateProgramMember2024-01-012024-03-310001022079dgx:InvigorateProgramMember2023-01-012023-03-310001022079us-gaap:CostOfSalesMemberdgx:InvigorateProgramMember2024-01-012024-03-310001022079us-gaap:SellingGeneralAndAdministrativeExpensesMemberdgx:InvigorateProgramMember2024-01-012024-03-310001022079us-gaap:CostOfSalesMemberdgx:InvigorateProgramMember2023-01-012023-03-310001022079us-gaap:SellingGeneralAndAdministrativeExpensesMemberdgx:InvigorateProgramMember2023-01-012023-03-310001022079us-gaap:AccountsPayableAndAccruedLiabilitiesMemberdgx:InvigorateProgramMember2024-03-310001022079us-gaap:AccountsPayableAndAccruedLiabilitiesMemberdgx:InvigorateProgramMember2023-12-3100010220792023-01-012023-12-310001022079us-gaap:CustomerRelationshipsMember2024-03-310001022079dgx:LencoDiagnosticsLaboratoriesIncMember2024-02-122024-02-120001022079dgx:LencoDiagnosticsLaboratoriesIncMember2024-02-120001022079dgx:LencoDiagnosticsLaboratoriesIncMemberus-gaap:CustomerRelationshipsMember2024-02-120001022079us-gaap:FairValueMeasurementsRecurringMember2024-03-310001022079us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001022079us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001022079us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001022079us-gaap:FairValueMeasurementsRecurringMember2023-12-310001022079us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001022079us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001022079us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001022079dgx:HaystackOncologyIncMemberdgx:AdditionalBasedOnRevenueMember2023-06-300001022079dgx:AdditionalReimbursementCoverageMemberdgx:HaystackOncologyIncMember2023-06-300001022079dgx:MeasurementInputComparableCompanyRevenueVolatilityMemberdgx:HaystackOncologyIncMember2024-03-310001022079dgx:HaystackOncologyIncMemberus-gaap:MeasurementInputDiscountRateMember2024-03-310001022079dgx:HaystackOncologyIncMemberus-gaap:MeasurementInputDiscountRateMemberdgx:AdditionalImpactMember2024-03-310001022079dgx:MeasurementInputComparableCompanyRevenueVolatilityMemberdgx:ChangingComparableCompanyRevenueVolatilityMemberdgx:HaystackOncologyIncMember2024-03-310001022079dgx:MeasurementInputComparableCompanyRevenueVolatilityMemberdgx:ChangingComparableCompanyRevenueVolatilityMemberdgx:HaystackOncologyIncMember2024-01-012024-03-310001022079dgx:HaystackOncologyIncMemberdgx:ChangingDiscountRateMemberus-gaap:MeasurementInputDiscountRateMember2024-03-310001022079dgx:MeasurementInputComparableCompanyRevenueVolatilityMemberdgx:HaystackOncologyIncMemberdgx:ChangingDiscountRateMember2024-01-012024-03-310001022079us-gaap:FairValueInputsLevel3Memberdgx:ContingentConsiderationMember2023-12-310001022079us-gaap:FairValueInputsLevel3Memberdgx:ContingentConsiderationMember2024-01-012024-03-310001022079us-gaap:FairValueInputsLevel3Memberdgx:ContingentConsiderationMember2024-03-310001022079us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberdgx:ContingentConsiderationMember2024-03-310001022079us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberdgx:ContingentConsiderationMember2024-03-310001022079us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberdgx:ContingentConsiderationMember2023-12-310001022079us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberdgx:ContingentConsiderationMember2023-12-310001022079dgx:UMassJointVentureMember2015-07-010001022079us-gaap:SeniorNotesMemberdgx:ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member2024-03-310001022079us-gaap:LongTermDebtMemberus-gaap:FairValueHedgingMember2024-03-310001022079us-gaap:LongTermDebtMemberus-gaap:FairValueHedgingMember2023-12-3100010220792023-10-012023-12-3100010220792023-04-012023-06-3000010220792023-07-012023-09-300001022079us-gaap:SecuredDebtMember2023-10-310001022079dgx:SeniorunsecuredrevolvingcreditfacilityMember2021-11-300001022079us-gaap:SecuredDebtMember2024-03-310001022079us-gaap:SecuredDebtMember2022-10-310001022079dgx:A401kPlanLawsuitMemberus-gaap:PendingLitigationMember2020-12-31dgx:claim0001022079dgx:A401kPlanLawsuitMemberus-gaap:PendingLitigationMember2020-10-310001022079dgx:ExcludesgeneralandprofessionalliabilityclaimsMember2024-03-310001022079dgx:ExcludesgeneralandprofessionalliabilityclaimsMember2023-12-310001022079dgx:DiagnosticInformationServicesBusinessMembersrt:MinimumMember2024-01-012024-03-310001022079dgx:DiagnosticInformationServicesBusinessMembersrt:MinimumMember2023-01-012023-03-310001022079dgx:DiagnosticInformationServicesBusinessMember2024-01-012024-03-310001022079dgx:DiagnosticInformationServicesBusinessMember2023-01-012023-03-310001022079us-gaap:AllOtherSegmentsMember2024-01-012024-03-310001022079us-gaap:AllOtherSegmentsMember2023-01-012023-03-310001022079us-gaap:CorporateMember2024-01-012024-03-310001022079us-gaap:CorporateMember2023-01-012023-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:HealthcareInsurersMemberdgx:FeeforserviceMember2024-01-012024-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:HealthcareInsurersMemberdgx:FeeforserviceMember2023-01-012023-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:HealthcareInsurersMemberdgx:CapitatedMember2024-01-012024-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:HealthcareInsurersMemberdgx:CapitatedMember2023-01-012023-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:HealthcareInsurersMember2024-01-012024-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:HealthcareInsurersMember2023-01-012023-03-310001022079dgx:GovernmentPayersMemberdgx:DiagnosticInformationServicesBusinessMember2024-01-012024-03-310001022079dgx:GovernmentPayersMemberdgx:DiagnosticInformationServicesBusinessMember2023-01-012023-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:ClientPayersMember2024-01-012024-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:ClientPayersMember2023-01-012023-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:PatientsMember2024-01-012024-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:PatientsMember2023-01-012023-03-310001022079dgx:DSBusinessesMemberus-gaap:AllOtherSegmentsMember2024-01-012024-03-310001022079dgx:DSBusinessesMemberus-gaap:AllOtherSegmentsMember2023-01-012023-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:HealthcareInsurersMember2024-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:HealthcareInsurersMember2023-12-310001022079dgx:GovernmentPayersMemberdgx:DiagnosticInformationServicesBusinessMember2024-03-310001022079dgx:GovernmentPayersMemberdgx:DiagnosticInformationServicesBusinessMember2023-12-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:ClientPayersMember2024-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:ClientPayersMember2023-12-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:PatientsMember2024-03-310001022079dgx:DiagnosticInformationServicesBusinessMemberdgx:PatientsMember2023-12-310001022079dgx:DiagnosticInformationServicesBusinessMember2024-03-310001022079dgx:DiagnosticInformationServicesBusinessMember2023-12-310001022079dgx:DSBusinessesMemberus-gaap:AllOtherSegmentsMember2024-03-310001022079dgx:DSBusinessesMemberus-gaap:AllOtherSegmentsMember2023-12-310001022079us-gaap:SeniorNotesMemberdgx:FourpointtwofivepercentSeniorNotesDue2024Memberus-gaap:SubsequentEventMember2024-04-012024-04-240001022079us-gaap:SeniorNotesMemberdgx:FourpointtwofivepercentSeniorNotesDue2024Memberus-gaap:SubsequentEventMember2024-04-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q

(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024

Or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission file number 001-12215

Quest Diagnostics Incorporated
Delaware16-1387862
(State of Incorporation)(I.R.S. Employer Identification Number)
500 Plaza Drive
Secaucus,NJ07094
(973)520-2700
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of April 15, 2024, there were outstanding 111,091,574 shares of the registrant’s common stock, $.01 par value.

PART I - FINANCIAL INFORMATION
 Page
Item 1. Financial Statements (unaudited) 
  
Index to unaudited consolidated financial statements filed as part of this report: 
  
  
  
 
 
  
 
 
  
 
 
  

1
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
(unaudited)
(in millions, except per share data)

Three Months Ended March 31,
20242023
Net revenues $2,366 $2,331 
Operating costs and expenses and other operating income:  
Cost of services1,595 1,560 
Selling, general and administrative 440 439 
Amortization of intangible assets29 26 
Other operating expense, net2 1 
Total operating costs and expenses, net 2,066 2,026 
Operating income300 305 
Other income (expense):  
Interest expense, net(43)(35)
Other income, net9 7 
Total non-operating expense, net(34)(28)
Income before income taxes and equity in earnings of equity method investees266 277 
Income tax expense(66)(65)
Equity in earnings of equity method investees, net of taxes8 5 
Net income208 217 
Less: Net income attributable to noncontrolling interests14 15 
Net income attributable to Quest Diagnostics$194 $202 
Earnings per share attributable to Quest Diagnostics’ common stockholders:  
Basic$1.74 $1.80 
Diluted$1.72 $1.78 
Weighted average common shares outstanding:  
Basic111 112 
Diluted112 113 









The accompanying notes are an integral part of these statements.

2
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
(unaudited)
(in millions)
Three Months Ended March 31,
20242023
Net income$208 $217 
Other comprehensive income (loss):
Foreign currency translation adjustment(2)3 
Other comprehensive (loss) income(2)3 
Comprehensive income206 220 
Less: Comprehensive income attributable to noncontrolling interests14 15 
Comprehensive income attributable to Quest Diagnostics$192 $205 






















The accompanying notes are an integral part of these statements.

3
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
MARCH 31, 2024 AND DECEMBER 31, 2023
(unaudited)
(in millions, except per share data)
March 31,
2024		December 31,
2023
Assets  
Current assets:  
Cash and cash equivalents$474 $686 
Accounts receivable, net of allowance for credit losses of $28 and $27 as of March 31, 2024 and December 31, 2023, respectively
1,322 1,210 
Inventories181 190 
Prepaid expenses and other current assets251 286 
Total current assets2,228 2,372 
Property, plant and equipment, net1,810 1,816 
Operating lease right-of-use assets579 602 
Goodwill7,830 7,733 
Intangible assets, net1,192 1,166 
Investments in equity method investees133 135 
Other assets182 198 
Total assets$13,954 $14,022 
Liabilities and Stockholders’ Equity  
Current liabilities:  
Accounts payable and accrued expenses$1,239 $1,359 
Current portion of long-term debt906 303 
Current portion of long-term operating lease liabilities153 153 
Total current liabilities2,298 1,815 
Long-term debt3,804 4,410 
Long-term operating lease liabilities489 503 
Other liabilities817 876 
Commitments and contingencies
Redeemable noncontrolling interest77 76 
Stockholders’ equity:  
Quest Diagnostics stockholders’ equity:  
Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2024 and December 31, 2023; 162 shares issued as of both March 31, 2024 and December 31, 2023
2 2 
Additional paid-in capital2,292 2,320 
Retained earnings8,935 8,825 
Accumulated other comprehensive loss(16)(14)
Treasury stock, at cost; 51 shares as of both March 31, 2024 and December 31, 2023
(4,781)(4,826)
Total Quest Diagnostics stockholders’ equity6,432 6,307 
Noncontrolling interests37 35 
Total stockholders’ equity6,469 6,342 
Total liabilities and stockholders’ equity$13,954 $14,022 


The accompanying notes are an integral part of these statements.

4
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
(unaudited)
(in millions)
Three Months Ended March 31,
20242023
Cash flows from operating activities:  
Net income$208 $217 
Adjustments to reconcile net income to net cash provided by operating activities:  
Depreciation and amortization116 107 
Provision (credit) for credit losses1 (1)
Deferred income tax benefit(18)(4)
Stock-based compensation expense22 24 
Other, net11 3 
Changes in operating assets and liabilities:  
Accounts receivable(114)(58)
Accounts payable and accrued expenses(152)(211)
Income taxes payable42 11 
Other assets and liabilities, net38 6 
Net cash provided by operating activities154 94 
Cash flows from investing activities:  
Business acquisitions, net of cash acquired(142)(31)
Capital expenditures(104)(127)
Other investing activities33 — 
Net cash used in investing activities(213)(158)
Cash flows from financing activities:  
Proceeds from borrowings— 140 
Repayments of debt— (140)
Exercise of stock options12 25 
Employee payroll tax withholdings on stock issued under stock-based compensation plans(23)(28)
Dividends paid(79)(74)
Distributions to noncontrolling interest partners(11)(14)
Other financing activities, net(52)15 
Net cash used in financing activities(153)(76)
Net change in cash and cash equivalents and restricted cash(212)(140)
Cash and cash equivalents and restricted cash, beginning of period686 315 
Cash and cash equivalents and restricted cash, end of period$474 $175 








The accompanying notes are an integral part of these statements.

5
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
(unaudited)
(in millions)

For the Three Months Ended March 31, 2024Quest Diagnostics Stockholders’ Equity
Shares of
Common Stock
Outstanding		Common
Stock		Additional
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Compre-
hensive Loss		Treasury
Stock, at
Cost		Non-
controlling
Interests		Total
Stock-
holders’
Equity		Redeemable Non-controlling Interest
Balance, December 31, 2023111 $2 $2,320 $8,825 $(14)$(4,826)$35 $6,342 $76 
Net income19413 207 1 
Other comprehensive loss, net of taxes(2)(2)
Dividends declared(84)(84)
Distributions to noncontrolling interest partners(11)(11)
Issuance of common stock under benefit plans(42)48 6 
Stock-based compensation expense22 22 
Exercise of stock options(2)14 12 
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans(6)(17)(23)
Balance, March 31, 2024111 $2 $2,292 $8,935 $(16)$(4,781)$37 $6,469 $77 


For the Three Months Ended March 31, 2023Quest Diagnostics Stockholders’ Equity
Shares of
Common Stock
Outstanding		Common
Stock		Additional
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Compre-
hensive Loss		Treasury
Stock, at
Cost		Non-
controlling
Interests		Total
Stock-
holders’
Equity		Redeemable Non-controlling Interest
Balance, December 31, 2022111 $2 $2,295 $8,290 $(21)$(4,673)$37 $5,930 $77 
Net income20214 216 1 
Other comprehensive income, net of taxes3 3 
Dividends declared(80)(80)
Distributions to noncontrolling interest partners
(13)(13)(1)
Issuance of common stock under benefit plans
1(42)48 6 
Stock-based compensation expense
24 24 
Exercise of stock options(1)31 30 
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans
(10)(18)(28)
Balance, March 31, 2023112 $2 $2,266 $8,412 $(18)$(4,612)$38 $6,088 $77 


The accompanying notes are an integral part of these statements.

6
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in millions, unless otherwise indicated)

1.    DESCRIPTION OF BUSINESS
    
    Background
    
    Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") work across the healthcare ecosystem to create a healthier world, one life at a time. The Company's diagnostic information services ("DIS") business provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, the diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. In the right hands and with the right context, the diagnostic insights can inspire actions that transform lives and create a healthier world. The Company provides services to a broad range of customers within its primary customer channels - physicians (including those associated with accountable care organizations and Federally Qualified Health Centers), hospitals, and patients and consumers. Other customers include health plans, employers, emerging retail healthcare providers, government agencies, pharmaceutical companies and other commercial clinical laboratories. The Company offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The Company's large in-house staff of medical and scientific experts, including medical directors, scientific directors, genetic counselors and board-certified geneticists, provide medical and scientific consultation to healthcare providers and patients regarding the Company's tests and test results, and help them best utilize Quest Diagnostics' services to improve outcomes and enhance satisfaction. The Company's Diagnostic Solutions ("DS") group, which represents the balance of the Company's consolidated net revenues, includes the Company's risk assessment services business, which offers solutions for insurers, and the Company's healthcare information technology businesses, which offer solutions for healthcare providers and payers.

2.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    Basis of Presentation
    
    The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2023 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023 but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”).

    The accounting policies of the Company are the same as those set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2023 Annual Report on Form 10-K.

    Use of Estimates
    
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

    Earnings Per Share

    The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially

7
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan (“ELTIP”) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan (“DLTIP”), as well as the dilutive effect of accelerated share repurchase agreements ("ASRs"), if applicable. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.

    New Accounting Standards to be Adopted

    In November 2023, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which will require companies to disclose significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"). The pronouncement is effective for annual filings for the year ended December 31, 2024 and for interim periods within the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows.

    In December 2023, the FASB issued a new accounting standard which will require companies to make additional income tax disclosures. The pronouncement is effective for annual filings for the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows.

    In March 2024, the Securities and Exchange Commission issued a rule which will require companies to make certain climate-related disclosures in periodic filings. The rule includes certain disclosures in the footnotes of the financial statements:

•capitalized costs, expenditures expensed, and losses incurred as a result of severe weather events and other natural conditions, such as hurricanes, tornadoes, flooding, drought, wildfires, extreme temperatures, and sea level rise;
•capitalized costs, expenditures expensed, and losses related to carbon offsets and renewable energy credits or certificates if they are used as a material component of a registrant’s plans to achieve its disclosed climate-related targets or goals; and
•whether estimates and assumptions used to produce the financial statements were materially impacted by risks and uncertainties associated with severe weather events and other natural conditions or any disclosed climate-related targets or transition plans.

    The footnote disclosures are effective for annual filings for the year ended December 31, 2025. The Company is currently evaluating the impact of the adoption of the rule.


8
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


3.    EARNINGS PER SHARE

    The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
Three Months Ended March 31,
 20242023
Amounts attributable to Quest Diagnostics’ common stockholders:  
Net income attributable to Quest Diagnostics$194 $202 
Less: Earnings allocated to participating securities1 1 
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted
$193 $201 
Weighted average common shares outstanding – basic111 112 
Effect of dilutive securities:  
Stock options and performance share units1 1 
Weighted average common shares outstanding – diluted112 113 
Earnings per share attributable to Quest Diagnostics’ common stockholders:  
Basic$1.74 $1.80 
Diluted$1.72 $1.78 
    

    The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
Three Months Ended March 31,
20242023
Stock options and performance share units1 — 
    
4.    RESTRUCTURING ACTIVITIES

    Invigorate Program

    The Company is engaged in a multi-year program called Invigorate, which includes structured plans to drive savings and improve productivity across the value chain, including in such areas as patient services, logistics and laboratory operations, revenue services, information technology and procurement. The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to partially offset pressures from the current inflationary environment, including labor and benefit cost increases and reimbursement pressures. The Company is leveraging automation and artificial intelligence to improve productivity and also improve quality across the entire value chain, not just in the laboratory. Other areas of focus include reducing denials and patient concessions, enhancing the digital experience, and selecting and retaining talent.

    Restructuring Charges
    
    The Company's pre-tax restructuring charges for the three months ended March 31, 2024 and 2023 were $6 million and $15 million, respectively, entirely related to employee separation costs associated with various workforce reduction initiatives as the Company continued to restructure its organization. Of the total restructuring charges incurred during the three months ended March 31, 2024, $4 million and $2 million were recorded in cost of services and selling, general and administrative expenses, respectively. Of the total restructuring charges incurred during the three months ended March 31, 2023, $9 million and $6 million were recorded in cost of services and selling, general and administrative expenses, respectively.

9
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    
    Charges for all periods presented were primarily recorded in the Company's DIS business.

    The restructuring liability as of March 31, 2024 and December 31, 2023, which is included in accounts payable and accrued expenses, was $13 million and $12 million, respectively.

5.     BUSINESS ACQUISITIONS

    During the three months ended March 31, 2024, the Company completed acquisitions for an aggregate purchase price of $148 million (including contingent consideration initially estimated at $6 million), net of cash acquired, including the acquisitions discussed below. Of such amount, $30 million was prepaid during the twelve months ended December 31, 2023. In the Company's consolidated statement of cash flows for the three months ended March 31, 2024, such $30 million is included in business acquisitions, net of cash acquired, with a corresponding offset in other investing activities.

    The acquisitions preliminarily resulted in goodwill of $99 million, all of which is deductible for tax purposes. The acquisitions also preliminarily resulted in $56 million of customer-related intangible assets.

    Acquisition of select assets of Lenco Diagnostic Laboratories, Inc. ("Lenco")

    On February 12, 2024, the Company acquired select assets of Lenco, an independent clinical diagnostic laboratory provider serving physicians in New York, in an all-cash transaction for $111 million. Based on the preliminary purchase price allocation, which may be revised as additional information becomes available during the measurement period, the assets acquired and liabilities assumed primarily consist of $75 million of tax-deductible goodwill, $43 million of customer-related intangible assets and $7 million of operating lease liabilities. The intangible assets are being amortized over a useful life of 15 years.

    The acquisitions were accounted for under the acquisition method of accounting. As such, the assets acquired and liabilities assumed were recorded based on their estimated fair values as of the closing dates. Supplemental pro forma combined financial information has not been presented as the impact of the acquisitions is not material to the Company's consolidated financial statements. The goodwill recorded primarily includes the expected synergies resulting from combining the operations of the acquired entity with those of the Company and the value associated with an assembled workforce and other intangible assets that do not qualify for separate recognition. All of the goodwill acquired in connection with the acquisitions has been allocated to the Company's DIS business. For further details regarding business segment information, see Note 12.

    For details regarding the Company's 2023 acquisitions, see Note 6 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.    


10
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


6.     FAIR VALUE MEASUREMENTS

    Assets and Liabilities Measured at Fair Value on a Recurring Basis

    The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:
Basis of Fair Value Measurements
Quoted Prices in Active Markets for Identical Assets/LiabilitiesSignificant Other Observable InputsSignificant Unobservable Inputs
March 31, 2024TotalLevel 1Level 2Level 3
Assets:    
Deferred compensation trading securities$74 $74 $— $— 
Cash surrender value of life insurance policies59 — 59 — 
Total$133 $74 $59 $— 
Liabilities:    
Deferred compensation liabilities$138 $— $138 $— 
Contingent consideration113 — — 113 
Total$251 $— $138 $113 
Redeemable noncontrolling interest$77 $— $— $77 
Basis of Fair Value Measurements
December 31, 2023TotalLevel 1Level 2Level 3
Assets:       
Deferred compensation trading securities$70 $70 $— $— 
Cash surrender value of life insurance policies55 — 55 — 
Available-for-sale debt securities2 — — 2 
Total$127 $70 $55 $2 
Liabilities:    
Deferred compensation liabilities$131 $— $131 $— 
Contingent consideration104 — — 104 
Total$235 $— $131 $104 
Redeemable noncontrolling interest$76 $— $— $76 
    
    A detailed description regarding the Company's fair value measurements is contained in Note 8 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.    

    The Company offers certain employees the opportunity to participate in a non-qualified supplemental deferred compensation plan. A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities. The trading securities are classified within Level 1 of the fair value hierarchy because the changes in the fair value of these securities are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held, exclusive of any transaction costs. A

11
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation. The deferred compensation liabilities are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the trading securities.

    The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program. A participant's deferrals, together with Company matching credits, are “invested” at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments. Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the deferred compensation obligation are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Deferrals under the plan currently may only be made by participants who made deferrals under the plan in 2017.

    The Company's available-for-sale debt securities are measured at fair value using discounted cash flows. These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable. Significant inputs include cash flows projections and a discount rate.

     During June 2023, the Company acquired Haystack Oncology, Inc. ("Haystack"), an early-stage oncology company focused on minimal residual disease testing to aid in the detection of residual or recurring cancer and better inform therapy decisions. In connection with the acquisition there is a contingent consideration obligation under which the seller can receive up to $100 million of additional consideration dependent upon the achievement of certain revenue benchmarks through 2028 and up to an additional $50 million of consideration dependent upon the Company receiving reimbursement coverage from the Centers for Medicare and Medicaid Services ("CMS"). The portion of the contingent consideration obligation which is dependent upon the achievement of certain revenue benchmarks was measured at fair value using a Monte Carlo method and is classified within Level 3 of the fair value hierarchy as the fair value is determined based on significant inputs that are not observable. Significant inputs include management’s estimate of revenue and other market inputs, including comparable company revenue volatility (40%) and a discount rate (10.5%). The portion of the contingent consideration obligation which is dependent upon the Company receiving reimbursement coverage from the CMS is also classified within Level 3 of the fair value hierarchy as the fair value is principally determined based on management's estimate, which is a significant input that is not observable. Additionally, the fair value of the entire contingent consideration obligation is also impacted by a market discount rate (5%) which adjusts the estimated payments to present value. The fair value of the contingent consideration obligation is not overly sensitive to movements in the comparable company revenue volatility or the discount rate used for the portion of the obligation that is dependent upon the achievement of certain revenue benchmarks. For example, changing the comparable company revenue volatility from 40% to 30% impacts the fair value by $8 million (assuming no other inputs are modified) and changing the discount rate from 10.5% to 7.0% impacts the fair value by $5 million (assuming no other inputs are modified).
    
    The Company has additional contingent consideration obligations in connection with other acquisitions. The liabilities related to such obligations are included in the amounts below.

    The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):
Contingent Consideration
Balance, December 31, 2023
$104 
Purchases, additions and issuances6 
Total fair value adjustments included in earnings - realized/unrealized3 
Balance, March 31, 2024$113 

    The $3 million net loss included in earnings associated with the change in the fair value of contingent consideration for the three months ended March 31, 2024 is reported in other operating expense, net.    

12
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)



    Of the aggregate $113 million contingent consideration obligation as of March 31, 2024, $79 million and $34 million were included in other liabilities and accounts payable and accrued expenses, respectively, in the Company's consolidated balance sheet. Of the aggregate $104 million contingent consideration obligation as of December 31, 2023, $99 million and $5 million were included in other liabilities and accounts payable and accrued expenses, respectively, in the Company's consolidated balance sheet.

    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. As of March 31, 2024, the redeemable noncontrolling interest was presented at its fair value. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy because the fair value is based on a discounted cash flow analysis that takes into account, among other items, the joint venture's expected future cash flows, long term growth rates, and a discount rate commensurate with economic risk.
    
    The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. As of both March 31, 2024 and December 31, 2023, the fair value of the Company’s debt was estimated at $4.6 billion. Principally all of the Company's debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates currently offered to the Company with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments.

7.    DEBT

    The Company has $600 million of 3.50% senior notes due March 2025. The senior notes are included in current portion of long-term debt in the Company's March 31, 2024 consolidated balance sheet. Such notes were included in long-term debt in the Company's December 31, 2023 consolidated balance sheet. For further details, see Note 14 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.

8.    FINANCIAL INSTRUMENTS

    The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral.

    Interest Rate Risk
    
    The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements.

    Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.

    Interest Rate Derivatives – Cash Flow Hedges

    From time to time, the Company has entered into various interest rate lock agreements and forward-starting interest rate swap agreements to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in interest rates.

13
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)



    Interest Rate Derivatives – Fair Value Hedges

    Historically, the Company has entered into various fixed-to-variable interest rate swap agreements in order to convert a portion of the Company's long-term debt into variable interest rate debt. All such fixed-to-variable interest rate swap agreements have been terminated and proceeds from the terminations have been reflected as basis adjustments to the hedged debt instruments and are being amortized as a reduction of interest expense, net over the remaining terms of such debt instruments.

    As of March 31, 2024 and December 31, 2023, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:
Hedge Accounting Basis Adjustment (a)
Balance Sheet ClassificationMarch 31, 2024December 31, 2023
Long-term debt$10 $13 

(a) As of both March 31, 2024 and December 31, 2023, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.

    A detailed description regarding the Company's use of derivative financial instruments is contained in Note 16 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.        

9.    STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
    
    Stockholders' Equity    

    Changes in Accumulated Other Comprehensive Loss by Component

    Comprehensive income (loss) includes:

•Foreign currency translation adjustments;
•Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 8); and
•Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.

    For the three months ended March 31, 2024 and 2023, the tax effects related to the deferred gains (losses) on cash flow hedges and net changes in available-for-sale debt securities were not material. Foreign currency translation adjustments related to indefinite investments in non-U.S. subsidiaries are not adjusted for income taxes.

    Dividend Program
    
    During the first quarter of 2024, the Company's Board of Directors declared a quarterly cash dividend of $0.75 per common share. During each of the four quarters of 2023, the Company's Board of Directors declared a quarterly cash dividend of $0.71 per common share.
    
    Share Repurchase Program
    
    As of March 31, 2024, $1.0 billion remained available under the Company’s share repurchase authorization. The share repurchase authorization has no set expiration or termination date.
        
    Share Repurchases

    For both the three months ended March 31, 2024 and 2023, the Company repurchased no shares of its common stock.

14
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


        
    Shares Reissued from Treasury Stock

    For the three months ended March 31, 2024 and 2023, the Company reissued 0.5 million shares and 0.7 million shares, respectively, from treasury stock under its Employee Stock Purchase Plan and its stock-based compensation program. For details regarding the Company's stock ownership and compensation plans, see Note 18 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.
    
    Redeemable Noncontrolling Interest

    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. The subsidiary performs diagnostic information services in a defined territory within the state of Massachusetts. Since the redemption of the noncontrolling interest is outside of the Company's control, it has been presented outside of stockholders' equity at the greater of its carrying amount or its fair value. As of March 31, 2024 and December 31, 2023, the redeemable noncontrolling interest was presented at its fair value. For further details regarding the fair value of the redeemable noncontrolling interest, see Note 6.


15
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)



10.    SUPPLEMENTAL CASH FLOW AND OTHER DATA

    Supplemental cash flow and other data for the three months ended March 31, 2024 and 2023 was as follows:
Three Months Ended March 31,
20242023
Depreciation expense$87 $81 
Amortization expense29 26 
Depreciation and amortization expense$116 $107 
Interest expense$(49)$(37)
Interest income6 2 
Interest expense, net$(43)$(35)
Interest paid$44 $32 
Income taxes paid$3 $33 
Accounts payable associated with capital expenditures$28 $22 
Dividends payable$84 $80 
Businesses acquired:  
Fair value of assets acquired$155 $31 
Fair value of liabilities assumed7 — 
Fair value of net assets acquired148 31 
Merger consideration payable(6)— 
Cash paid for business acquisitions142 31 
Less: Cash acquired— — 
Business acquisitions, net of cash acquired$142 $31 
Leases:
Leased assets obtained in exchange for new operating lease liabilities$35 $44 
    During the three months ended March 31, 2024 and 2023, other financing activities, net in the Company's consolidated statement of cash flows included changes in bank overdrafts, which are generally settled in cash in the short term, of $(51) million and $33 million, respectively.    
    
11.     COMMITMENTS AND CONTINGENCIES

    Letters of Credit

    The Company can issue letters of credit under its $525 million secured receivables credit facility and its $750 million senior unsecured revolving credit facility. For further discussion regarding the facilities, see Note 14 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.
    

16
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    In support of its risk management program, $73 million in letters of credit under the $525 million secured receivables credit facility were outstanding as of March 31, 2024, providing collateral for current and future automobile liability and workers’ compensation loss payments.

    Contingent Lease Obligations
    
    The Company remains subject to contingent obligations under certain real estate leases for which no liability has been recorded. For further details, see Note 19 to the audited consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K.

    Certain Legal Matters

    The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues. The Company has insurance coverage rights in place (limited in amount; subject to deductible) for certain potential costs and liabilities related to these proceedings and investigations.

    In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Company’s 401(k) plan. The complaint alleges, among other things, that the fiduciaries of the 401(k) plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments. In October 2020, the court consolidated the two lawsuits under the caption In re: Quest Diagnostics ERISA Litigation and plaintiffs filed a consolidated amended complaint. In May 2021, the court denied the Company's motion to dismiss the complaint. Discovery has been completed. Plaintiffs' motion for class certification and the Company's motion for summary judgment are pending.

    On June 3, 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (“AMCA”) had informed the Company and Optum360 LLC that an unauthorized user had access to AMCA’s system between August 1, 2018 and March 30, 2019 (the “AMCA Data Security Incident”). Optum360 provides revenue management services to the Company, and AMCA provided debt collection services to Optum360. AMCA first informed the Company of the AMCA Data Security Incident on May 14, 2019. AMCA’s affected system included financial information (e.g., credit card numbers and bank account information), medical information and other personal information (e.g., social security numbers). Test results were not included. Neither Optum360’s nor the Company’s systems or databases were involved in the incident. AMCA also informed the Company that information pertaining to other laboratories’ customers was also affected. Following announcement of the AMCA Data Security Incident, AMCA sought protection under the U.S. bankruptcy laws. The bankruptcy proceeding has been dismissed.

    Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident. The U.S. Judicial Panel on Multidistrict Litigation transferred the cases that were then still pending to, and consolidated them for pre-trial proceedings in, the U.S. District Court for New Jersey. In November 2019, the plaintiffs in the multidistrict proceeding filed a consolidated putative class action complaint against the Company and Optum360 that named additional individuals as plaintiffs and that asserted a variety of common law and statutory claims in connection with the AMCA Data Security Incident. In January 2020, the Company moved to dismiss the consolidated complaint; the motion to dismiss was granted in part and denied in part. Plaintiffs filed an amended complaint, which the Company also moved to dismiss. The motion was granted in part and denied in part. Discovery is proceeding.


17
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    In addition, a group of state attorney general offices are investigating the Company in connection with the AMCA Data Security Incident. The Company is cooperating with the investigation.

    ReproSource Fertility Diagnostics, Inc. (“ReproSource”), a subsidiary of the Company, is subject to two putative class action lawsuits related to a data security incident that occurred in August 2021 in which plaintiffs allege that an unauthorized party accessed or acquired protected health information and personally identifiable information of ReproSource patients. Bickham v. ReproSource Fertility Diagnostics, Inc. is pending in the U.S. District Court for the District of Massachusetts (the "Massachusetts District Court"), and Trouville v. ReproSource Fertility Diagnostics, Inc., which was originally filed in the U.S. District Court for the Eastern District of California, has now been transferred to the Massachusetts District Court. A third case filed in the Massachusetts District Court, Gordon v. ReproSource Fertility Diagnostics, Inc., was consolidated into the Bickham case. The Bickham and Trouville complaints seek to represent a class of all individuals potentially impacted by the August 2021 data security incident, and generally allege that ReproSource, among other claims, failed to adequately safeguard patients’ private information.

    On January 10, 2024, ReproSource agreed to settle the Bickham case on a class-wide basis. The settlement is pending approval by the District Court. If approved, ReproSource will receive a full release for all claims that the settlement class might possess arising out of the August 2021 data security incident. The Company’s motion to stay the Trouville case was granted.

    The Company is subject to a putative class action entitled Cole, et al. v Quest Diagnostics Incorporated, which was filed in the U. S. District Court for the Eastern District of California, for allegedly conspiring with Facebook to track customers’ internet communications on Company web platforms without authorization, in violation of the California Invasion of Privacy Act and the California Confidentiality of Medical Information Act. The complaint alleged that the Company’s actions were an invasion of privacy and contributed to a loss of value in plaintiffs’ personally identifiable information. The Company moved to dismiss the case or, in the alternative, transfer venue to the U.S. District Court for New Jersey. Subsequently, plaintiffs filed an amended complaint, which the Company also moved to dismiss. The Company's motion to transfer the case was granted. The Company has refiled its motion to dismiss with the New Jersey District Court.

    As previously disclosed, in August 2011, the Company had received a subpoena from the U.S. Attorney for the Northern District of Georgia seeking various business records, including records related to the Company's compliance program, certain marketing materials, certain product offerings, and certain test ordering and other policies. The Company cooperated with the request. In 2021, a third amended complaint in a qui tam action filed in the U.S. District Court for the Northern District of Georgia was unsealed, which is related to the matter underlying the August 2011 subpoena. Both the U.S. Department of Justice and the State of Georgia declined to intervene in the action. The Company moved to dismiss the complaint and the complaint was dismissed without prejudice in August 2022. The relator subsequently filed a fourth amended complaint. The Company has moved to dismiss the fourth amended complaint.

    The Company also received subpoenas from the U.S. Attorney for the District of New Jersey. The subpoenas seek various records relating to the Company’s relationship with the New York Giants and adherence to certain company policies and federal laws. The Company is cooperating with the investigation.

    Other Legal Matters

    In the normal course of business, the Company has been named, from time to time, as a defendant in various legal actions, including arbitrations, class actions and other litigation, arising in connection with the Company's activities as a provider of diagnostic testing, information and services. These actions could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on the Company's client base and reputation.

    The Company is also involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief.


18
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    The federal or state governments may bring claims based on the Company's current practices, which it believes are lawful. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of government or private payers. The Company is aware of lawsuits, and from time to time has received subpoenas, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws. The Company understands that there may be other pending qui tam claims brought by former employees or other "whistleblowers" as to which the Company cannot determine the extent of any potential liability.

    Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the Company's consolidated results of operations or cash flows in the period in which the impact of such matters is determined or paid.

    These matters are in different stages. Some of these matters are in their early stages. Matters may involve responding to and cooperating with various government investigations and related subpoenas. As of March 31, 2024, the Company does not believe that material losses related to legal matters are probable.

    Reserves for legal matters totaled $1 million and $6 million as of March 31, 2024 and December 31, 2023, respectively.

    Reserves for General and Professional Liability Claims

    As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims. These suits could involve claims for substantial damages. Any professional liability litigation could also have an adverse impact on the Company's client base and reputation. The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures. The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims.

    The Company is subject to a series of individual claims brought by persons in Ireland related to allegations stemming from pap smear screening services performed by the Company. In general, claimants have alleged that the results of certain pap smear screening tests performed by the Company and other providers, pursuant to a program coordinated by the Irish government, were incorrect for individuals who were later diagnosed with cervical cancer. The Irish government and an independent scoping inquiry commissioned by the Irish government found that the Company’s performance of its screening services for the Irish cervical cancer screening program were in accordance with both Ireland’s requirements and international standards. The Company has settled claims made by certain individuals, is a party in multiple lawsuits and may be served as a party in additional lawsuits. The Company does not believe that the resolution of existing or future claims will have a material adverse effect on its financial position or liquidity, but the ultimate outcomes of these claims are unpredictable and subject to significant uncertainties.

    Reserves for general and professional liability claims matters, including those associated with both asserted and incurred but not reported claims, are established on an undiscounted basis by considering actuarially determined losses based upon the Company's historical and projected loss experience. Such reserves totaled $166 million and $173 million as of March 31, 2024 and December 31, 2023, respectively.

    While the basis for claims reserves is actuarially determined losses based upon the Company's historical and projected loss experience, the process of analyzing, assessing and establishing reserve estimates relative to these types of claims involves a high degree of judgment. Although the Company believes that its present reserves and insurance coverage are sufficient to cover currently estimated exposures, it is possible that the Company may incur liabilities in excess of its recorded reserves or insurance coverage. Changes in the facts and circumstances associated with claims could have a material impact on the Company’s results of operations (principally costs of services), cash flows and financial condition in the period that reserve estimates are adjusted or paid.


19
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


12.    BUSINESS SEGMENT INFORMATION

    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's CODM, assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers within its primary customer channels - physicians, hospitals, and patients and consumers. The DIS business accounted for greater than 95% of net revenues in 2024 and 2023.

    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses offer solutions for insurers and offer solutions for healthcare providers and payers.
        
    As of March 31, 2024, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.

    The following table is a summary of segment information for the three months ended March 31, 2024 and 2023. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2023 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended March 31,
20242023
Net revenues:  
DIS business$2,298 $2,259 
All other operating segments68 72 
Total net revenues $2,366 $2,331 
Operating earnings (loss):  
DIS business$373 $374 
All other operating segments9 8 
General corporate activities(82)(77)
Total operating income300 305 
Non-operating expense, net(34)(28)
Income before income taxes and equity in earnings of equity method investees266 277 
Income tax expense(66)(65)
Equity in earnings of equity method investees, net of taxes8 5 
Net income208 217 
Less: Net income attributable to noncontrolling interests14 15 
Net income attributable to Quest Diagnostics$194 $202 




20
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


13.    REVENUE RECOGNITION

    DIS

    Net revenues in the Company’s DIS business accounted for over 95% of the Company’s total net revenues for the three months ended March 31, 2024 and 2023 and are primarily comprised of a high volume of relatively low-dollar transactions. The DIS business, which provides clinical testing services and other services, satisfies its performance obligations and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered. The Company estimates the amount of consideration it expects to be entitled to receive from payer customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials), and patient price concessions. The portfolios determined using the portfolio approach consist of the following groups of payer customers: healthcare insurers, government payers (Medicare and Medicaid programs), client payers and patients.

    For further details regarding revenue recognition in the Company's DIS business, see Note 3 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.

    DS

    The Company’s DS businesses primarily satisfy their performance obligations and recognize revenues when delivery has occurred or services have been rendered.

    Net Revenue and Net Accounts Receivable by Payer Customer Type

    The approximate percentage of net revenue by type of payer customer was as follows:
    
Three Months Ended March 31,
20242023
Healthcare insurers:
Fee-for-service37 %37 %
Capitated3 3 
Total healthcare insurers40 40 
Government payers12 12 
Client payers33 33 
Patients (including coinsurance and deductible responsibilities)12 12 
Total DIS97 97 
DS3 3 
Net revenues100 %100 %
    
    The approximate percentage of net accounts receivable by type of payer customer was as follows:
March 31, 2024December 31, 2023
Healthcare Insurers28 %24 %
Government Payers7 7 
Client Payers40 45 
Patients (including coinsurance and deductible responsibilities)21 20 
Total DIS96 96 
DS4 4 
Net accounts receivable100 %100 %
    

21
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)




14.    SUBSEQUENT EVENTS

    During April 2024, the Company repaid in full the outstanding indebtedness under the Company's $300 million of 4.25% senior notes which matured on April 1, 2024.



22
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

Our Company

    Diagnostic Information Services

    Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. Our diagnostic information services ("DIS") business provides diagnostic insights from the results of our laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. In the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. We provide services to a broad range of customers within our primary customer channels - physicians (including those associated with accountable care organizations and Federally Qualified Health Centers), hospitals, and patients and consumers. Our other customers include health plans, employers, emerging retail healthcare providers, government agencies, pharmaceutical companies and other commercial clinical laboratories. We offer broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and our connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. Our large in-house staff of medical and scientific experts, including medical directors, scientific directors, genetic counselors and board-certified geneticists, provide medical and scientific consultation to healthcare providers and patients regarding our tests and test results, and help them best utilize our services to improve outcomes and enhance satisfaction. Our DIS business makes up greater than 95% of our consolidated net revenues.

    We assess our revenue performance for our DIS business based upon, among other factors, volume (measured by test requisitions) and revenue per requisition. Each test requisition accompanies patient specimens, indicating the test(s) to be performed and the party to be billed for the test(s). Revenue per requisition is impacted by various factors, including, among other items, the impact of fee schedule changes (i.e., unit price), test mix, payer mix, business mix and the number of tests per requisition. Management uses number of requisitions and revenue per requisition data to assist with assessing the growth and performance of the business, including understanding trends affecting number of requisitions, pricing and test mix. Therefore, we believe that information related to changes in these metrics from period to period are useful information for investors as it allows them to assess the performance of the business.

    Diagnostic Solutions

    Our Diagnostic Solutions ("DS") group, which represents the balance of our consolidated net revenues, includes our risk assessment services business, which offers solutions for insurers, and our healthcare information technology businesses, which offer solutions for healthcare providers and payers.


23
First Quarter Highlights
    
Three Months Ended March 31,
20242023
(dollars in millions, except per share data)
Net revenues$2,366$2,331
DIS revenues$2,298$2,259
Revenue per requisition change0.1%(7.7)%
Requisition volume change1.6%(3.8)%
Organic requisition volume change1.0%(3.9)%
DS revenues$68$72
Operating income$300$305
Net income attributable to Quest Diagnostics$194$202
Diluted earnings per share$1.72$1.78
Net cash provided by operating activities$154$94
Capital expenditures$104$127

    For further discussion of the year-over-year changes for the three months ended March 31, 2024 compared to the three months ended March 31, 2023, see "Results of Operations" below.

Acquisition of select assets of Lenco Diagnostic Laboratories, Inc. ("Lenco")

    On February 12, 2024, we acquired select assets of Lenco, an independent clinical diagnostic laboratory provider serving physicians in New York, in an all-cash transaction for $111 million. The acquired business is included in our DIS business.

    For further details, see Note 5 to the interim unaudited consolidated financial statements.

Invigorate Program
        
    We are engaged in a multi-year program called Invigorate, which includes structured plans to drive savings and improve productivity across the value chain, including in such areas as patient services, logistics and laboratory operations, revenue services, information technology and procurement. The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to partially offset pressures from the current inflationary environment, including labor and benefit cost increases and reimbursement pressures. We are leveraging automation and artificial intelligence to improve productivity and also improve quality across our entire value chain, not just in the laboratory. Other areas of focus include reducing denials and patient concessions, enhancing the digital experience, and selecting and retaining talent.

    For the three months ended March 31, 2024, we incurred $17 million of pre-tax charges in connection with restructuring and integration activities, including $6 million of employee separation costs, with the remainder primarily consisting of integration costs related to facility closures. Most of the charges will result in cash expenditures. Additional restructuring and integration charges may be incurred in future periods, including as we identify additional opportunities to achieve further savings and productivity improvements.

Critical Accounting Policies
    
    There have been no significant changes to our critical accounting policies from those disclosed in our 2023 Annual Report on Form 10-K.
    
Impact of New Accounting Standards

    The adoption of new accounting standards, if any, is discussed in Note 2 to the interim unaudited consolidated financial statements.


24
    The impact of recent accounting pronouncements not yet effective on our consolidated financial statements, if any, is also discussed in Note 2 to the interim unaudited consolidated financial statements.

25

Results of Operations
    
    The following tables set forth certain results of operations data for the periods presented:

Three Months Ended March 31,
20242023$ Change% Change
(dollars in millions, except per share amounts)
Net revenues:
DIS business $2,298 $2,259 $39 1.7 %
DS businesses68 72 (4)(5.0)
Total net revenues$2,366 $2,331 $35 1.5 %
Operating costs and expenses and other operating income:  
Cost of services$1,595 $1,560 $35 2.3 %
Selling, general and administrative 440 439 1 0.1 
Amortization of intangible assets29 26 3 9.1 
Other operating expense, net2 1 1 NM
Total operating costs and expenses, net $2,066 $2,026 $40 2.0 %
Operating income$300 $305 $(5)(1.7)%
Other income (expense):
Interest expense, net$(43)$(35)$(8)24.4 %
Other income, net9 7 2 NM
Total non-operating expense, net$(34)$(28)$(6)NM
Income tax expense$(66)$(65)$(1)1.5 %
Effective income tax rate
25.0 %23.6 %
Equity in earnings of equity method investees, net of taxes$8 $5 $3 51.0 %
Net income attributable to Quest Diagnostics$194 $202 $(8)(3.9)%
Diluted earnings per common share attributable to Quest Diagnostics' common stockholders$1.72 $1.78 $(0.06)(3.4)%
NM - Not Meaningful

    The following table sets forth certain results of operations data as a percentage of net revenues for the periods presented:

26
Three Months Ended March 31,
20242023
Net revenues:
DIS business 97.1 %96.9 %
DS businesses 2.9 3.1 
Total net revenues100.0 %100.0 %
Operating costs and expenses and other operating income:
  
Cost of services67.4 %67.0 %
Selling, general and administrative 18.6 18.8 
Amortization of intangible assets1.2 1.1 
Other operating expense, net0.1 — 
Total operating costs and expenses, net 87.3 %86.9 %
Operating income12.7 %13.1 %
    
    Operating Results

    Results for the three months ended March 31, 2024 were affected by certain items that on a net basis decreased diluted earnings per share by $0.32 as follows:

•pre-tax amortization expense of $29 million recorded in amortization of intangible assets or $0.19 per diluted share;
•pre-tax charges of $17 million ($13 million in cost of services and $4 million in selling, general and administrative expenses), or $0.12 per diluted share, primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business; and
•pre-tax charges of $3 million, or $0.03 per diluted share, representing a loss associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions, recorded in other operating expense, net; partially offset by
•excess tax benefits associated with stock-based compensation arrangements of $2 million, or $0.02 per diluted share, recorded in income tax expense.
        
    Results for the three months ended March 31, 2023 were affected by certain items that on a net basis decreased diluted earnings per share by $0.26 as follows:

•pre-tax amortization expense of $26 million recorded in amortization of intangible assets or $0.17 per diluted share;
•pre-tax charges of $19 million ($10 million in cost of services and $9 million in selling, general and administrative expenses), or $0.12 per diluted share, primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business, and
•pre-tax charges of $3 million, or $0.02 per diluted share, representing net losses associated with changes in the carrying value of our strategic investments, recorded in equity in earnings of equity method investees, net of taxes; partially offset by
•excess tax benefits associated with stock-based compensation arrangements of $5 million, or $0.05 per diluted share, recorded in income tax expense.

    Net Revenues

    Net revenues for the three months ended March 31, 2024 increased by 1.5% compared to the prior year period.

    DIS revenues for the three months ended March 31, 2024 increased by 1.7% compared to the prior year period.

    For the three months ended March 31, 2024:

27

•The increase in DIS revenues compared to the prior year period was driven primarily by growth in the base business (which excludes COVID-19 testing) and, to a lesser extent, the impact of recent acquisitions, largely offset by a decrease in COVID-19 testing. For the three months ended March 31, 2024, recent acquisitions contributed approximately 0.7% to DIS revenues.
•DIS volume increased by 1.6% compared to the prior year period driven primarily by growth in the base business and the impact of recent acquisitions, which contributed approximately 0.6% to DIS volume, largely offset by a decrease in COVID-19 testing.
•Revenue per requisition increased by 0.1% compared to the prior year period principally due to an increase in the number of tests per requisition and favorable test mix, largely offset by the impact of the decrease in COVID-19 testing.
•DIS revenues in the base business (including the impact of recent acquisitions) increased by 6.1% compared to the prior year period.
•Testing volume in the base business (including the impact of recent acquisitions) was up 3.3% compared to the prior year period.
•Revenue per requisition in the base business increased by 2.6% compared to the prior year period principally due to an increase in the number of tests per requisition and favorable test mix.

    DS revenues for the three months ended March 31, 2024 decreased by 5.0% compared to the prior year period due to lower revenues associated with both our risk assessment services offered to insurers and our healthcare information technology businesses.
        
    Cost of Services

    Cost of services consists principally of costs for obtaining, transporting and testing specimens as well as facility costs used for the delivery of our services.

    For the three months ended March 31, 2024, cost of services increased by $35 million compared to the prior year period. The increase was primarily driven by higher supplies expenses (principally due to the increased volumes), wage increases and higher benefit costs, partially offset by cost savings and productivity improvements from our Invigorate program.
    
    Selling, General and Administrative Expenses ("SG&A")
    
    SG&A consist principally of the costs associated with our sales and marketing efforts, billing operations, credit loss expense and general management and administrative support as well as administrative facility costs.
    
    SG&A for the three months ended March 31, 2024 was principally consistent with the prior year period. Year-over-year wage increases were principally offset by the impact of year-over-year reductions in headcount.
    
    The changes in the value of our deferred compensation obligations is largely offset by changes in the value of the associated investments, which are recorded in other income, net. For further details regarding our deferred compensation plans, see Note 18 to the audited consolidated financial statements included in our 2023 Annual Report on Form 10-K.
        
    Amortization Expense
        
    For the three months ended March 31, 2024, amortization expense increased by $3 million compared to the prior year period as a result of recent acquisitions.
    
    Interest Expense, Net

    For the three months ended March 31, 2024, interest expense, net increased by $8 million compared to the prior year period primarily due to increased borrowings associated with the issuance, during November 2023, of $750 million aggregate principal amount of 6.40% senior notes due 2033.

    Other Income, Net

    Other income, net represents miscellaneous income and expense items related to non-operating activities, such as gains and losses associated with investments and other non-operating assets.

28

    For the three months ended March 31, 2024, other income, net included $9 million of gains associated with investments in our deferred compensation plans.
    
    For the three months ended March 31, 2023, other income, net included $7 million of gains associated with investments in our deferred compensation plans.
    
    Income Tax Expense
    
    Income tax expense for the three months ended March 31, 2024 and 2023 was $66 million and $65 million, respectively.

    The effective income tax rates for the three months ended March 31, 2024 and 2023 were 25.0% and 23.6%, respectively. The effective income tax rates benefited from $2 million and $5 million of excess tax benefits associated with stock-based compensation arrangements for the three months ended March 31, 2024 and 2023, respectively.

    Equity in Earnings of Equity Method Investees, Net of Taxes

    Equity in earnings of equity method investees, net of taxes, increased by $3 million for the three months ended March 31, 2024 compared to the prior year period primarily due to the three months ended March 31, 2023 including losses associated with changes in the carrying value of our strategic investments.
    
Quantitative and Qualitative Disclosures About Market Risk

    We address our exposure to market risks, principally the risk of changes in interest rates, through a controlled program of risk management that includes the use of derivative financial instruments. We do not hold or issue derivative financial instruments for speculative purposes. We seek to mitigate the variability in cash outflows that result from changes in interest rates by maintaining a balanced mix of fixed-rate and variable-rate debt obligations. In order to achieve this objective, we have historically entered into interest rate swap agreements. Interest rate swap agreements involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements are recognized as an adjustment to interest expense, net. We believe that our exposures to foreign exchange impacts and changes in commodity prices are not material to our consolidated results of operations, financial position or cash flows.
    
    As of both March 31, 2024 and December 31, 2023, the fair value of our debt was estimated at approximately $4.6 billion, principally using quoted prices in active markets and yields for the same or similar types of borrowings, taking into account the underlying terms of the debt instruments. As of March 31, 2024 and December 31, 2023, the estimated fair value was less than the carrying value of the debt by $159 million and $127 million, respectively. A hypothetical 10% increase in interest rates (representing 50 basis points as of both March 31, 2024 and December 31, 2023) would potentially reduce the estimated fair value of our debt by approximately $139 million as of both March 31, 2024 and December 31, 2023.

    Borrowings under our secured receivables credit facility and our senior unsecured revolving credit facility are subject to variable interest rates. Interest on our secured receivables credit facility is based on either commercial paper rates for highly-rated issuers or the adjusted Term Secured Overnight Financing Rate ("Term SOFR"), plus a spread. Interest on our senior unsecured revolving credit facility is based on certain published rates plus an applicable margin based on changes in our public debt ratings. As such, our borrowing cost under this credit arrangement is subject to fluctuations in interest rates and changes in our public debt ratings. As of March 31, 2024, the borrowing rates under these debt instruments were: for our secured receivables credit facility, commercial paper rates for highly-rated issuers or the adjusted Term SOFR, plus a spread of 0.80%; and for our senior unsecured revolving credit facility, the adjusted Term SOFR, plus 1.00%. As of March 31, 2024, there were no borrowings outstanding under the secured receivables credit facility and there were no borrowings outstanding under the senior unsecured revolving credit facility.

    Based on our net exposure to interest rate changes, a hypothetical 10% change to the variable rate component of our variable rate indebtedness would not materially change our annual interest expense.

    For further details regarding our outstanding debt, see Note 7 to the interim unaudited consolidated financial statements and Note 14 to the audited consolidated financial statements included in our 2023 Annual Report on Form 10-K. For details regarding our financial instruments and hedging activities, see Note 8 to the interim unaudited consolidated financial statements and Note 16 to the audited consolidated financial statements included in our 2023 Annual Report on Form 10-K.


29
    Risk Associated with Investment Portfolio

    Our investment portfolio primarily includes equity investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries. Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) with readily determinable fair values are measured at fair value in our consolidated balance sheet with changes in fair value recorded in current earnings in our consolidated statement of operations. Equity investments that do not have readily determinable fair values (which consist of investments in preferred and common shares of private companies) are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes.

    We regularly evaluate equity investments that do not have readily determinable fair values to determine if there are any indicators that the investments are impaired. The carrying value of our equity investments that do not have readily determinable fair values was $26 million as of March 31, 2024. In conjunction with the preparation of our March 31, 2024 financial statements, we considered whether the carrying values of our investments were impaired and concluded that no such impairment existed.
    
    We do not hedge our equity price risk. The impact of an adverse movement in equity prices on our holdings in privately held companies cannot be easily quantified as our ability to realize returns on investments depends on, among other things, the enterprises’ ability to raise additional capital or derive cash inflows from continuing operations or through liquidity events such as initial public offerings, mergers or private sales.

Liquidity and Capital Resources
Three Months Ended March 31,
20242023Change
(dollars in millions)
Net cash provided by operating activities$154 $94 $60 
Net cash used in investing activities(213)(158)(55)
Net cash used in financing activities(153)(76)(77)
Net change in cash and cash equivalents and restricted cash$(212)$(140)$(72)
    
    Cash and Cash Equivalents

    Cash and cash equivalents consist of cash and highly-liquid short-term investments with original maturities, at the time of acquisition, of three months or less. Cash and cash equivalents as of March 31, 2024 totaled $474 million, compared to $686 million as of December 31, 2023.

    As of March 31, 2024, approximately 8% of our $474 million of consolidated cash and cash equivalents were held outside of the United States.

    Cash Flows from Operating Activities

    Net cash provided by operating activities for the three months ended March 31, 2024 and 2023 was $154 million and $94 million, respectively. The $60 million increase in net cash provided by operating activities for the three months ended March 31, 2024, compared to the prior year period, was primarily a result of:

•lower performance-based compensation payments in 2024; and
•the timing of income tax payments.
    
    Days sales outstanding, a measure of billing and collection efficiency, was 50 days as of March 31, 2024, 50 days as of of December 31, 2023 and 47 days as of March 31, 2023.


30
    Cash Flows from Investing Activities

    Net cash used in investing activities for the three months ended March 31, 2024 and 2023 was $213 million and $158 million, respectively. This $55 million increase in net cash used in investing activities for the three months ended March 31, 2024, compared to the prior year period, was primarily a result of increased cash used for business acquisitions (see above for further discussion), partially offset by decreased capital expenditures.

    Cash Flows from Financing Activities

    Net cash used in financing activities for the three months ended March 31, 2024 and 2023 was $153 million and $76 million, respectively. This $77 million increase in net cash used in financing activities for the three months ended March 31, 2024, compared to the prior year period, was primarily a result of a change in bank overdrafts, which are generally settled in cash in the short term.

    During the three months ended March 31, 2024, there were no borrowings or repayments under our secured receivables credit facility and our senior unsecured revolving credit facility.

    During the three months ended March 31, 2023, we borrowed $140 million under our secured receivables credit facility, which was repaid prior to March 31, 2023, and there were no borrowings or repayments under our senior unsecured revolving credit facility.

    Dividend Program
    
    During the first quarter of 2024, our Board of Directors declared a quarterly cash dividend of $0.75 per common share. During each of the four quarters of 2023, our Board of Directors declared a quarterly cash dividend of $0.71 per common share.
    
    Share Repurchase Program

    As of March 31, 2024, $1.0 billion remained available under our share repurchase authorization. The share repurchase authorization has no set expiration or termination date.

    Share Repurchases

    For both the three months ended March 31, 2024 and 2023, we repurchased no shares of our common stock.

    Equity Method Investees

    Our equity method investees primarily consist of a diagnostic information services joint venture and an investment in a fund that purchases strategic holdings in private companies in the healthcare industry. Such investees are accounted for under the equity method of accounting. Our investment in equity method investees is less than 5% of our consolidated total assets. Our proportionate share of income before income taxes associated with our equity method investees is less than 5% of our consolidated income before income taxes and equity in earnings of equity method investees. We have no material unconditional obligations or guarantees to, or in support of, our equity method investees and their operations.

    In conjunction with the preparation of our March 31, 2024 financial statements, we considered whether the carrying values of our equity method investments were impaired and concluded that no such impairment existed.

    Requirements and Capital Resources

    We estimate that we will invest approximately $420 million during 2024 for capital expenditures, to support and grow our existing operations, principally related to investments in laboratory equipment and facilities, including laboratory automations and information technology to support our diagnostic offerings.


31
    During April 2024, we repaid in full the outstanding indebtedness under our $300 million of 4.25% senior notes which matured on April 1, 2024. Additionally, we have $600 million of 3.50% senior notes due March 2025.

    As of March 31, 2024, we had $1.2 billion of borrowing capacity available under our existing credit facilities, including $452 million available under our secured receivables credit facility and $750 million available under our senior unsecured revolving credit facility. There were no borrowings outstanding under either the secured receivables credit facility or the senior unsecured revolving credit facility as of March 31, 2024. In support of our risk management program, $73 million in letters of credit under the secured receivables credit facility were outstanding as of March 31, 2024.

    Our secured receivables credit facility is subject to customary affirmative and negative covenants, and certain financial covenants with respect to the receivables that comprise the borrowing base and secure the borrowings under the facility. Our senior unsecured revolving credit facility is also subject to certain financial covenants and limitations on indebtedness. As of March 31, 2024, we were in compliance with all such applicable financial covenants.

    We believe that our cash and cash equivalents and cash from operations, together with our borrowing capacity under our credit facilities, will provide sufficient financial flexibility to fund seasonal and other working capital requirements, capital expenditures, debt service requirements and other obligations, cash dividends on common shares, share repurchases and additional growth opportunities, including acquisitions, for the foreseeable future. However, should it become necessary, we believe that our credit profile should provide us with access to additional financing in order to fund normal business operations, make interest payments, fund growth opportunities and satisfy upcoming debt maturities.


32
Forward-Looking Statements
    
    Some statements and disclosures in this document are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan”, "aim", or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Risks and uncertainties that may affect our future results include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in our most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk
      
    See Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations."

Item 4.    Controls and Procedures

    Management, including our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended). Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report.

    During the first quarter of 2024, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


PART II - OTHER INFORMATION

Item 1.    Legal Proceedings
    
    See Note 11 to the interim unaudited consolidated financial statements for information regarding the status of legal proceedings involving the Company.


33
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

    The table below sets forth the information with respect to purchases made by or on behalf of the Company of its common stock during the first quarter of 2024.

ISSUER PURCHASES OF EQUITY SECURITIES
PeriodTotal Number of
Shares
Purchased		Average Price
Paid per Share		Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the Plans
or Programs
 (in thousands)
January 1, 2024 – January 31, 2024    
Share Repurchase Program (A)— $— — $1,035,913 
Employee Transactions (B)— $— N/AN/A
February 1, 2024 - February 29, 2024   
Share Repurchase Program (A)— $— — $1,035,913 
Employee Transactions (B)183,728 $125.55 N/AN/A
March 1, 2024 – March 31, 2024 
Share Repurchase Program (A)— $— — $1,035,913 
Employee Transactions (B)556 $127.29 N/AN/A
Total   
Share Repurchase Program (A)— $— — $1,035,913 
Employee Transactions (B)184,284 $125.56 N/AN/A

(A)Since the share repurchase program’s inception in May 2003, our Board of Directors has authorized $13 billion of share repurchases of our common stock through March 31, 2024. The share repurchase authorization has no set expiration or termination date.

(B)Includes: (1) shares delivered or attested to in satisfaction of the exercise price and/or tax withholding obligations by holders of stock options (granted under the Company’s Amended and Restated Employee Long-Term Incentive Plan) who exercised options; and (2) shares withheld (under the terms of grants under the Amended and Restated Employee Long-Term Incentive Plan) to offset tax withholding obligations that occur upon the delivery of outstanding common shares underlying restricted stock units and performance share units.


34
Item 5.    Other Information

    None.


    

35
Item 6.Exhibits

    Exhibits:
10.1
22
31.1
  
31.2
  
32.1
  
32.2
  
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
  
101.SCH
Inline XBRL Taxonomy Extension Schema Document - dgx-20240331.xsd
  
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document - dgx-20240331_cal.xml
  
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document - dgx-20240331_def.xml
  
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document - dgx-20240331_lab.xml
  
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document - dgx-20240331_pre.xml
104Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)


36
Signatures
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
April 24, 2024
Quest Diagnostics Incorporated

By /s/ James E. Davis
 James E. Davis
 Chairman, Chief Executive Officer
 and President
  
By/s/ Sam A. Samad
 Sam A. Samad
 Executive Vice President and
Chief Financial Officer


37
 EX-10.1 2 dgx03312024ex101.htm EX-10.1 Document
Equity Award Agreement    
[Grant Date]    EXHIBIT 10.1
Page | 1

Quest Diagnostics Incorporated
2024 Equity Award Agreement
This Equity Award Agreement (the “Agreement”) dated as of [Grant Date] (the “Grant Date”) between Quest Diagnostics Incorporated, 500 Plaza Drive, Secaucus, NJ 07094 (the “Company”) and the employee to whom the awards described herein are made (the “Employee”) is subject in all respects to the Company’s Amended and Restated Employee Long-Term Incentive Plan (the “Plan”). All references to “Shares” mean shares of the Company’s Common Stock.
This Agreement and the awards described herein are effective as of the grant date but shall be canceled if the Employee fails to complete, not later than thirty (30) days after such awards are communicated electronically to the Employee, all the steps to accept the Options (as hereinafter defined) electronically at the Fidelity Net Benefits website (https://nb.fidelity.com) (the “Site”), including without limitation acknowledging that the Employee has read all of the documentation provided at the Site and confirming acceptance of the Options.
If the Site does not reflect confirmation of acceptance of the Options by Midnight on the thirtieth (30th) day after the awards described herein are communicated electronically to the Employee, this Agreement, and the awards described herein, shall be cancelled.
The Employee’s taking the necessary steps so that the Site reflects confirmation of acceptance for the Options will suffice to reflect the Employee’s acceptance of the RSUs (as hereinafter defined) and the Performance Shares (as hereinafter defined) as well as the Options. Thus, it is not necessary for the Employee to make a separate electronic acceptance of the RSUs or the Performance Shares.
If you are not a United States citizen or resident as such term is defined by the Internal Revenue Code and you are employed outside the United States, please consult the “International Supplement” attached as Appendix B to this Agreement. The International Supplement amends certain terms and conditions of this Agreement as they apply to individuals employed outside the United States.
AWARDS COVERED BY THIS AGREEMENT
SECTION 1.    Award of Stock Options. The Company hereby awards stock options (each, an “Option”) to the Employee under the Plan. The number of Options awarded to the Employee is indicated at the Site. Each Option entitles the Employee, subject to the terms and conditions of this Agreement and the Plan, to purchase from the Company at the exercise price set forth for the Options at the Site (the “Exercise Price”) one Share (an “Option Share”). The Options shall vest and become exercisable on the terms set forth in Section 4. The Options shall expire on, and no Option Shares may be purchased pursuant to this Agreement after, the tenth anniversary of the Grant Date (such tenth anniversary is referred to as the “Option


Equity Award Agreement    
[Grant Date]    
Page | 2
Expiration Date”). The Compensation and Leadership Development Committee of the Board of Directors of the Company (the “Compensation Committee”) may, in its sole discretion, convert any or all of the Options at any time to a stock-settled stock appreciation grant. The Options are not intended to be “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), and this Agreement shall be construed and interpreted in accordance with such intention.
SECTION 2.    Restricted Share Units. The Company hereby awards restricted share units (each, an “RSU”) to the Employee under the Plan. The number of RSUs awarded to the Employee is indicated at the Site. Each RSU corresponds to one Share and constitutes a contingent and unsecured promise of the Company to pay the Employee one Share for each vested RSU, subject to the terms and conditions set forth in the Plan and this Agreement. The RSUs shall vest and convert to Shares on the terms set forth in Section 4. For purposes of this Agreement, an “RSU Share” means a Share delivered upon conversion of an RSU.
SECTION 3.    Performance Shares. Capitalized terms used in this Section 3 without definition have the meanings set forth in Appendix A. The Employee shall be eligible to receive and vest in Shares as provided in this Section 3 and Section 8 based on (a) the number of target performance shares indicated for the Employee at the Site (“Target Performance Shares”) and (b) the Company’s performance during the Performance Period. Performance will be measured as of the end of the performance period that began on January 1, 2024, and will continue through December 31, 2026 (the “Performance Period”). 50% of the Target Performance Shares will be earned based on the annual compounded growth of Net Revenues (“Revenue Growth”) during the Performance Period, determined by comparing the Company’s Net Revenues for the Final Year of the Performance Period (as reported by the Company for the relevant year) with the Company’s Net Revenues for the Baseline Year (as reported by Company for the year). After the Performance Period, Revenue Growth will be calculated and the number of Shares to be issued (subject to vesting under Section 8 and withholding of taxes under Section 15) in respect of the Revenue Growth performance measure shall be based upon the following formula (such Shares, and the Shares determined using the Average ROIC and Relative TSR performance measures described below in this Section 3 being “Earned Performance Shares”):
Annual Compounded Revenue Growth*“Earnings Multiple”* multiplied by 50% of Target Performance Shares = Earned Performance Shares
Greater Than or Equal to %
Equal to %………………………………...
2 x 50% x Target Performance Shares
1 x 50% x Target Performance Shares
Equal to %     0.25 x 50% x Target Performance Shares
Less Than %     0 x 50% x Target Performance Shares
*The Earnings Multiple for Revenue Growth between the percentages designated in the above table will be interpolated.
30% of the Target Performance Shares will be earned based on the Company’s Average ROIC (as defined in Appendix A) during the Performance Period. After the Performance Period, the Average ROIC will be calculated and the number of Earned Performance Shares to be issued (subject to vesting under Section 8 and withholding of taxes under Section 15) in respect of the Average ROIC performance measure shall be based upon the following formula:


Equity Award Agreement    
[Grant Date]    
Page | 3
Average ROIC*“Earnings Multiple”* multiplied by 30% of Target Performance Shares = Earned Performance Shares
Greater Than or Equal to %
Equal to % …………………………...
2 x 30% x Target Performance Shares
1 x 30% x Target Performance Shares
Equal to %     0.25 x 30% x Target Performance Shares
Less Than %     0 x 30% x Target Performance Shares

*The Earnings Multiple for Average ROIC between the percentages designated in the above table will be interpolated.
The remaining 20% of the Target Performance Shares will be earned based on the Company’s Relative TSR (as defined in Appendix A) during the Performance Period. After the Performance Period, the Relative TSR will be calculated and the number of Earned Performance Shares to be issued (subject to vesting under Section 8 and withholding of taxes under Section 15) in respect of the Relative TSR performance measure shall be based upon the following formula:
Relative TSR* †
“Earnings Multiple”* multiplied by 20% of Target Performance Shares = Earned Performance Shares
Greater Than or Equal to Percentile    2 x 20% x Target Performance Shares
Equal to Percentile     1 x 20% x Target Performance Shares
Equal to Percentile    0.5 x 20% x Target Performance Shares
Less Than Percentile     0 x 20% x Target Performance Shares

*The Earnings Multiple for Relative TSR between the percentiles designated in the above table will be interpolated.
† Notwithstanding the formula set forth in the table, the Earnings Multiple shall be no greater than 1.25x if the Company’s TSR for the Performance Period is negative.
The aggregate number of Earned Performance Shares will equal the sum of the number of Performance Shares earned in respect of the Revenue Growth performance measure, the number of Earned Performance Shares earned in respect of the Average ROIC performance measure and the number of Earned Performance Shares earned in respect of the Relative TSR performance measure. The maximum number of Earned Performance Shares is 2x the number of Target Performance Shares.
STOCK OPTIONS AND RESTRICTED SHARE UNITS
SECTION 4.    Vesting of Options and RSUs.
(a)General Vesting Requirements for Options. Except as otherwise provided below, the Options shall vest and become exercisable on the vesting dates set forth below (the “Option Vesting Dates”), provided that the Employee remains in continuous employment with the Company Group (as defined in Section 24) through the applicable Option Vesting Date. Options shall be exercisable only to the extent vested.
Option Vesting Dates            Vesting Percent        Cumulative
First anniversary of Grant Date        33.3%            33.3%
Second anniversary of Grant Date        33.3%            66.6%
Third anniversary of Grant Date        33.4%            100%



Equity Award Agreement    
[Grant Date]    
Page | 4
(b)General Vesting Requirements and Conversion Rules for RSUs. Except as otherwise provided in this Agreement, the RSUs shall vest on the vesting dates set forth below (the “RSU Vesting Dates”), provided that the Employee remains in continuous employment with the Company Group through the applicable RSU Vesting Date.
RSU Vesting Dates            Vesting Percent        Cumulative
First anniversary of Grant Date        33.3%            33.3%
Second anniversary of Grant Date        33.3%            66.6%
Third anniversary of Grant Date        33.4%            100%
In the case of an Employee who continues in employment through an RSU Vesting Date, the RSUs that vest on that RSU Vesting Date will convert to Shares as soon as practicable, and in all cases within fourteen (14) days, after the RSU Vesting Date. In the case of RSUs that vest as provided in Sections 4(d) through 4(f), the RSUs, although vested, will not convert to shares by virtue of having vested and instead will convert to Shares as soon as practical, and in all cases within fourteen (14) days, after each remaining RSU Vesting Date following the relevant vesting event specified in Sections 4(d) through 4(f); in other words, the RSUs will convert to Shares as though the Employee’s employment had continued through the applicable RSU Vesting Date. In all cases, upon conversion, the RSU Shares, net of required tax withholding as described in Section 15 below, shall be transferred into the Employee’s account at the Company’s dedicated broker.
(c)Termination of Employment Generally. If the Employee’s employment terminates for any reason other than those described in Section 4(d) through 4(f) prior to the third anniversary of the Grant Date, any Options and any RSUs that have not vested as of the date of termination of employment (the Employee’s “Termination Date”) will be canceled.
(d)Death and Disability. If the Employee’s employment terminates due to death or Disability (as defined in Section 24), all Options and all RSUs shall immediately vest.
(e)Change in Control. If within two years following the date of a Change in Control (as defined in the Plan), the Employee’s employment is terminated by the Company Group (or its successor) without Cause (as defined in Section 24) or the Employee resigns from his or her employment for Good Reason (as defined in Section 24), then all Options and all RSUs shall immediately vest on the Employee’s Termination Date. Notwithstanding the preceding sentence, in the event of a Change in Control in which the Company is not the surviving entity, and the surviving entity or successor to the Company does not agree to assume the Company’s obligations with respect to the Options under this Equity Award Agreement or to grant the Employee a Replacement Award (as defined in Section 24), then all Options and all RSUs shall vest immediately prior to the Change in Control in such a manner that will enable the Employee to participate in the Change in Control with respect to the Shares issuable upon exercise of the Options and conversion of the RSUs on the same basis as other holders of the Company’s outstanding Common Stock.
(f)Retirement. If on or after the first anniversary of the Grant Date, the Employee’s employment with the Company Group terminates due to Retirement (as defined in Section 24), the Employee will immediately vest in any Options and any RSUs that have not vested as of the Termination Date.


Equity Award Agreement    
[Grant Date]    
Page | 5
SECTION 5.    Exercise of Options.     The Employee may exercise Options in accordance with the procedures specified by the Company from time to time. The Exercise Price of Options shall be paid in full with, or in a combination of: (a) cash; (b) Shares that are owned by the Employee and are fully vested and freely transferable by the Employee, duly endorsed or accompanied by stock powers executed in blank; (c) a net share settlement procedure; or (d) through the withholding of Shares subject to the Options. The Company in its discretion may permit the Employee (if the Employee owns Shares that are fully vested and fully transferable by the Employee) to “attest” to his/her ownership of the number of Shares required to pay all or part of the purchase price (and not require delivery of the Shares), in which case the Company will deliver to the Employee the number of Shares to which the Employee is entitled, net of the “attested” Shares. If payment is made in whole or in part with Shares (including through the withholding of Shares subject to Options), the value of such Shares shall be the mean of its high and low prices on the New York Stock Exchange Composite list (or such other stock exchange as shall be the principal public trading market for the Shares) on the day of exercise. No “reload” or other option will be granted by reason of any such exercise.
SECTION 6.    Exercise of Option After Termination of Employment, Death, Disability or Retirement. The provisions covering the exercise of the Options following termination of employment are as follows, provided that in no event may any Options be exercised after the Option Expiration Date:
(a)Termination in General. If the Employee’s employment terminates for any reason other than those described in Section 6(b) through 6(d), the Options that have vested simultaneously with or before the Employee’s termination of employment may be exercised for ninety (90) days following such termination (but not beyond the Option Expiration Date) and such vested Options shall thereafter expire and cease to be exercisable.
(b)Death. If the Employee shall die while employed, then any Options that are vested and exercisable (including any Options that become vested and exercisable under Section 4(d)) may be exercised through the fifth anniversary of the date of termination (but not beyond the Option Expiration Date) and shall thereafter expire. If the Employee shall die after termination of employment but while all or any portion of the Options are still exercisable, they shall remain exercisable through the first anniversary of the date of death but not beyond the Option Expiration Date.
(c)Disability. If the Employee’s employment shall terminate due to Disability, then any Options that are vested and exercisable (including any Options that become vested and exercisable under Section 4(d)), may be exercised through the fifth anniversary of the date of termination (but not beyond the Option Expiration Date) and shall thereafter expire.
(d)Retirement. If the Employee’s employment with the Company Group terminates due to Retirement, then any Options that are vested and exercisable (including any Options that become vested and exercisable under Section 4(f)) may be exercised through the fifth anniversary of the date of termination (but not beyond the Option Expiration Date) and shall thereafter expire.



Equity Award Agreement    
[Grant Date]    
Page | 6

SECTION 7.    Automatic Exercise.
(a)At market open on the earliest of (i) the Option Expiration Date and (ii) the last date that the Option may be exercised as determined pursuant to Section 6 (the “Automatic Exercise Time”) (or market open on the immediately preceding trading date if the Automatic Exercise Time is not on a trading day), if the Exercise Spread Test (as defined in Section 24) is met, then the Options shall be automatically exercised using the method described in clause (d) of Section 5, with additional shares retained for purposes of satisfying the applicable tax withholdings (the “Automatic Exercise”). For the avoidance of doubt, if the Exercise Spread Test is not met, the Options shall expire at the Automatic Exercise Time.
(b)The Automatic Exercise procedure is provided as a convenience for the Employee and as a protection against inadvertent expiration of an Option. The Employee agrees that the Employee is normally responsible for the exercise of the Options and neither the Company nor any of its employees or agents will be liable for any damages if an Automatic Exercise does not occur for any reason and the Option expires.
(c)The Employee acknowledges and agrees that the Automatic Exercise procedure set forth in this Section 7 shall apply to all Options granted to the Employee prior to the date hereof and is incorporated into the Award Agreements for the Prior Awards (as defined below) mutatis mutandis.
PERFORMANCE SHARES
SECTION 8.    Vesting of Performance Shares.
(a)Performance Share Vesting Period. Except as otherwise provided in this Agreement, Earned Performance Shares will vest at the end of the vesting period beginning on the Grant Date and continuing through February 14, 2027 (the “Performance Share Vesting Period”), provided that the Employee remains in continuous employment with the Company Group through the end of the Performance Share Vesting Period. Earned Performance Shares, net of required tax withholding as described in Section 15 below, will be transferred into the Employee’s account at the Company’s dedicated broker as soon as practicable after the final calculation of the number of Earned Performance Shares but in any event on or prior to March 15, 2027.
(b)Change in Control. If a Change in Control occurs prior to the end of the Performance Share Vesting Period then a number of Earned Performance Shares shall be calculated as of the Change in Control and shall be equal to the greater of:
(i)the number of Earned Performance Shares that would be awarded if the calculation under Section 3 were based on the most recent fiscal year end results of the Company (rather than the Final Year of the Performance Period); and
(ii)the number of Target Performance Shares.


Equity Award Agreement    
[Grant Date]    
Page | 7
Such Earned Performance Shares shall not vest solely by virtue of the occurrence of the Change in Control but shall instead remain subject to vesting, and shall be transferred into the Employee’s account at the Company’s dedicated broker, as provided in Section 8(a); provided, however, that in the event of a Change in Control in which the Company is not the surviving entity, and the surviving entity or successor to the Company does not agree to assume the Company’s obligations with respect to the Performance Shares under this Equity Award Agreement or to grant the Employee a Replacement Award, such Earned Performance Shares, net of required tax withholding as described in Section 15 below, will be transferred to the Employee’s account at the Company’s dedicated broker within five business days after the consummation of the Change in Control. If within two years following the date of a Change in Control, the Employee’s employment is terminated by the Company Group (or successor to the Employee’s employer within the Company Group) without Cause or the Employee resigns from his or her employment for Good Reason, the Employee shall immediately vest in the number of Earned Performance Shares calculated in accordance with the first sentence of this Section 8(b), and (to the extent not previously transferred pursuant to the preceding sentence) such Earned Performance Shares, net of required tax withholding as described in Section 15 below, will be transferred to the Employee’s account at the Company’s dedicated broker within five business days after the Employee’s Termination Date. If (and only if) the Company continues to file annual reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, following the Change in Control, including for the Final Year of the Performance Period, then following the end of the Performance Period, to the extent that the number of Earned Performance Shares calculated pursuant to Section 3 exceeds the number of Earned Performance Shares calculated pursuant to the first sentence of this Section 8(b), the full amount of Earned Performance Shares resulting from the calculation in accordance with Section 3 (net of the number of Earned Performance Shares, if any, previously delivered or withheld for taxes under the preceding two sentences) will be so transferred as provided in Section 8(a). If the Employee terminates employment prior to the Change in Control, the Earned Performance Shares will vest, be pro-rated or be canceled, as applicable, in accordance with Section 8(c).
(c)Adjustments to Earned Performance Shares and Vesting of Earned Performance Shares on Termination of Employment. The Employee (or, in the case of death, the Employee’s beneficiary or estate) shall be entitled to receive 100% of the Earned Performance Shares calculated pursuant to Section 3, and such Earned Performance Shares shall not be subject to a service-based vesting requirement, if prior to the end of the Performance Share Vesting Period (x) the Employee’s employment terminates by reason of death or Disability or (y) the Employee’s employment terminates by reason of Retirement on or after the first anniversary of the Grant Date. Such Earned Performance Shares (if any) will be delivered as provided in Section 8(a) or Section 8(b), if applicable. The number of Earned Performance Shares calculated pursuant to Section 3 to which the Employee is entitled will be adjusted in the following circumstances:
(i)Termination of Employment Generally. If the Employee’s employment terminates prior to the end of the Performance Share Vesting Period for any reason other than death, Disability, Retirement on or after the first anniversary of the Grant Date or the circumstances described in Section 8(b) or 8(c)(ii), all of the Target


Equity Award Agreement    
[Grant Date]    
Page | 8
Performance Shares will be canceled and none of the Earned Performance Shares will vest.
(ii)Involuntary Termination without Cause or Divestiture. If prior to the end of the Performance Share Vesting Period the Employee’s employment is terminated by the Company Group without Cause or as a result of a divestiture and the Employee is employed by the divested or purchasing entity, then, notwithstanding the provision of Section 8(c)(i), the Employee shall vest in the number of Earned Performance Shares determined by multiplying the Earned Performance Shares by a fraction (A) the numerator of which is the number of full months that the Employee was employed by the Company Group during the Performance Share Vesting Period and (B) the denominator of which is the number of months in the Performance Share Vesting Period; and the balance of the Earned Performance Shares will be canceled.
TERMS AND CONDITIONS APPLICABLE TO ALL AWARDS
SECTION 9.    Cancellation. The Employee acknowledges and agrees that, in consideration for the Employee’s being granted the award covered by this Agreement, the Employee shall abide by the terms and conditions of the restrictive covenant agreement attached hereto as Appendix C (the “Restrictive Covenant Agreement”), which terms and conditions are incorporated herein by reference. Notwithstanding anything to the contrary contained herein, this Agreement shall expire and be canceled, the Employee will not vest in any additional Options, the Employee may not exercise any Options, whether or not vested, and all RSUs, RSU Shares, Target Performance Shares (whether or not vested or earned) and Earned Performance Shares shall be canceled if:
(a)the Employee shall cause the Company or any other member of the Company Group to suffer financial harm or damage to its reputation (either before or after termination of employment) through (x) dishonesty, (y) violation of law in the course of the Employee’s employment or violation of the Company’s Corporate Compliance Manual and compliance bulletins or other written policies or (z) material deviation from the duties owed the Company Group by the Employee; or
(b)the Employee is subject to the Executive Share Ownership Policy, as such policy may be amended from time to time (the “Ownership Policy”), and the Employee makes any false attestation under the Ownership Policy; or
(c)the Employee violates the terms of the Restrictive Covenant Agreement or any other confidentiality, non-solicit or non-compete obligation, or any other restrictive covenant set forth in any agreement between the Employee and the Company or any other member of the Company Group, or otherwise pursuant to any written policy of the Company or any other member of the Company Group (each, a “Restrictive Covenant”).
The Company may require the Employee to provide a written certification or other evidence, from time to time in the Company’s sole discretion, to confirm that no cancellation event identified in clauses (a), (b) or (c) above has occurred, including upon or following a termination of employment for any reason and/or during a specified period of time prior to the exercise of any Options or the scheduled delivery of any Option Shares, RSU Shares or Earned Performance Shares. If the Employee fails to provide any required certification or other evidence by the


Equity Award Agreement    
[Grant Date]    
Page | 9
specified deadline, the Company shall have the right to cancel the Employee’s awards and/or, as discussed in the next paragraph, to cause the exercise of any Option and the delivery of any Option Shares, RSU Shares or Earned Performance Shares under this Agreement to be rescinded (and if the Employee has previously sold the Shares issued pursuant to this Agreement, the Employee would be required to pay back to the Company the pre-tax proceeds received from the sale of such Shares).
The Employee understands that the cancellation of any awards or rights under this Agreement is only one of the remedies that potentially may be asserted against the Employee for injuries or damages sustained by the Company or any other member of the Company Group as a result of any action described in this Section 9 or a violation of any Restrictive Covenant. Such cancellation shall be in addition to any equitable and legal rights the Company or any other member of the Company Group has or may have and shall not constitute a release of any claim that the Company or any other member of the Company Group may have for damages, past, present, or future. In addition, a breach by the Employee of any provisions of any Restrictive Covenant that occurs after any exercise of any Option or delivery of Shares pursuant to this Agreement (including any breach occurring after termination of employment) shall cause the exercise of the Option and the delivery of any Option Shares, RSU Shares or Earned Performance Shares under this Agreement to be rescinded (and if the Employee has previously sold the Shares issued pursuant to this Agreement, the Employee would be required to pay back to the Company the pre-tax proceeds received from the sale of such Shares).
SECTION 10.    Executive Share Ownership Policy.
(a)Employees Subject to Ownership Policy. In consideration of the grant of the awards under this Agreement, the Employee agrees that, if the Employee is or becomes subject to the Ownership Policy, the Options and all Option Shares, the RSUs and all RSU Shares, the Target Performance Shares and all Earned Performance Shares shall be subject to cancellation pursuant to Section 9(b) of this Agreement and all Options, Option Shares, RSUs, RSU Shares, Target Performance Shares, Earned Performance Shares and shares of restricted stock granted to the Employee by the Company prior to the date hereof (the “Prior Awards”) shall be subject to cancellation pursuant to Section 9(b) of this Agreement (for false attestation under the Ownership Policy), the Shares obtained on exercise of such Prior Awards after the date hereof shall be subject to the Ownership Policy pursuant to Section 10(b) of this Agreement and the terms of Sections 9 and 10(b) hereof are made a part of the terms of each of the Prior Awards.
(b)Shares Subject to Ownership Policy. If the Employee is subject to the Ownership Policy, any Shares issued under this Agreement or pursuant to any Prior Award (in each case net of tax withholdings) are subject to such Policy. The Employee hereby acknowledges and agrees that the investment risk associated with the retention of any Shares, whether pursuant to the Ownership Policy or otherwise, is the sole responsibility of the Employee and the Employee hereby holds the Company and each other member of the Company Group harmless against any claim of loss related to the retention of the Shares.



Equity Award Agreement    
[Grant Date]    
Page | 10
SECTION 11.    Non-Transferability; Voting Rights and Dividends.
(a)Non-Transferability. The awards and rights under this Agreement shall not be transferable other than by will or the laws of descent and distribution. The Options may be exercised during the lifetime of the Employee only by the Employee except in the case of the Employee’s Disability, in which case the Options may be exercised by the Employee’s legal representative.
(b)Voting and Dividend Rights. The Employee will not have any voting, dividend or other rights as a stockholder with respect to any Option Shares, RSUs, RSU Shares, Target Performance Shares or Earned Performance Shares prior to the date on which he/she is recorded as the holder of such Option Shares, RSU Shares or Earned Performance Shares on the records of the Company; provided, however, that until RSUs convert to Shares, if the Company declares and pays a regular or ordinary dividend on its Common Stock, the Employee will be paid a dividend equivalent for vested and unvested RSUs, but no dividend equivalents will be paid on any RSUs that are canceled. The Employee understands that the Option Shares will not be issued to the Employee until after (and to the extent that) Options are exercised, that Shares will not be issued to the Employee in respect of RSUs until after (and to the extent that) RSUs convert to Shares and that, except as provided in Section 8(b), Earned Performance Shares will not be issued to the Employee until after the final calculation of the Earnings Multiple as contemplated by Section 3 and any adjustment under Section 8, it being understood that such issuance shall occur in any event on or prior to March 15, 2027. The Employee further understands that all deliveries of Shares under this Agreement shall be net of required tax withholding as described in Section 15 below. Until Shares have been delivered to or on behalf of the Employee in respect of any RSUs or Earned Performance Shares, the Employee shall have only the rights of a general unsecured creditor.
(c)Assignment. Until Shares are transferred to the Employee’s account at the Company’s dedicated broker or the Employee otherwise receives possession of any such Shares, the Employee shall have no right to sell, assign, transfer, pledge or otherwise encumber Shares in any manner. Any purported attempt to sell, assign, transfer, pledge or otherwise encumber any award under this Agreement will be void and shall result in the cancellation of such award. Unless otherwise provided at the time of such transfer or delivery to the Employee of any Shares issued in respect of vested RSUs or Earned Performance Shares or Shares issued upon full or partial exercise of the Options, upon such transfer or delivery to the Employee the Shares will not be subject to any restrictions on transfer other than those that may arise under the securities laws or the Company’s policies, but the Shares shall remain subject to cancellation as provided in Section 9.
SECTION 12.    Consideration. In consideration for the awards under this Agreement, the Employee hereby agrees to be bound by the Restrictive Covenant Agreement and all other Restrictive Covenants applicable to the Employee.
SECTION 13.    Clawback. By accepting the awards under this Agreement the Employee agrees that all awards hereunder, and any other awards granted to the Employee under the Plan or any other equity or cash incentive plan of the Company (whether before or after the date of this Agreement), shall be subject to cancellation and recoupment by the Company, and shall be repaid by the Employee to the Company, to the extent required by law, regulation or


Equity Award Agreement    
[Grant Date]    
Page | 11
listing requirement, or as determined in accordance with any Company incentive compensation recoupment policy, in each case, as in effect from time to time.
SECTION 14.    The Plan. The Plan is incorporated herein by reference. The Employee acknowledges that he/she has read the terms of the Plan and that those terms shall govern in the event of any conflict with the terms of this Agreement. Capitalized terms not defined in this Agreement have the meanings set forth in the Plan.
SECTION 15.    Taxes. The partial or full exercise of any Option, the transfer of Shares upon conversion of any vested RSUs and the delivery of any Earned Performance Shares under this Agreement will result in the Employee’s recognition of income for U.S. federal income tax purposes and shall be subject to tax and tax withholdings as appropriate. The Company or any other member of the Company Group that employs the Employee may make such provisions and take such steps as it may deem necessary or appropriate for the withholding of all federal, state, local and other taxes required or permitted by law to be withheld with respect to the exercise of any Options. On the delivery of Shares upon conversion of any RSUs and upon payment of any Earned Performance Shares, the Company will reduce the number of Shares to be delivered to the Employee by the amount of the taxes due (with the Shares valued at the mean of its high and low prices on the New York Stock Exchange Composite list (or such other stock exchange as shall be the principal public trading market for the Shares) on the date that the Shares are valued for purposes of reporting compensation for Federal income tax purposes). The Company or any other member of the Company Group that employs the Employee shall have the authority to make arrangements for payment of the Employee’s share of any employment/payroll taxes (including Federal Insurance Contributions Act taxes), whether imposition of such taxes occurs upon exercise of Options, conversion of RSUs, transfer of Earned Performance Shares or at some other time. In particular, the Employee authorizes his or her employer to withhold such taxes from any payroll or other payment or compensation owed to the Employee, subject to the limitations imposed under Section 409A of the Code.
SECTION 16.    Consent Requirement. If the Company shall at any time determine that any consent (as hereinafter defined) is necessary or desirable as a condition of, or in connection with, the granting of the Options, the issuance or purchase of Shares or other rights hereunder, or the taking of any other action hereunder (a “Plan Action”), then no such Plan Action shall be taken, in whole or in part, unless and until such consent shall have been effected or obtained to the full satisfaction of the Company. The term “consent” as used herein with respect to any action referred to in this Section 16 means (a) any and all listings, registrations or qualifications in respect thereof upon any securities exchange or under any federal, state or local law, rule or regulation, (b) any and all written agreements and representations by the Employee with respect to the disposition of Shares, or with respect to any other matter, which the Company shall deem necessary or desirable to comply with the terms of any such listing, registration or qualification or to obtain an exemption from the requirement that any such listing, qualification or registration be made, (c) any and all consents, clearances and approvals in respect of a Plan Action by any governmental or other regulatory bodies, and (d) any and all consents or authorizations required to comply with, or required to be obtained under, applicable local law or otherwise required by the Company. Nothing herein shall require the Company to list, register or qualify the Shares on any securities exchange.
SECTION 17.    Invalidity and Enforcement. If any provision of this Agreement is deemed invalid or unenforceable, either in whole or in part, this Agreement shall be deemed amended to delete or to modify, as set forth in this Section, the offending provision or provisions and to alter the bounds of this Agreement in order to render it valid and enforceable. The Company and the Employee specifically request that any court having jurisdiction over any dispute relating to this Agreement modify, if possible, any offending provision so that such provision will be enforceable to the maximum extent permitted by law.


Equity Award Agreement    
[Grant Date]    
Page | 12
SECTION 18.    No Entitlements. This Agreement is not an employment agreement, and nothing in this Agreement or the Plan shall alter an Employee’s status as an “at-will” employee of the Company Group subject to the rights (if any) that the Employee may have under any employment agreement existing between any member of the Company Group and the Employee.
SECTION 19.    Entire Agreement. Other than with respect to any Restrictive Covenant and the Ownership Policy, this Agreement constitutes the entire agreement between the Company and the Employee regarding the Options, the RSUs and the Performance Shares. No modification of this Agreement will have any force or effect unless such modification is in writing, signed by the Chief Executive Officer (or by the Senior Vice President, Chief Human Resources Officer or successor officer) of the Company and the Employee, and expressly indicates an intent to modify this Agreement.
SECTION 20.    Interpretation. Any dispute, disagreement or matter of interpretation which shall arise under the Agreement shall be finally determined by the Compensation Committee in its absolute discretion.
SECTION 21.    Governing Law. This Agreement and all rights hereunder shall be governed by, and construed and interpreted in accordance with, the laws of the state of New Jersey applicable to contracts made and to be performed entirely within such state (without reference to its principles of conflicts of law). Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of any New Jersey state court or federal court of the United States of America sitting in New Jersey, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in any such New Jersey state court or, to the extent permitted by law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Each of the parties hereto irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in state or federal court in New Jersey. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.
SECTION 22.    Enforcement by Successors and Assigns. The Company and any of its successors or assignees may enforce the Company’s rights under this Agreement.
SECTION 23.    Section 409A. It is the intention and understanding of the parties that the RSUs are either exempt from or comply with the provisions of Section 409A of the Code, and that none of the Options or the Performance Shares provide for a deferral of compensation subject to Section 409A of the Code. This Agreement shall be interpreted and administered to give effect to such intention and understanding and to avoid the imposition on the Employee of any tax, interest or penalty under Section 409A of the Code in respect of any Options, RSUs or Performance Shares. Notwithstanding any other provision of this Agreement, the Employee’s consent shall not be required for any amendment to this Agreement which, in the reasonable, good faith judgment of the Company, is necessary or appropriate to avoid the imposition on the Employee of any tax, interest or penalty under Section 409A of the Code.
SECTION 24.    Defined Terms. As used in this Equity Award Agreement, the following terms have the meanings indicated below:


Equity Award Agreement    
[Grant Date]    
Page | 13
(a)Cause. “Cause” means:
(i)as to any Employee who is a party to an employment agreement with the Company or any other member of the Company Group which contains a definition of “cause,” the definition set forth in such employment agreement;
(ii)as to any Employee who is not a party to such an employment agreement but who is eligible to receive severance under a severance plan of the Company or any other member of the Company Group (other than the Quest Diagnostics Severance Pay Plan) which contains a definition of “cause”, the definition set forth in such severance plan; and
(iii)as to any other Employee:
(A)repeated failure or refusal to perform duties and responsibilities of his or her job as required by the Employee’s employer (other than any such failure resulting from the Employee’s incapacity due to physical or mental illness);
(B)violation of any fiduciary duty or duty of loyalty owed to the Company or any other member of the Company Group, including without limitation any acts of theft or dishonesty;
(C)conduct or misconduct that is or threatens to be injurious to the Company or any other member of the Company Group or that harms or threatens to harm the reputation or financial position of the Company or any other member of the Company Group;
(D)the commission of conduct that meets the definition of any felony under state or federal law, or conviction of, or plea of nolo contendere to, any other criminal charge that is or threatens to be injurious to the Company or any member of the Company Group;
(E)willful conduct that violates the Company’s Corporate Compliance Manual, compliance bulletins or other written policies;
(F)(x) obstructing or impeding, (y) endeavoring to influence, obstruct or impede or (z) failing to cooperate with a Company investigation, whether or not related to the Employee’s employment, or the willful destruction of or willful failure to preserve documents or other material known to be relevant to any such investigation;
(G)being found liable in any Securities and Exchange Commission or other civil or criminal securities law action; or
(H)other egregious conduct that has or could have a serious and detrimental impact on the Company or any other member of the Company Group.


Equity Award Agreement    
[Grant Date]    
Page | 14
(b)Company Group. The “Company Group” means (i) the Company, (ii) any company or other entity in which the Company owns at least a 50% interest within the meaning of Section 424(f) of the Code, and (iii) any company or other entity in which the Company owns at least a 20% interest within the meaning of Section 424(f) of the Code and which the Administrator has designated as a member of the Company Group for purposes of awards under the Plan. References to employment by or with the Company Group shall be understood to refer to employment by or with the Company or any other member of the Company Group.
(c)Disability. “Disability” means permanent and total disability as determined under the Company’s long-term disability program for employees then in effect.
(d)Exercise Spread Test. “Exercise Spread Test” means the price of a Share at the Automatic Exercise Time (or market open on the immediately preceding trading date if the Automatic Exercise Time is not on a trading day) is greater than the Exercise Price.
(e)Good Reason. “Good Reason” means:
(i)as to any Employee who is a party to an employment agreement with the Company or any other member of the Company Group which contains a definition of “good reason,” the definition set forth in such employment agreement;
(ii)as to any Employee who is not a party to such an employment agreement but who is eligible to receive severance under a severance plan of the Company or any member of the Company Group which contains a definition of “good reason,” the definition set forth in such severance plan; and
(iii)as to any other Employee, the termination of the Employee’s employment by the Employee after one of the following events, provided that the Employee’s termination of employment occurs within sixty (60) days after the occurrence of any such event:
(A)any material change in the duties, responsibilities or status (including reporting responsibilities) of the Employee that is inconsistent in any material and adverse respect with the Employee’s position(s), duties, responsibilities or authority with his or her employer immediately prior to such Change in Control (including any material and adverse diminution of such duties or responsibilities); provided, however, that Good Reason shall not be deemed to occur upon a change in duties, responsibilities (other than reporting responsibilities) or status that is solely and directly a result of the Company no longer being a publicly traded entity and does not involve any other event set forth in this paragraph (d);
(B)a material reduction in the Employee’s aggregate rate of annual base salary, annual bonus opportunity and equity incentive compensation target opportunity (including any material and adverse


Equity Award Agreement    
[Grant Date]    
Page | 15
change in the formula for such targets) as in effect immediately prior to such Change in Control;
(C)the Employee’s employer requiring the Employee to be based at any office or location more than fifty (50) miles from the office where the Employee is located at the time of the Change in Control and as a result causing the Employee’s commute from his residence at the time of the Change in Control to the new location to increase by more than fifty (50) miles; or
(D)a material reduction in the Employee’s retirement, welfare, perquisite (if any) and other benefits taken as a whole, unless the Employee is permitted to participate in other plans providing the Employee with materially equivalent benefits in the aggregate (at materially equivalent or lower cost with respect to welfare benefit plans);
provided, however, that an event described in (A) through (D) above shall permit an Employee to terminate his or her employment for Good Reason only if written notice of such event has been provided by the Employee to his or her employer and the employer failed to cure such action within thirty (30) days following receipt of such notice.
(f)Replacement Award. “Replacement Award” means an equity award that is made by the surviving entity in a Change in Control in substitution for Options, RSUs or Performance Shares covered by this Equity Award Agreement and that, in the sole judgment of the Compensation Committee, affords the Employee economic opportunity and protections in the event of termination of employment that are at least as favorable to the Employee in the aggregate as the economic opportunity and protections afforded by the terms of the Options, RSUs or Performance Shares, as the case may be, set forth in this Equity Award Agreement.
(g)Retirement. “Retirement” means the voluntary cessation of employment by the Employee upon the attainment of age sixty (60) and the completion of not less than five (5) completed years of service with the Company or any other member of the Company Group; provided, however, that there is no basis for the Company or any member of the Company Group to terminate the employment of the Employee for Cause at the time of the Employee’s voluntary cessation of employment.
SECTION 25.    Leave of Absence and Transfer.
(a)Leave of Absence. Unless the Administrator expressly provides otherwise, the Employee’s employment with the Company Group will be deemed to have terminated when the Employee is no longer employed by or in a service relationship with the Company or another member of the Company Group (including by reason of a member of the Company Group ceasing to be such a member); provided, however, that the Employee’s employment will not be deemed to have terminated during a bona fide leave of absence approved by the Employee’s direct employer for medical, personal, educational and/or other permissible purposes pursuant to policies of the Company Group as in effect from time to time if such absence does not exceed six months or, if longer, so long as the Participant retains a right by


Equity Award Agreement    
[Grant Date]    
Page | 16
statute or by contract to return to employment or other service relationship with the Company Group. The Employee’s leave of absence shall be considered “bona fide” only if there is a reasonable expectation that the Employee will return to perform services for the employer.
(b)Transfers. If the Employee shall be transferred from the Company to another member of the Company Group or vice versa or from one member of the Company Group to another, the Employee’s employment shall not be deemed to have terminated for purposes of this Equity Award Agreement. If, while the Employee is employed by a member of the Company Group, such entity shall cease to be a member of the Company Group (whether by virtue of a sale, spin-off or other disposition or otherwise) and the Employee is not thereupon transferred to and employed by the Company or another member of the Company Group, then the Employee’s employment will be treated as a termination due to a divestiture on the date that the Employee’s employer ceases to be a member of the Company Group, and the provisions of Section 8(c)(ii) (Performance Shares) shall govern, as applicable.
SECTION 26.    Acknowledgements. By accepting this Equity Award Agreement, the Employee agrees that he/she has received and reviewed a copy of:
(a)the Prospectus (link to Prospectus) relating to the Company’s Employee Equity Participation Program;
(b)the Quest Diagnostics Incorporated 2023 Annual Report on Form 10-K (link to 2023 Annual Report); and
(c)the Company’s Policy for Purchasing and Selling Securities (the “Policy”) (link to Trading Policy). The Employee further agrees to fully comply with the terms of the Policy.


Equity Award Agreement    
[Grant Date]    
Page | 17

Appendix A
Quest Diagnostics Incorporated
Performance Shares Award Terms
2024 – 2026 Performance Period
Baseline Year – 2023.
Final Year – The Company’s Fiscal Year ended December 31, 2026.
Performance Period – January 1, 2024 through December 31, 2026.
ROIC – NOPAT/Invested Capital.
Net Revenues – The net revenues of the Company’s business.
Net Revenues for the Baseline Year – The Company’s Net Revenues during the Baseline Year were $ million.
NOPAT – (Income from continuing operations – net income attributable to non-controlling interests) + (gross interest expense x (1 – statutory tax rate)).
Invested Capital – Average total Quest Diagnostics stockholders equity + average total debt.
Average ROIC – Average of the Annual Average ROIC for each year in the Performance Period.
Annual Average ROIC – For a given year within the Performance Period, NOPAT/Invested Capital.
Peer Index – The companies listed in the S&P 500 Health Care Industry Index at the start of the Performance Period. The Compensation Committee may, in its sole discretion, adjust the Peer Index in the event of: (i) the merger of two members of the Peer Index; (ii) the acquisition of a member of the Peer Index by another member of the Peer Index; (iii) the acquisition of a member of the Peer Index by a company that is not a member of the Peer Index; and (iv) a split of a member of the Peer Index (in which case the Compensation Committee may, in its sole discretion, include both companies in the Peer Index). A Peer Company shall remain in the Peer Index following its bankruptcy or delisting (and shall be listed at the bottom of the Peer Index).
Relative TSR – The percentile rank of the Company’s TSR as compared to the TSR of each member of the Peer Index, determined by dividing the number of members of the Peer Index with TSR equal to or lower than the Company’s TSR for the Performance Period by the total number of members of the Peer Index minus 1.
Total Shareholder Return or TSR – The change in a company’s stock price over the Performance Period (counting any dividends paid as if such dividends were reinvested at the time of issuance) divided by that company’s stock price at the beginning of the Performance


Equity Award Agreement    
[Grant Date]    
Page | 18
Period, expressed as a percentage. The stock price at the beginning of the Performance Period shall be calculated using the relevant company’s 20 trading-day average closing stock price leading up to, but not including, January 1, 2024. The stock price at the end of the Performance Period shall be calculated using the relevant company’s 20 trading-day average closing stock price leading up to, and including, December 31, 2026.
Performance Share Vesting Period – February 14, 2024 through February 14, 2027.



Equity Award Agreement    
[Grant Date]    
Page | 19
Appendix B
International Supplement

This International Supplement amends certain terms and conditions of, and is made a part of, the Quest Diagnostics Incorporated Equity Award Agreement dated as of [Grant Date], 2024 (the “Agreement”) to which this International Supplement is attached as Appendix B. This International Supplement applies to awards made to individuals who are not United States citizens or residents, as such term is defined by the Internal Revenue Code, and who are employed outside the United States. Capitalized terms that are used without definition in this International Supplement have the meanings set forth in the Agreement.
A.    Provisions applicable to all individuals who are not United States citizens or residents.
1.    Disability. Section 4(d) is amended to provide that if the Employee’s employment shall terminate as a result of a medical condition for which the Employee receives disability income benefits from a governmental program, all Options and all RSUs shall vest. All references in the Agreement to Section 4(d), including without limitation the reference to Section 4(d) set forth in Section 6(c), shall be understood as referring to Section 4(d) as so amended.
2.    Taxes. The first two sentences of Section 15 are replaced in their entirety to read as follows: “Depending on applicable tax rules, the Employee may recognize income for income tax purposes upon the grant, vesting, exercise or settlement of the awards covered by this Agreement, and the Employee shall be subject to tax and tax withholdings as appropriate.” References in Section 15 to Federal income tax and Federal Insurance Contribution Act taxes shall be understood as references to the comparable taxes in the jurisdiction in which the Employee is employed.
B.    Provisions applicable to individuals who are citizens or residents of Finland.

1.Definition of Termination Date. The definition of “Termination Date” in Section 4(c) is replaced in its entirety with the defined term “Expiry Date”, which shall mean the date of the Employee’s expiry of employment. All references in the Agreement to Termination Date shall be understood as referring to Expiry Date.

2.Leave of Absence and Transfer. Each use of the term “terminated” in Section 25 is replaced with the term “expired.” Section 25 is amended to provide that, in addition to the enumerated permissible bona fide leaves of absence, an Employee’s employment will not be deemed to have expired as a result of a bona fide leave of absence permitted pursuant to statute.

3.Definition of Good Reason. Section 24(e)(iii) is amended to provide that the events set forth in Sections 24(e)(iii)(A) through (D) shall provide grounds for a termination by the Employee with Good Reason if the Employee serves notice of Employee’s termination of employment within sixty (60) days of the occurrence of any such event and the employer fails to cure the event giving rise to Good Reason within thirty (30) days following receipt of such notice.


Equity Award Agreement    
[Grant Date]    
Page | 20
Appendix C
RESTRICTIVE COVENANT AGREEMENT


 EX-22 3 dgx03312024ex22.htm EX-22 Document

Exhibit 22

Subsidiary Guarantors of Securities
As of April 24, 2024, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended:

Securities
Issuer
Subsidiary Guarantor
State of Organization
6.95% Senior Notes due 2037
5.75% Senior Notes due 2040
Quest Diagnostics Incorporated
American Medical Laboratories, Incorporated
Delaware
AmeriPath, Inc.
Delaware
AmeriPath Consolidated Labs, Inc.
Florida
AmeriPath Florida, LLC
Delaware
AmeriPath Hospital Services Florida, LLC
Delaware
AmeriPath Kentucky, Inc.
Kentucky
AmeriPath New York, LLC
Delaware
AmeriPath Texas, Inc.
Delaware
Blueprint Genetics Inc.
Delaware
Diagnostic Pathology Services, Inc.
Oklahoma
ExamOne World Wide, Inc.
Pennsylvania
ExamOne World Wide of NJ, Inc.
New Jersey
Kailash B. Sharma, M.D., Inc.
Georgia
LabOne, LLC
Missouri
LabOne of Ohio, Inc.
Delaware
Ocmulgee Medical Pathology Association, Inc.
Georgia
Quest Diagnostics Clinical Laboratories, Inc.
Delaware
Quest Diagnostics Holdings Incorporated
Delaware
Quest Diagnostics Incorporated
Maryland
Quest Diagnostics Incorporated
Nevada
Quest Diagnostics Investments LLC
Delaware
Quest Diagnostics LLC
Connecticut
Quest Diagnostics LLC
Illinois
Quest Diagnostics LLC
Massachusetts
Quest Diagnostics Nichols Institute
California
Quest Diagnostics Nichols Institute, Inc.
Virginia
Quest Diagnostics of Pennsylvania Inc.
Delaware
Specialty Laboratories, Inc.
California
Unilab Corporation
Delaware


 EX-31.1 4 dgx03312024ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, James E. Davis, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Quest Diagnostics Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

April 24, 2024
By/s/ James E. Davis
James E. Davis
Chairman, Chief Executive Officer and
President



 EX-31.2 5 dgx03312024ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Sam Samad, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Quest Diagnostics Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

April 24, 2024
By/s/ Sam Samad
Sam Samad
Executive Vice President and
Chief Financial Officer


 EX-32.1 6 dgx03312024ex321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. § 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended March 31, 2024 of Quest Diagnostics Incorporated, as being filed with the Securities and Exchange Commission concurrently herewith, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. § 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Quest Diagnostics Incorporated.
Dated:April 24, 2024/s/ James E. Davis
James E. Davis
Chairman, Chief Executive Officer and
President



 EX-32.2 7 dgx03312024ex322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. § 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended March 31, 2024 of Quest Diagnostics Incorporated, as being filed with the Securities and Exchange Commission concurrently herewith, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. § 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Quest Diagnostics Incorporated.
Dated:April 24, 2024/s/ Sam Samad
Sam Samad
Executive Vice President and
Chief Financial Officer



 EX-101.SCH 8 dgx-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - RESTRUCTURING ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - BUSINESS ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - BUSINESS SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - BUSINESS SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - RESTRUCTURING ACTIVITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - BUSINESS ACQUISITIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - FAIR VALUE MEASUREMENTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Assets and Liabilities Unobservable Inputs) (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - FINANCIAL INSTRUMENTS (Balance Sheets) (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - BUSINESS SEGMENT INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - REVENUE RECOGNITION (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 dgx-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 dgx-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 dgx-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Total fair value adjustments included in earnings - realized/unrealized Total fair value adjustments included in earnings - realized/unrealized Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Less: Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Other Liabilities Other Noncurrent Liabilities [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Credit facility capacity Line of Credit Facility, Maximum Borrowing Capacity Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value DEBT Debt Disclosure [Text Block] Deferred compensation trading securities Debt Securities, Trading, and Equity Securities, FV-NI Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Cash paid for business acquisitions Payments to Acquire Businesses, Gross Excludes general and professional liability claims Excludes general and professional liability claims [Member] Excludes general and professional liability claims [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Restatement Determination Date: Restatement Determination Date [Axis] Total non-operating expense, net Non-operating expense, net Nonoperating Income (Expense) Class action lawsuits Loss Contingency, Pending Claims, Number Commitments and contingencies Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Equity [Text Block] Ownership [Axis] Ownership [Axis] UMass Joint Venture UMass Joint Venture [Member] UMass Joint Venture [Member] Net income Net Income (Loss), Excluding Redeemable Noncontrolling Interest Net Income (Loss), Excluding Redeemable Noncontrolling Interest Business Acquisition [Line Items] Business Acquisition [Line Items] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Dividends paid Payments of Ordinary Dividends, Common Stock Diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Additional, Reimbursement Coverage Additional, Reimbursement Coverage [Member] Additional, Reimbursement Coverage Hedging Relationship [Axis] Hedging Relationship [Axis] Treasury stock, at cost; 51 shares as of both March 31, 2024 and December 31, 2023 Treasury Stock, Value Accounts receivable, net of allowance for credit losses of $28 and $27 as of March 31, 2024 and December 31, 2023, respectively Accounts Receivable, after Allowance for Credit Loss, Current Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Extinguishment of debt Extinguishment of Debt, Amount Significant Unobservable Inputs, Level 3 Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Treasury stock (in shares) Treasury Stock, Common, Shares Litigation reserves Estimated Litigation Liability Litigation Case [Axis] Litigation Case [Axis] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Redeemable noncontrolling interest Redeemable Noncontrolling Interest, Equity, Carrying Amount Trading Symbol Trading Symbol Letters of credit outstanding, amount Letters of Credit Outstanding, Amount Restructuring Plan [Domain] Restructuring Plan [Domain] Percentage of net revenues Percentage of Net Revenues Percentage of Net Revenues Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net income attributable to Quest Diagnostics Net income attributable to Quest Diagnostics Net Income (Loss) Less: Cash acquired Cash Acquired from Acquisition Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Operating costs and expenses and other operating income: Cost of Revenue [Abstract] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Capitated Capitated [Member] Capitated [Member] Quest Diagnostics stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Equity, Attributable to Parent [Abstract] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Litigation Status [Domain] Litigation Status [Domain] Executive Category: Executive Category [Axis] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Quoted Prices in Active Markets for Identical Assets / Liabilities, Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Dividends per common share Common Stock, Dividends, Per Share, Declared Selling, general and administrative Selling, General and Administrative Expenses [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Comparable Company Revenue Volatility Measurement Input, Comparable Company Revenue Volatility [Member] Measurement Input, Comparable Company Revenue Volatility [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation expense Depreciation Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accounts Receivable Disaggregation Accounts Receivable Disaggregation [Table Text Block] Accounts Receivable Disaggregation [Table Text Block] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Product and Service [Domain] Product and Service [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Litigation Status [Axis] Litigation Status [Axis] Restructuring reserve Restructuring Reserve Net accounts receivable Percentage of Net Accounts Receivable Percentage of Net Accounts Receivable Award Type Award Type [Axis] Stock options and performance share units (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Accounts payable associated with capital expenditures Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Leased assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Patients (including coinsurance and deductible responsibilities) Patients [Member] Patients [Member] Use Of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Discount rate Measurement Input, Discount Rate [Member] Current portion of long-term operating lease liabilities Operating Lease, Liability, Current Amortization of intangible assets Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] New Accounting Standards to be Adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Income taxes payable Increase (Decrease) in Income Taxes Payable Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and cash equivalents and restricted cash, beginning of period Cash and cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Fair value of debt Debt Instrument, Fair Value Disclosure Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] DS Businesses DS Businesses [Member] DS Businesses [Member] Description of Business (Abstract) Description of Business (Abstract) Description of Business (Abstract) Common stock, shares issued (in shares) Common Stock, Shares, Issued Consideration Business Combination, Consideration Transferred Pre-tax restructuring charges Severance Costs Security Exchange Name Security Exchange Name Total Assets, Fair Value Disclosure Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Employee Stock Option [Member] FINANCIAL INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] DIS business Diagnostic Information Services Business [Member] Diagnostic Information Services Business [Member] Total operating costs and expenses, net Costs and Expenses Other financing activities, net Proceeds from (Payments for) Other Financing Activities Comprehensive income attributable to Quest Diagnostics Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Goodwill acquired during the period Goodwill, Acquired During Period Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Subsequent Event [Table] Subsequent Event [Table] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other, net Other Noncash Income (Expense) Business Acquisition [Axis] Business Acquisition [Axis] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Subsequent Event Subsequent Event [Member] Client Payers Client Payers [Member] Client Payers [Member] Derivative [Table] Derivative [Table] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] BUSINESS ACQUISITIONS Business Combination Disclosure [Text Block] Distributions to noncontrolling interest partners Payments of Ordinary Dividends, Noncontrolling Interest Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Ownership percentage by noncontrolling owners Subsidiary, Ownership Percentage, Noncontrolling Owner Issuance of common stock under benefit plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Fair value of liabilities assumed Liabilities Assumed Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Tax Identification Number Entity Tax Identification Number Investments in equity method investees Equity Method Investments Additional, Based on Revenue Additional, Based on Revenue [Member] Additional, Based on Revenue Inventories Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Contingent Consideration Contingent Consideration [Member] Contingent Consideration [Member] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] 3.50% Senior Notes due March 2025 Three Point Five Zero Percent Senior Notes due March 2025 [Member] Three Point Five Zero Percent Senior Notes due March 2025 [Member] Invigorate Program Invigorate Program [Member] Invigorate Program [Member] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Derivative Financial Instruments Derivatives, Policy [Policy Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Balance, shares Balance, shares Common Stock, Shares, Outstanding PEO PEO [Member] Fair value of net assets acquired Fair value of net assets acquired Fair value of net assets acquired Redeemable Non-controlling Interest [Abstract] Increase (Decrease) in Temporary Equity [Roll Forward] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Repayments of debt Repayments of Debt Measurement Input Type [Domain] Measurement Input Type [Domain] Changing Comparable Company Revenue Volatility Changing Comparable Company Revenue Volatility [Member] Changing Comparable Company Revenue Volatility Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] General corporate activities Corporate Segment [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items] Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items] [Line Items] for Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table] 401(k) Plan Lawsuit 401(k) Plan Lawsuit [Member] 401(k) Plan Lawsuit Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings per share attributable to Quest Diagnostics’ common stockholders: Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2024 and December 31, 2023; 162 shares issued as of both March 31, 2024 and December 31, 2023 Common Stock, Value, Issued Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Senior Notes Senior Notes [Member] Total current assets Assets, Current Contingent consideration Business Combination, Contingent Consideration, Liability Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Litigation Case [Domain] Litigation Case [Domain] Other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Restructuring Type [Axis] Restructuring Type [Axis] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Balance, Value Balance, Value Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Statement [Table] Statement [Table] Subsegments [Domain] Subsegments [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Earnings Per Share Earnings Per Share, Policy [Policy Text Block] PEO Name PEO Name Liability Balance, December 31, 2023 Balance, March 31, 2024 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Cash surrender value of life insurance policies Cash Surrender Value, Fair Value Disclosure Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Changing Discount Rate Changing Discount Rate [Member] Changing Discount Rate Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Less: Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted DESCRIPTION OF BUSINESS Nature of Operations [Text Block] Other assets and liabilities, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Depreciation and amortization Depreciation and amortization expense Depreciation, Depletion and Amortization Changes in bank overdrafts Increase (Decrease) in Bank Overdrafts Increase (Decrease) in Bank Overdrafts Other operating expense, net Other Operating Income (Expense), Net Debt instrument, interest rate Debt Instrument, Interest Rate, Stated Percentage Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total Quest Diagnostics stockholders' equity Equity, Attributable to Parent Net income Temporary Equity, Net Income Subsegments [Axis] Subsegments [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Subsequent Events [Abstract] Subsequent Events [Abstract] Long-term debt Long-Term Debt and Lease Obligation Amounts attributable to Quest Diagnostics’ common stockholders: Income Amounts Attributable to Parent, Disclosures [Abstract] RESTRUCTURING ACTIVITIES Restructuring and Related Activities Disclosure [Text Block] Significant Other Observable Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Accounts Payable and Accrued Expenses Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities [Member] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Document Fiscal Period Focus Document Fiscal Period Focus Intangible assets, useful life Finite-Lived Intangible Asset, Useful Life Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Government Payers Government Payers [Member] Government Payers [Member] Product and Service [Axis] Product and Service [Axis] EARNINGS (LOSS) PER SHARE Earnings Per Share [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Total stockholders' equity Balance, value Balance, value Equity, Including Portion Attributable to Noncontrolling Interest Distributions to noncontrolling interest partners Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Minimum Minimum [Member] Triggering Event [Axis] Triggering Event [Axis] Triggering Event Property, plant and equipment, net Property, Plant and Equipment, Net Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Other comprehensive (loss) income Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Maximum contingent consideration payment Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Dividends declared Dividends, Common Stock, Cash Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Total Liabilities, Fair Value Disclosure Senior Unsecured Revolving Credit Facility Senior unsecured revolving credit facility [Member] Senior unsecured revolving credit facility [Member] Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt [Table Text Block] Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt [Table Text Block] Employee payroll tax withholdings on stock issued under stock-based compensation plans Payment, Tax Withholding, Share-Based Payment Arrangement Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Other investing activities Payments for (Proceeds from) Other Investing Activities Retained Earnings Retained Earnings [Member] Goodwill, expected tax deductible amount Business Acquisition, Goodwill, Expected Tax Deductible Amount Current portion of long-term debt Long-Term Debt, Current Maturities Triggering Event [Domain] Triggering Event [Domain] Triggering Event Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders' equity Liabilities and Equity Other assets Other Assets, Noncurrent Other income (expense): Nonoperating Income (Expense) [Abstract] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Basic (in dollars per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Healthcare Insurers Healthcare Insurers [Member] Healthcare Insurers [Member] Earnings available to Quest Diagnostics’ common stockholders – basic and diluted Net Income (Loss) Available to Common Stockholders, Diluted Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Summary of Segment Reporting Information by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Reissuance of shares for employee benefit plan Stock Issued During Period, Shares, Treasury Stock Reissued Pending Litigation Pending Litigation [Member] Income taxes paid Income Taxes Paid Proceeds from borrowings Proceeds from Issuance of Debt Total restructuring charges Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Combinations [Abstract] Business Combinations [Abstract] Share repurchase authorization remaining available Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Available-for-sale debt securities Debt Securities, Available-for-Sale Distributions to noncontrolling interest partners Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders Redeemable noncontrolling interest Redeemable Noncontrolling Interest, Equity, Fair Value Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table] Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table] Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table] Amount outstanding Long-Term Debt, Gross Liability Class [Axis] Liability Class [Axis] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Dividends payable Dividends Payable Less: Comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Prepayments to acquire businesses Prepayments to Acquire Businesses, Net of Cash Acquired Prepayments to Acquire Businesses, Net of Cash Acquired Deferred income tax benefit Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Restructuring Plan [Axis] Restructuring Plan [Axis] Exercise of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] SUPPLEMENTAL CASH FLOW & OTHER DATA Cash Flow, Supplemental Disclosures [Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Insider Trading Arrangements [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Issuance of common stock under benefit plans, shares Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture All other operating segments Other Segments [Member] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Stock options and performance share units Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Adjustment to Compensation, Amount Adjustment to Compensation Amount Increase in contingent consideration liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Cost of services Cost of Sales [Member] Fee-for-service Fee-for-service [Member] Fee-for-service [Member] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Provision (credit) for credit losses Contract with Customer, Asset, Credit Loss Expense (Reversal) Target percent for annual productivity savings Restructuring and Related Activities, Target Percent For Annual Productivity Savings Restructuring and Related Activities, Target Percent For Annual Productivity Savings Operating lease liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities Treasury Stock, at Cost Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Long-term Debt Long-Term Debt [Member] Purchases, additions and issuances Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Additions and Issuances Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Additions and Issuances Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax expense Income Tax Expense (Benefit) Four point two five percent Senior Notes Due 2024 Four point two five percent Senior Notes Due 2024 [Member] Four point two five percent Senior Notes Due 2024 [Member] Deferred compensation liabilities Deferred Compensation Liability, Classified, Noncurrent Lenco Diagnostics Laboratories, Inc. Lenco Diagnostics Laboratories, Inc. [Member] Lenco Diagnostics Laboratories, Inc. FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Haystack Oncology, Inc. Haystack Oncology, Inc. [Member] Haystack Oncology, Inc. Net revenues Total net revenues Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Fair Value Hedging Fair Value Hedging [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Business acquisitions, net of cash acquired Business acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Interest expense, net Interest expense, net Interest Income (Expense), Net Additional Impact Additional Impact [Member] Additional Impact Self-insurance reserves Malpractice Loss Contingency, Accrual, Undiscounted Purchases of treasury stock- shares Treasury Stock, Shares, Acquired Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Diluted (in Shares) Weighted average common shares outstanding - diluted Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Interest income Interest and Dividend Income, Operating REVENUE RECOGITION Revenue from Contract with Customer [Text Block] Capital expenditures Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Fair value of assets acquired Fair Value of Assets Acquired Additional Paid-In Capital Additional Paid-in Capital [Member] Leases: Lease, Cost [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Equity in earnings of equity method investees, net of taxes Income (Loss) from Equity Method Investments Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] SUBSEQUENT EVENTS Subsequent Events [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Recurring Basis Fair Value, Recurring [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Fair Value, Measurement Inputs Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Other liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Supplemental Cash Flow and Other Data Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] BUSINESS SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Net change in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Income before income taxes and equity in earnings of equity method investees Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Hedge Accounting Basis Adjustment Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Secured Receivables Credit Facility Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in Shares) Weighted average common shares outstanding - basic Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating income Total operating income Operating Income (Loss) Cost of services Cost of Revenue Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer Relationships Customer Relationships [Member] Merger consideration payable Merger Consideration Paid (Payable), Net Merger Consideration Paid (Payable), Net Type of Restructuring [Domain] Type of Restructuring [Domain] Stockholders' equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Non-controlling Interests Noncontrolling Interest [Member] EX-101.PRE 12 dgx-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page - shares
 3 Months Ended
Mar. 31, 2024
Apr. 15, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-12215  
Entity Registrant Name Quest Diagnostics Inc  
Entity Central Index Key 0001022079  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 16-1387862  
Entity Address, Address Line One 500 Plaza Drive  
Entity Address, City or Town Secaucus,  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07094  
City Area Code (973)  
Local Phone Number 520-2700  
Title of 12(b) Security Common Stock, $0.01 Par Value  
Trading Symbol DGX  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   111,091,574
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net revenues $ 2,366 $ 2,331
Operating costs and expenses and other operating income:    
Cost of services 1,595 1,560
Selling, general and administrative 440 439
Amortization of intangible assets 29 26
Other operating expense, net 2 1
Total operating costs and expenses, net 2,066 2,026
Operating income 300 305
Other income (expense):    
Interest expense, net (43) (35)
Other income, net 9 7
Total non-operating expense, net (34) (28)
Income before income taxes and equity in earnings of equity method investees 266 277
Income tax expense (66) (65)
Equity in earnings of equity method investees, net of taxes 8 5
Net income 208 217
Less: Net income attributable to noncontrolling interests 14 15
Net income attributable to Quest Diagnostics $ 194 $ 202
Earnings per share attributable to Quest Diagnostics’ common stockholders:    
Basic (in dollars per share) $ 1.74 $ 1.80
Diluted (in dollars per share) $ 1.72 $ 1.78
Weighted average common shares outstanding:    
Basic (in Shares) 111 112
Diluted (in Shares) 112 113
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net income $ 208 $ 217
Other comprehensive income (loss):    
Foreign currency translation adjustment (2) 3
Other comprehensive (loss) income (2) 3
Comprehensive income 206 220
Less: Comprehensive income attributable to noncontrolling interests 14 15
Comprehensive income attributable to Quest Diagnostics $ 192 $ 205
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Assets    
Cash and cash equivalents $ 474 $ 686
Accounts receivable, net of allowance for credit losses of $28 and $27 as of March 31, 2024 and December 31, 2023, respectively 1,322 1,210
Inventories 181 190
Prepaid expenses and other current assets 251 286
Total current assets 2,228 2,372
Property, plant and equipment, net 1,810 1,816
Operating lease right-of-use assets 579 602
Goodwill 7,830 7,733
Intangible assets, net 1,192 1,166
Investments in equity method investees 133 135
Other assets 182 198
Total assets 13,954 14,022
Liabilities and Stockholders' Equity    
Accounts payable and accrued expenses 1,239 1,359
Current portion of long-term debt 906 303
Current portion of long-term operating lease liabilities 153 153
Total current liabilities 2,298 1,815
Long-term debt 3,804 4,410
Long-term operating lease liabilities 489 503
Other liabilities 817 876
Commitments and contingencies
Redeemable noncontrolling interest 77 76
Quest Diagnostics stockholders’ equity:    
Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2024 and December 31, 2023; 162 shares issued as of both March 31, 2024 and December 31, 2023 2 2
Additional paid-in capital 2,292 2,320
Retained earnings 8,935 8,825
Accumulated other comprehensive loss (16) (14)
Treasury stock, at cost; 51 shares as of both March 31, 2024 and December 31, 2023 (4,781) (4,826)
Total Quest Diagnostics stockholders' equity 6,432 6,307
Noncontrolling interests 37 35
Total stockholders' equity 6,469 6,342
Total liabilities and stockholders' equity $ 13,954 $ 14,022
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
shares in Millions, $ in Millions
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 28 $ 27
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 600 600
Common stock, shares issued (in shares) 162 162
Treasury stock (in shares) 51 51
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net income $ 208 $ 217
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 116 107
Provision (credit) for credit losses 1 (1)
Deferred income tax benefit (18) (4)
Stock-based compensation expense 22 24
Other, net 11 3
Changes in operating assets and liabilities:    
Accounts receivable (114) (58)
Accounts payable and accrued expenses (152) (211)
Income taxes payable 42 11
Other assets and liabilities, net 38 6
Net cash provided by operating activities 154 94
Cash flows from investing activities:    
Business acquisitions, net of cash acquired (142) (31)
Capital expenditures (104) (127)
Other investing activities 33 0
Net cash used in investing activities (213) (158)
Cash flows from financing activities:    
Proceeds from borrowings 0 140
Repayments of debt 0 (140)
Exercise of stock options 12 25
Employee payroll tax withholdings on stock issued under stock-based compensation plans (23) (28)
Dividends paid (79) (74)
Distributions to noncontrolling interest partners (11) (14)
Other financing activities, net (52) 15
Net cash used in financing activities (153) (76)
Net change in cash and cash equivalents and restricted cash (212) (140)
Cash and cash equivalents and restricted cash, beginning of period 686 315
Cash and cash equivalents and restricted cash, end of period $ 474 $ 175
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury Stock, at Cost
Non-controlling Interests
Balance, shares at Dec. 31, 2022   111          
Balance, value at Dec. 31, 2022 $ 5,930 $ 2 $ 2,295 $ 8,290 $ (21) $ (4,673) $ 37
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 216     202     14
Other comprehensive income (loss), net of taxes 3       3    
Dividends declared (80)     (80)      
Distributions to noncontrolling interest partners $ (13)           (13)
Issuance of common stock under benefit plans, shares 1            
Issuance of common stock under benefit plans $ 6   (42)     48  
Stock-based compensation expense 24   24        
Exercise of stock options 30   (1)     31  
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans (28)   (10)     (18)  
Balance, shares at Mar. 31, 2023   112          
Balance, value at Mar. 31, 2023 6,088 $ 2 2,266 8,412 (18) (4,612) 38
Balance, Value at Dec. 31, 2022 77            
Redeemable Non-controlling Interest [Abstract]              
Net income 1            
Distributions to noncontrolling interest partners (1)            
Balance, Value at Mar. 31, 2023 77            
Balance, shares at Dec. 31, 2023   111          
Balance, value at Dec. 31, 2023 6,342 $ 2 2,320 8,825 (14) (4,826) 35
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 207     194     13
Other comprehensive income (loss), net of taxes (2)       (2)    
Dividends declared (84)     (84)      
Distributions to noncontrolling interest partners (11)           (11)
Issuance of common stock under benefit plans 6   (42)     48  
Stock-based compensation expense 22   22        
Exercise of stock options 12   (2)     14  
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans (23)   (6)     (17)  
Balance, shares at Mar. 31, 2024   111          
Balance, value at Mar. 31, 2024 6,469 $ 2 $ 2,292 $ 8,935 $ (16) $ (4,781) $ 37
Balance, Value at Dec. 31, 2023 76            
Redeemable Non-controlling Interest [Abstract]              
Net income 1            
Balance, Value at Mar. 31, 2024 $ 77            
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DESCRIPTION OF BUSINESS
 3 Months Ended
Mar. 31, 2024
Description of Business (Abstract)  
DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESS
    
    Background
    
    Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") work across the healthcare ecosystem to create a healthier world, one life at a time. The Company's diagnostic information services ("DIS") business provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, the diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. In the right hands and with the right context, the diagnostic insights can inspire actions that transform lives and create a healthier world. The Company provides services to a broad range of customers within its primary customer channels - physicians (including those associated with accountable care organizations and Federally Qualified Health Centers), hospitals, and patients and consumers. Other customers include health plans, employers, emerging retail healthcare providers, government agencies, pharmaceutical companies and other commercial clinical laboratories. The Company offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The Company's large in-house staff of medical and scientific experts, including medical directors, scientific directors, genetic counselors and board-certified geneticists, provide medical and scientific consultation to healthcare providers and patients regarding the Company's tests and test results, and help them best utilize Quest Diagnostics' services to improve outcomes and enhance satisfaction. The Company's Diagnostic Solutions ("DS") group, which represents the balance of the Company's consolidated net revenues, includes the Company's risk assessment services business, which offers solutions for insurers, and the Company's healthcare information technology businesses, which offer solutions for healthcare providers and payers.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    Basis of Presentation
    
    The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2023 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023 but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”).

    The accounting policies of the Company are the same as those set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2023 Annual Report on Form 10-K.

    Use of Estimates
    
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

    Earnings Per Share

    The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially
dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan (“ELTIP”) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan (“DLTIP”), as well as the dilutive effect of accelerated share repurchase agreements ("ASRs"), if applicable. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.

    New Accounting Standards to be Adopted

    In November 2023, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which will require companies to disclose significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"). The pronouncement is effective for annual filings for the year ended December 31, 2024 and for interim periods within the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows.

    In December 2023, the FASB issued a new accounting standard which will require companies to make additional income tax disclosures. The pronouncement is effective for annual filings for the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows.

    In March 2024, the Securities and Exchange Commission issued a rule which will require companies to make certain climate-related disclosures in periodic filings. The rule includes certain disclosures in the footnotes of the financial statements:

•capitalized costs, expenditures expensed, and losses incurred as a result of severe weather events and other natural conditions, such as hurricanes, tornadoes, flooding, drought, wildfires, extreme temperatures, and sea level rise;
•capitalized costs, expenditures expensed, and losses related to carbon offsets and renewable energy credits or certificates if they are used as a material component of a registrant’s plans to achieve its disclosed climate-related targets or goals; and
•whether estimates and assumptions used to produce the financial statements were materially impacted by risks and uncertainties associated with severe weather events and other natural conditions or any disclosed climate-related targets or transition plans.

    The footnote disclosures are effective for annual filings for the year ended December 31, 2025. The Company is currently evaluating the impact of the adoption of the rule.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EARNINGS PER SHARE
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE EARNINGS PER SHARE
    The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
Three Months Ended March 31,
 20242023
Amounts attributable to Quest Diagnostics’ common stockholders:  
Net income attributable to Quest Diagnostics$194 $202 
Less: Earnings allocated to participating securities1 1 
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted
$193 $201 
Weighted average common shares outstanding – basic111 112 
Effect of dilutive securities:  
Stock options and performance share units1 1 
Weighted average common shares outstanding – diluted112 113 
Earnings per share attributable to Quest Diagnostics’ common stockholders:  
Basic$1.74 $1.80 
Diluted$1.72 $1.78 
    

    The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
Three Months Ended March 31,
20242023
Stock options and performance share units1 — 
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RESTRUCTURING ACTIVITIES
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
RESTRUCTURING ACTIVITIES RESTRUCTURING ACTIVITIES
    Invigorate Program

    The Company is engaged in a multi-year program called Invigorate, which includes structured plans to drive savings and improve productivity across the value chain, including in such areas as patient services, logistics and laboratory operations, revenue services, information technology and procurement. The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to partially offset pressures from the current inflationary environment, including labor and benefit cost increases and reimbursement pressures. The Company is leveraging automation and artificial intelligence to improve productivity and also improve quality across the entire value chain, not just in the laboratory. Other areas of focus include reducing denials and patient concessions, enhancing the digital experience, and selecting and retaining talent.

    Restructuring Charges
    
    The Company's pre-tax restructuring charges for the three months ended March 31, 2024 and 2023 were $6 million and $15 million, respectively, entirely related to employee separation costs associated with various workforce reduction initiatives as the Company continued to restructure its organization. Of the total restructuring charges incurred during the three months ended March 31, 2024, $4 million and $2 million were recorded in cost of services and selling, general and administrative expenses, respectively. Of the total restructuring charges incurred during the three months ended March 31, 2023, $9 million and $6 million were recorded in cost of services and selling, general and administrative expenses, respectively.
    
    Charges for all periods presented were primarily recorded in the Company's DIS business.

    The restructuring liability as of March 31, 2024 and December 31, 2023, which is included in accounts payable and accrued expenses, was $13 million and $12 million, respectively.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS ACQUISITIONS
 3 Months Ended
Mar. 31, 2024
Business Combinations [Abstract]  
BUSINESS ACQUISITIONS BUSINESS ACQUISITIONS
    During the three months ended March 31, 2024, the Company completed acquisitions for an aggregate purchase price of $148 million (including contingent consideration initially estimated at $6 million), net of cash acquired, including the acquisitions discussed below. Of such amount, $30 million was prepaid during the twelve months ended December 31, 2023. In the Company's consolidated statement of cash flows for the three months ended March 31, 2024, such $30 million is included in business acquisitions, net of cash acquired, with a corresponding offset in other investing activities.

    The acquisitions preliminarily resulted in goodwill of $99 million, all of which is deductible for tax purposes. The acquisitions also preliminarily resulted in $56 million of customer-related intangible assets.

    Acquisition of select assets of Lenco Diagnostic Laboratories, Inc. ("Lenco")

    On February 12, 2024, the Company acquired select assets of Lenco, an independent clinical diagnostic laboratory provider serving physicians in New York, in an all-cash transaction for $111 million. Based on the preliminary purchase price allocation, which may be revised as additional information becomes available during the measurement period, the assets acquired and liabilities assumed primarily consist of $75 million of tax-deductible goodwill, $43 million of customer-related intangible assets and $7 million of operating lease liabilities. The intangible assets are being amortized over a useful life of 15 years.

    The acquisitions were accounted for under the acquisition method of accounting. As such, the assets acquired and liabilities assumed were recorded based on their estimated fair values as of the closing dates. Supplemental pro forma combined financial information has not been presented as the impact of the acquisitions is not material to the Company's consolidated financial statements. The goodwill recorded primarily includes the expected synergies resulting from combining the operations of the acquired entity with those of the Company and the value associated with an assembled workforce and other intangible assets that do not qualify for separate recognition. All of the goodwill acquired in connection with the acquisitions has been allocated to the Company's DIS business. For further details regarding business segment information, see Note 12.
    For details regarding the Company's 2023 acquisitions, see Note 6 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE MEASUREMENTS
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
    Assets and Liabilities Measured at Fair Value on a Recurring Basis

    The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:
Basis of Fair Value Measurements
Quoted Prices in Active Markets for Identical Assets/LiabilitiesSignificant Other Observable InputsSignificant Unobservable Inputs
March 31, 2024TotalLevel 1Level 2Level 3
Assets:    
Deferred compensation trading securities$74 $74 $— $— 
Cash surrender value of life insurance policies59 — 59 — 
Total$133 $74 $59 $— 
Liabilities:    
Deferred compensation liabilities$138 $— $138 $— 
Contingent consideration113 — — 113 
Total$251 $— $138 $113 
Redeemable noncontrolling interest$77 $— $— $77 
Basis of Fair Value Measurements
December 31, 2023TotalLevel 1Level 2Level 3
Assets:       
Deferred compensation trading securities$70 $70 $— $— 
Cash surrender value of life insurance policies55 — 55 — 
Available-for-sale debt securities2 — — 2 
Total$127 $70 $55 $2 
Liabilities:    
Deferred compensation liabilities$131 $— $131 $— 
Contingent consideration104 — — 104 
Total$235 $— $131 $104 
Redeemable noncontrolling interest$76 $— $— $76 
    
    A detailed description regarding the Company's fair value measurements is contained in Note 8 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.    

    The Company offers certain employees the opportunity to participate in a non-qualified supplemental deferred compensation plan. A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities. The trading securities are classified within Level 1 of the fair value hierarchy because the changes in the fair value of these securities are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held, exclusive of any transaction costs. A
corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation. The deferred compensation liabilities are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the trading securities.

    The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program. A participant's deferrals, together with Company matching credits, are “invested” at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments. Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the deferred compensation obligation are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Deferrals under the plan currently may only be made by participants who made deferrals under the plan in 2017.

    The Company's available-for-sale debt securities are measured at fair value using discounted cash flows. These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable. Significant inputs include cash flows projections and a discount rate.

     During June 2023, the Company acquired Haystack Oncology, Inc. ("Haystack"), an early-stage oncology company focused on minimal residual disease testing to aid in the detection of residual or recurring cancer and better inform therapy decisions. In connection with the acquisition there is a contingent consideration obligation under which the seller can receive up to $100 million of additional consideration dependent upon the achievement of certain revenue benchmarks through 2028 and up to an additional $50 million of consideration dependent upon the Company receiving reimbursement coverage from the Centers for Medicare and Medicaid Services ("CMS"). The portion of the contingent consideration obligation which is dependent upon the achievement of certain revenue benchmarks was measured at fair value using a Monte Carlo method and is classified within Level 3 of the fair value hierarchy as the fair value is determined based on significant inputs that are not observable. Significant inputs include management’s estimate of revenue and other market inputs, including comparable company revenue volatility (40%) and a discount rate (10.5%). The portion of the contingent consideration obligation which is dependent upon the Company receiving reimbursement coverage from the CMS is also classified within Level 3 of the fair value hierarchy as the fair value is principally determined based on management's estimate, which is a significant input that is not observable. Additionally, the fair value of the entire contingent consideration obligation is also impacted by a market discount rate (5%) which adjusts the estimated payments to present value. The fair value of the contingent consideration obligation is not overly sensitive to movements in the comparable company revenue volatility or the discount rate used for the portion of the obligation that is dependent upon the achievement of certain revenue benchmarks. For example, changing the comparable company revenue volatility from 40% to 30% impacts the fair value by $8 million (assuming no other inputs are modified) and changing the discount rate from 10.5% to 7.0% impacts the fair value by $5 million (assuming no other inputs are modified).
    
    The Company has additional contingent consideration obligations in connection with other acquisitions. The liabilities related to such obligations are included in the amounts below.

    The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):
Contingent Consideration
Balance, December 31, 2023
$104 
Purchases, additions and issuances6 
Total fair value adjustments included in earnings - realized/unrealized3 
Balance, March 31, 2024$113 

    The $3 million net loss included in earnings associated with the change in the fair value of contingent consideration for the three months ended March 31, 2024 is reported in other operating expense, net.    
    Of the aggregate $113 million contingent consideration obligation as of March 31, 2024, $79 million and $34 million were included in other liabilities and accounts payable and accrued expenses, respectively, in the Company's consolidated balance sheet. Of the aggregate $104 million contingent consideration obligation as of December 31, 2023, $99 million and $5 million were included in other liabilities and accounts payable and accrued expenses, respectively, in the Company's consolidated balance sheet.

    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. As of March 31, 2024, the redeemable noncontrolling interest was presented at its fair value. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy because the fair value is based on a discounted cash flow analysis that takes into account, among other items, the joint venture's expected future cash flows, long term growth rates, and a discount rate commensurate with economic risk.
    
    The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. As of both March 31, 2024 and December 31, 2023, the fair value of the Company’s debt was estimated at $4.6 billion. Principally all of the Company's debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates currently offered to the Company with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
DEBT DEBT
    The Company has $600 million of 3.50% senior notes due March 2025. The senior notes are included in current portion of long-term debt in the Company's March 31, 2024 consolidated balance sheet. Such notes were included in long-term debt in the Company's December 31, 2023 consolidated balance sheet. For further details, see Note 14 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS
    The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral.

    Interest Rate Risk
    
    The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements.

    Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.

    Interest Rate Derivatives – Cash Flow Hedges

    From time to time, the Company has entered into various interest rate lock agreements and forward-starting interest rate swap agreements to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in interest rates.
    Interest Rate Derivatives – Fair Value Hedges

    Historically, the Company has entered into various fixed-to-variable interest rate swap agreements in order to convert a portion of the Company's long-term debt into variable interest rate debt. All such fixed-to-variable interest rate swap agreements have been terminated and proceeds from the terminations have been reflected as basis adjustments to the hedged debt instruments and are being amortized as a reduction of interest expense, net over the remaining terms of such debt instruments.

    As of March 31, 2024 and December 31, 2023, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:
Hedge Accounting Basis Adjustment (a)
Balance Sheet ClassificationMarch 31, 2024December 31, 2023
Long-term debt$10 $13 

(a) As of both March 31, 2024 and December 31, 2023, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.
    A detailed description regarding the Company's use of derivative financial instruments is contained in Note 16 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
 3 Months Ended
Mar. 31, 2024
Equity, Attributable to Parent [Abstract]  
STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
    
    Stockholders' Equity    

    Changes in Accumulated Other Comprehensive Loss by Component

    Comprehensive income (loss) includes:

•Foreign currency translation adjustments;
•Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 8); and
•Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.

    For the three months ended March 31, 2024 and 2023, the tax effects related to the deferred gains (losses) on cash flow hedges and net changes in available-for-sale debt securities were not material. Foreign currency translation adjustments related to indefinite investments in non-U.S. subsidiaries are not adjusted for income taxes.

    Dividend Program
    
    During the first quarter of 2024, the Company's Board of Directors declared a quarterly cash dividend of $0.75 per common share. During each of the four quarters of 2023, the Company's Board of Directors declared a quarterly cash dividend of $0.71 per common share.
    
    Share Repurchase Program
    
    As of March 31, 2024, $1.0 billion remained available under the Company’s share repurchase authorization. The share repurchase authorization has no set expiration or termination date.
        
    Share Repurchases

    For both the three months ended March 31, 2024 and 2023, the Company repurchased no shares of its common stock.
        
    Shares Reissued from Treasury Stock

    For the three months ended March 31, 2024 and 2023, the Company reissued 0.5 million shares and 0.7 million shares, respectively, from treasury stock under its Employee Stock Purchase Plan and its stock-based compensation program. For details regarding the Company's stock ownership and compensation plans, see Note 18 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.
    
    Redeemable Noncontrolling Interest

    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. The subsidiary performs diagnostic information services in a defined territory within the state of Massachusetts. Since the redemption of the noncontrolling interest is outside of the Company's control, it has been presented outside of stockholders' equity at the greater of its carrying amount or its fair value. As of March 31, 2024 and December 31, 2023, the redeemable noncontrolling interest was presented at its fair value. For further details regarding the fair value of the redeemable noncontrolling interest, see Note 6.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUPPLEMENTAL CASH FLOW & OTHER DATA
 3 Months Ended
Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]  
SUPPLEMENTAL CASH FLOW & OTHER DATA SUPPLEMENTAL CASH FLOW AND OTHER DATA
    Supplemental cash flow and other data for the three months ended March 31, 2024 and 2023 was as follows:
Three Months Ended March 31,
20242023
Depreciation expense$87 $81 
Amortization expense29 26 
Depreciation and amortization expense$116 $107 
Interest expense$(49)$(37)
Interest income6 2 
Interest expense, net$(43)$(35)
Interest paid$44 $32 
Income taxes paid$3 $33 
Accounts payable associated with capital expenditures$28 $22 
Dividends payable$84 $80 
Businesses acquired:  
Fair value of assets acquired$155 $31 
Fair value of liabilities assumed7 — 
Fair value of net assets acquired148 31 
Merger consideration payable(6)— 
Cash paid for business acquisitions142 31 
Less: Cash acquired— — 
Business acquisitions, net of cash acquired$142 $31 
Leases:
Leased assets obtained in exchange for new operating lease liabilities$35 $44 
    During the three months ended March 31, 2024 and 2023, other financing activities, net in the Company's consolidated statement of cash flows included changes in bank overdrafts, which are generally settled in cash in the short term, of $(51) million and $33 million, respectively.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
    Letters of Credit

    The Company can issue letters of credit under its $525 million secured receivables credit facility and its $750 million senior unsecured revolving credit facility. For further discussion regarding the facilities, see Note 14 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.
    
    In support of its risk management program, $73 million in letters of credit under the $525 million secured receivables credit facility were outstanding as of March 31, 2024, providing collateral for current and future automobile liability and workers’ compensation loss payments.

    Contingent Lease Obligations
    
    The Company remains subject to contingent obligations under certain real estate leases for which no liability has been recorded. For further details, see Note 19 to the audited consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K.

    Certain Legal Matters

    The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues. The Company has insurance coverage rights in place (limited in amount; subject to deductible) for certain potential costs and liabilities related to these proceedings and investigations.

    In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Company’s 401(k) plan. The complaint alleges, among other things, that the fiduciaries of the 401(k) plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments. In October 2020, the court consolidated the two lawsuits under the caption In re: Quest Diagnostics ERISA Litigation and plaintiffs filed a consolidated amended complaint. In May 2021, the court denied the Company's motion to dismiss the complaint. Discovery has been completed. Plaintiffs' motion for class certification and the Company's motion for summary judgment are pending.

    On June 3, 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (“AMCA”) had informed the Company and Optum360 LLC that an unauthorized user had access to AMCA’s system between August 1, 2018 and March 30, 2019 (the “AMCA Data Security Incident”). Optum360 provides revenue management services to the Company, and AMCA provided debt collection services to Optum360. AMCA first informed the Company of the AMCA Data Security Incident on May 14, 2019. AMCA’s affected system included financial information (e.g., credit card numbers and bank account information), medical information and other personal information (e.g., social security numbers). Test results were not included. Neither Optum360’s nor the Company’s systems or databases were involved in the incident. AMCA also informed the Company that information pertaining to other laboratories’ customers was also affected. Following announcement of the AMCA Data Security Incident, AMCA sought protection under the U.S. bankruptcy laws. The bankruptcy proceeding has been dismissed.

    Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident. The U.S. Judicial Panel on Multidistrict Litigation transferred the cases that were then still pending to, and consolidated them for pre-trial proceedings in, the U.S. District Court for New Jersey. In November 2019, the plaintiffs in the multidistrict proceeding filed a consolidated putative class action complaint against the Company and Optum360 that named additional individuals as plaintiffs and that asserted a variety of common law and statutory claims in connection with the AMCA Data Security Incident. In January 2020, the Company moved to dismiss the consolidated complaint; the motion to dismiss was granted in part and denied in part. Plaintiffs filed an amended complaint, which the Company also moved to dismiss. The motion was granted in part and denied in part. Discovery is proceeding.
    In addition, a group of state attorney general offices are investigating the Company in connection with the AMCA Data Security Incident. The Company is cooperating with the investigation.

    ReproSource Fertility Diagnostics, Inc. (“ReproSource”), a subsidiary of the Company, is subject to two putative class action lawsuits related to a data security incident that occurred in August 2021 in which plaintiffs allege that an unauthorized party accessed or acquired protected health information and personally identifiable information of ReproSource patients. Bickham v. ReproSource Fertility Diagnostics, Inc. is pending in the U.S. District Court for the District of Massachusetts (the "Massachusetts District Court"), and Trouville v. ReproSource Fertility Diagnostics, Inc., which was originally filed in the U.S. District Court for the Eastern District of California, has now been transferred to the Massachusetts District Court. A third case filed in the Massachusetts District Court, Gordon v. ReproSource Fertility Diagnostics, Inc., was consolidated into the Bickham case. The Bickham and Trouville complaints seek to represent a class of all individuals potentially impacted by the August 2021 data security incident, and generally allege that ReproSource, among other claims, failed to adequately safeguard patients’ private information.

    On January 10, 2024, ReproSource agreed to settle the Bickham case on a class-wide basis. The settlement is pending approval by the District Court. If approved, ReproSource will receive a full release for all claims that the settlement class might possess arising out of the August 2021 data security incident. The Company’s motion to stay the Trouville case was granted.

    The Company is subject to a putative class action entitled Cole, et al. v Quest Diagnostics Incorporated, which was filed in the U. S. District Court for the Eastern District of California, for allegedly conspiring with Facebook to track customers’ internet communications on Company web platforms without authorization, in violation of the California Invasion of Privacy Act and the California Confidentiality of Medical Information Act. The complaint alleged that the Company’s actions were an invasion of privacy and contributed to a loss of value in plaintiffs’ personally identifiable information. The Company moved to dismiss the case or, in the alternative, transfer venue to the U.S. District Court for New Jersey. Subsequently, plaintiffs filed an amended complaint, which the Company also moved to dismiss. The Company's motion to transfer the case was granted. The Company has refiled its motion to dismiss with the New Jersey District Court.

    As previously disclosed, in August 2011, the Company had received a subpoena from the U.S. Attorney for the Northern District of Georgia seeking various business records, including records related to the Company's compliance program, certain marketing materials, certain product offerings, and certain test ordering and other policies. The Company cooperated with the request. In 2021, a third amended complaint in a qui tam action filed in the U.S. District Court for the Northern District of Georgia was unsealed, which is related to the matter underlying the August 2011 subpoena. Both the U.S. Department of Justice and the State of Georgia declined to intervene in the action. The Company moved to dismiss the complaint and the complaint was dismissed without prejudice in August 2022. The relator subsequently filed a fourth amended complaint. The Company has moved to dismiss the fourth amended complaint.

    The Company also received subpoenas from the U.S. Attorney for the District of New Jersey. The subpoenas seek various records relating to the Company’s relationship with the New York Giants and adherence to certain company policies and federal laws. The Company is cooperating with the investigation.

    Other Legal Matters

    In the normal course of business, the Company has been named, from time to time, as a defendant in various legal actions, including arbitrations, class actions and other litigation, arising in connection with the Company's activities as a provider of diagnostic testing, information and services. These actions could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on the Company's client base and reputation.

    The Company is also involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief.
    The federal or state governments may bring claims based on the Company's current practices, which it believes are lawful. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of government or private payers. The Company is aware of lawsuits, and from time to time has received subpoenas, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws. The Company understands that there may be other pending qui tam claims brought by former employees or other "whistleblowers" as to which the Company cannot determine the extent of any potential liability.

    Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the Company's consolidated results of operations or cash flows in the period in which the impact of such matters is determined or paid.

    These matters are in different stages. Some of these matters are in their early stages. Matters may involve responding to and cooperating with various government investigations and related subpoenas. As of March 31, 2024, the Company does not believe that material losses related to legal matters are probable.

    Reserves for legal matters totaled $1 million and $6 million as of March 31, 2024 and December 31, 2023, respectively.

    Reserves for General and Professional Liability Claims

    As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims. These suits could involve claims for substantial damages. Any professional liability litigation could also have an adverse impact on the Company's client base and reputation. The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures. The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims.

    The Company is subject to a series of individual claims brought by persons in Ireland related to allegations stemming from pap smear screening services performed by the Company. In general, claimants have alleged that the results of certain pap smear screening tests performed by the Company and other providers, pursuant to a program coordinated by the Irish government, were incorrect for individuals who were later diagnosed with cervical cancer. The Irish government and an independent scoping inquiry commissioned by the Irish government found that the Company’s performance of its screening services for the Irish cervical cancer screening program were in accordance with both Ireland’s requirements and international standards. The Company has settled claims made by certain individuals, is a party in multiple lawsuits and may be served as a party in additional lawsuits. The Company does not believe that the resolution of existing or future claims will have a material adverse effect on its financial position or liquidity, but the ultimate outcomes of these claims are unpredictable and subject to significant uncertainties.

    Reserves for general and professional liability claims matters, including those associated with both asserted and incurred but not reported claims, are established on an undiscounted basis by considering actuarially determined losses based upon the Company's historical and projected loss experience. Such reserves totaled $166 million and $173 million as of March 31, 2024 and December 31, 2023, respectively.

    While the basis for claims reserves is actuarially determined losses based upon the Company's historical and projected loss experience, the process of analyzing, assessing and establishing reserve estimates relative to these types of claims involves a high degree of judgment. Although the Company believes that its present reserves and insurance coverage are sufficient to cover currently estimated exposures, it is possible that the Company may incur liabilities in excess of its recorded reserves or insurance coverage. Changes in the facts and circumstances associated with claims could have a material impact on the Company’s results of operations (principally costs of services), cash flows and financial condition in the period that reserve estimates are adjusted or paid.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
BUSINESS SEGMENT INFORMATION BUSINESS SEGMENT INFORMATION
    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's CODM, assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers within its primary customer channels - physicians, hospitals, and patients and consumers. The DIS business accounted for greater than 95% of net revenues in 2024 and 2023.

    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses offer solutions for insurers and offer solutions for healthcare providers and payers.
        
    As of March 31, 2024, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.

    The following table is a summary of segment information for the three months ended March 31, 2024 and 2023. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2023 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended March 31,
20242023
Net revenues:  
DIS business$2,298 $2,259 
All other operating segments68 72 
Total net revenues $2,366 $2,331 
Operating earnings (loss):  
DIS business$373 $374 
All other operating segments9 8 
General corporate activities(82)(77)
Total operating income300 305 
Non-operating expense, net(34)(28)
Income before income taxes and equity in earnings of equity method investees266 277 
Income tax expense(66)(65)
Equity in earnings of equity method investees, net of taxes8 5 
Net income208 217 
Less: Net income attributable to noncontrolling interests14 15 
Net income attributable to Quest Diagnostics$194 $202 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE RECOGNITION
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGITION REVENUE RECOGNITION
    DIS

    Net revenues in the Company’s DIS business accounted for over 95% of the Company’s total net revenues for the three months ended March 31, 2024 and 2023 and are primarily comprised of a high volume of relatively low-dollar transactions. The DIS business, which provides clinical testing services and other services, satisfies its performance obligations and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered. The Company estimates the amount of consideration it expects to be entitled to receive from payer customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials), and patient price concessions. The portfolios determined using the portfolio approach consist of the following groups of payer customers: healthcare insurers, government payers (Medicare and Medicaid programs), client payers and patients.

    For further details regarding revenue recognition in the Company's DIS business, see Note 3 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.

    DS

    The Company’s DS businesses primarily satisfy their performance obligations and recognize revenues when delivery has occurred or services have been rendered.

    Net Revenue and Net Accounts Receivable by Payer Customer Type

    The approximate percentage of net revenue by type of payer customer was as follows:
    
Three Months Ended March 31,
20242023
Healthcare insurers:
Fee-for-service37 %37 %
Capitated3 3 
Total healthcare insurers40 40 
Government payers12 12 
Client payers33 33 
Patients (including coinsurance and deductible responsibilities)12 12 
Total DIS97 97 
DS3 3 
Net revenues100 %100 %
    
    The approximate percentage of net accounts receivable by type of payer customer was as follows:
March 31, 2024December 31, 2023
Healthcare Insurers28 %24 %
Government Payers7 7 
Client Payers40 45 
Patients (including coinsurance and deductible responsibilities)21 20 
Total DIS96 96 
DS4 4 
Net accounts receivable100 %100 %
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUBSEQUENT EVENTS
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS    During April 2024, the Company repaid in full the outstanding indebtedness under the Company's $300 million of 4.25% senior notes which matured on April 1, 2024.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net income attributable to Quest Diagnostics $ 194 $ 202
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2023 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023 but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”).
Use Of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Earnings Per Share The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially
dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan (“ELTIP”) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan (“DLTIP”), as well as the dilutive effect of accelerated share repurchase agreements ("ASRs"), if applicable. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.
New Accounting Standards to be Adopted In November 2023, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which will require companies to disclose significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"). The pronouncement is effective for annual filings for the year ended December 31, 2024 and for interim periods within the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows.
    In December 2023, the FASB issued a new accounting standard which will require companies to make additional income tax disclosures. The pronouncement is effective for annual filings for the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows.

    In March 2024, the Securities and Exchange Commission issued a rule which will require companies to make certain climate-related disclosures in periodic filings. The rule includes certain disclosures in the footnotes of the financial statements:

•capitalized costs, expenditures expensed, and losses incurred as a result of severe weather events and other natural conditions, such as hurricanes, tornadoes, flooding, drought, wildfires, extreme temperatures, and sea level rise;
•capitalized costs, expenditures expensed, and losses related to carbon offsets and renewable energy credits or certificates if they are used as a material component of a registrant’s plans to achieve its disclosed climate-related targets or goals; and
•whether estimates and assumptions used to produce the financial statements were materially impacted by risks and uncertainties associated with severe weather events and other natural conditions or any disclosed climate-related targets or transition plans.

    The footnote disclosures are effective for annual filings for the year ended December 31, 2025. The Company is currently evaluating the impact of the adoption of the rule.
Derivative Financial Instruments The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral.
    Interest Rate Risk
    
    The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements.

    Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EARNINGS PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
Three Months Ended March 31,
 20242023
Amounts attributable to Quest Diagnostics’ common stockholders:  
Net income attributable to Quest Diagnostics$194 $202 
Less: Earnings allocated to participating securities1 1 
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted
$193 $201 
Weighted average common shares outstanding – basic111 112 
Effect of dilutive securities:  
Stock options and performance share units1 1 
Weighted average common shares outstanding – diluted112 113 
Earnings per share attributable to Quest Diagnostics’ common stockholders:  
Basic$1.74 $1.80 
Diluted$1.72 $1.78 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
Three Months Ended March 31,
20242023
Stock options and performance share units1 — 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE MEASUREMENTS (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value, Measurement Inputs The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:
Basis of Fair Value Measurements
Quoted Prices in Active Markets for Identical Assets/LiabilitiesSignificant Other Observable InputsSignificant Unobservable Inputs
March 31, 2024TotalLevel 1Level 2Level 3
Assets:    
Deferred compensation trading securities$74 $74 $— $— 
Cash surrender value of life insurance policies59 — 59 — 
Total$133 $74 $59 $— 
Liabilities:    
Deferred compensation liabilities$138 $— $138 $— 
Contingent consideration113 — — 113 
Total$251 $— $138 $113 
Redeemable noncontrolling interest$77 $— $— $77 
Basis of Fair Value Measurements
December 31, 2023TotalLevel 1Level 2Level 3
Assets:       
Deferred compensation trading securities$70 $70 $— $— 
Cash surrender value of life insurance policies55 — 55 — 
Available-for-sale debt securities2 — — 2 
Total$127 $70 $55 $2 
Liabilities:    
Deferred compensation liabilities$131 $— $131 $— 
Contingent consideration104 — — 104 
Total$235 $— $131 $104 
Redeemable noncontrolling interest$76 $— $— $76 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):
Contingent Consideration
Balance, December 31, 2023
$104 
Purchases, additions and issuances6 
Total fair value adjustments included in earnings - realized/unrealized3 
Balance, March 31, 2024$113 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS (Tables)
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt As of March 31, 2024 and December 31, 2023, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:
Hedge Accounting Basis Adjustment (a)
Balance Sheet ClassificationMarch 31, 2024December 31, 2023
Long-term debt$10 $13 

(a) As of both March 31, 2024 and December 31, 2023, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables)
 3 Months Ended
Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow and Other Data Supplemental cash flow and other data for the three months ended March 31, 2024 and 2023 was as follows:
Three Months Ended March 31,
20242023
Depreciation expense$87 $81 
Amortization expense29 26 
Depreciation and amortization expense$116 $107 
Interest expense$(49)$(37)
Interest income6 2 
Interest expense, net$(43)$(35)
Interest paid$44 $32 
Income taxes paid$3 $33 
Accounts payable associated with capital expenditures$28 $22 
Dividends payable$84 $80 
Businesses acquired:  
Fair value of assets acquired$155 $31 
Fair value of liabilities assumed7 — 
Fair value of net assets acquired148 31 
Merger consideration payable(6)— 
Cash paid for business acquisitions142 31 
Less: Cash acquired— — 
Business acquisitions, net of cash acquired$142 $31 
Leases:
Leased assets obtained in exchange for new operating lease liabilities$35 $44 
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Summary of Segment Reporting Information by Segment The following table is a summary of segment information for the three months ended March 31, 2024 and 2023. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2023 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended March 31,
20242023
Net revenues:  
DIS business$2,298 $2,259 
All other operating segments68 72 
Total net revenues $2,366 $2,331 
Operating earnings (loss):  
DIS business$373 $374 
All other operating segments9 8 
General corporate activities(82)(77)
Total operating income300 305 
Non-operating expense, net(34)(28)
Income before income taxes and equity in earnings of equity method investees266 277 
Income tax expense(66)(65)
Equity in earnings of equity method investees, net of taxes8 5 
Net income208 217 
Less: Net income attributable to noncontrolling interests14 15 
Net income attributable to Quest Diagnostics$194 $202 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE RECOGNITION (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue The approximate percentage of net revenue by type of payer customer was as follows:
    
Three Months Ended March 31,
20242023
Healthcare insurers:
Fee-for-service37 %37 %
Capitated3 3 
Total healthcare insurers40 40 
Government payers12 12 
Client payers33 33 
Patients (including coinsurance and deductible responsibilities)12 12 
Total DIS97 97 
DS3 3 
Net revenues100 %100 %
Accounts Receivable Disaggregation The approximate percentage of net accounts receivable by type of payer customer was as follows:
March 31, 2024December 31, 2023
Healthcare Insurers28 %24 %
Government Payers7 7 
Client Payers40 45 
Patients (including coinsurance and deductible responsibilities)21 20 
Total DIS96 96 
DS4 4 
Net accounts receivable100 %100 %
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Amounts attributable to Quest Diagnostics’ common stockholders:    
Net income attributable to Quest Diagnostics $ 194 $ 202
Less: Earnings allocated to participating securities 1 1
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted $ 193 $ 201
Weighted average common shares outstanding - basic 111 112
Stock options and performance share units 1 1
Weighted average common shares outstanding - diluted 112 113
Basic (in dollars per share) $ 1.74 $ 1.80
Diluted (in dollars per share) $ 1.72 $ 1.78
Stock options and performance share units (in shares) 1 0
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RESTRUCTURING ACTIVITIES (Details) - Invigorate Program - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]      
Target percent for annual productivity savings 3.00%    
Pre-tax restructuring charges $ 6 $ 15  
Accounts Payable and Accrued Expenses      
Restructuring Cost and Reserve [Line Items]      
Restructuring reserve 13   $ 12
Cost of services      
Restructuring Cost and Reserve [Line Items]      
Total restructuring charges 4 9  
Selling, general and administrative      
Restructuring Cost and Reserve [Line Items]      
Total restructuring charges $ 2 $ 6  
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS ACQUISITIONS (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Feb. 12, 2024
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Business Acquisition [Line Items]        
Consideration   $ 148    
Contingent consideration   6    
Prepayments to acquire businesses   30   $ 30
Goodwill acquired during the period   99    
Cash paid for business acquisitions   142 $ 31  
Goodwill   7,830   $ 7,733
Goodwill, expected tax deductible amount   99    
Customer Relationships        
Business Acquisition [Line Items]        
Intangible assets   $ 56    
Lenco Diagnostics Laboratories, Inc.        
Business Acquisition [Line Items]        
Cash paid for business acquisitions $ 111      
Goodwill 75      
Goodwill, expected tax deductible amount 75      
Operating lease liabilities 7      
Lenco Diagnostics Laboratories, Inc. | Customer Relationships        
Business Acquisition [Line Items]        
Intangible assets $ 43      
Intangible assets, useful life 15 years      
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Contingent consideration $ 6  
Recurring Basis    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Deferred compensation trading securities 74 $ 70
Cash surrender value of life insurance policies 59 55
Available-for-sale debt securities   2
Total 133 127
Deferred compensation liabilities 138 131
Contingent consideration 113 104
Total 251 235
Redeemable noncontrolling interest 77 76
Recurring Basis | Quoted Prices in Active Markets for Identical Assets / Liabilities, Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Deferred compensation trading securities 74 70
Cash surrender value of life insurance policies 0 0
Available-for-sale debt securities   0
Total 74 70
Deferred compensation liabilities 0 0
Contingent consideration 0 0
Total 0 0
Redeemable noncontrolling interest 0 0
Recurring Basis | Significant Other Observable Inputs, Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Deferred compensation trading securities 0 0
Cash surrender value of life insurance policies 59 55
Available-for-sale debt securities   0
Total 59 55
Deferred compensation liabilities 138 131
Contingent consideration 0 0
Total 138 131
Recurring Basis | Significant Unobservable Inputs, Level 3    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Deferred compensation trading securities 0 0
Cash surrender value of life insurance policies 0 0
Available-for-sale debt securities   2
Total 0 2
Deferred compensation liabilities 0 0
Contingent consideration 113 104
Total 113 104
Redeemable noncontrolling interest $ 77 $ 76
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE MEASUREMENTS (Narrative) (Details)
 3 Months Ended
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jul. 01, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Fair value of debt $ 4,600,000,000 $ 4,600,000,000    
UMass Joint Venture        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Ownership percentage by noncontrolling owners       18.90%
Fair Value, Inputs, Level 3 | Contingent Consideration        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Total fair value adjustments included in earnings - realized/unrealized 3,000,000      
Liability 113,000,000 104,000,000    
Fair Value, Inputs, Level 3 | Contingent Consideration | Other Liabilities        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Liability 79,000,000 99,000,000    
Fair Value, Inputs, Level 3 | Contingent Consideration | Accounts Payable and Accrued Expenses        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Liability $ 34,000,000 $ 5,000,000    
Haystack Oncology, Inc. | Comparable Company Revenue Volatility        
Business Acquisition [Line Items]        
Measurement input 0.40      
Haystack Oncology, Inc. | Discount rate        
Business Acquisition [Line Items]        
Measurement input 0.105      
Haystack Oncology, Inc. | Additional, Based on Revenue        
Business Acquisition [Line Items]        
Maximum contingent consideration payment     $ 100,000,000  
Haystack Oncology, Inc. | Additional, Reimbursement Coverage        
Business Acquisition [Line Items]        
Maximum contingent consideration payment     $ 50,000,000  
Haystack Oncology, Inc. | Additional Impact | Discount rate        
Business Acquisition [Line Items]        
Measurement input 0.05      
Haystack Oncology, Inc. | Changing Comparable Company Revenue Volatility | Comparable Company Revenue Volatility        
Business Acquisition [Line Items]        
Measurement input 0.30      
Increase in contingent consideration liability $ 8,000,000      
Haystack Oncology, Inc. | Changing Discount Rate | Comparable Company Revenue Volatility        
Business Acquisition [Line Items]        
Increase in contingent consideration liability $ 5,000,000      
Haystack Oncology, Inc. | Changing Discount Rate | Discount rate        
Business Acquisition [Line Items]        
Measurement input 0.070      
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Assets and Liabilities Unobservable Inputs) (Details) - Significant Unobservable Inputs, Level 3 - Contingent Consideration
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Balance, December 31, 2023 $ 104
Purchases, additions and issuances 6
Total fair value adjustments included in earnings - realized/unrealized 3
Balance, March 31, 2024 $ 113
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT (Details) - Senior Notes - 3.50% Senior Notes due March 2025
Mar. 31, 2024
USD ($)
Debt Instrument [Line Items]  
Face amount $ 600,000,000
Debt instrument, interest rate 3.50%
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS (Balance Sheets) (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Long-term Debt | Fair Value Hedging    
Derivative [Line Items]    
Hedge Accounting Basis Adjustment $ 10 $ 13
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details) - USD ($)
$ / shares in Units, $ in Billions
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Jul. 01, 2015
Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items]            
Dividends per common share $ 0.75 $ 0.71 $ 0.71 $ 0.71 $ 0.71  
Share repurchase authorization remaining available $ 1.0          
Reissuance of shares for employee benefit plan 500,000       700,000  
UMass Joint Venture            
Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items]            
Ownership percentage by noncontrolling owners           18.90%
Treasury Stock, at Cost            
Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items]            
Purchases of treasury stock- shares 0       0  
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUPPLEMENTAL CASH FLOW & OTHER DATA (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]    
Depreciation expense $ 87 $ 81
Amortization expense 29 26
Depreciation and amortization expense 116 107
Interest expense (49) (37)
Interest income 6 2
Interest expense, net (43) (35)
Interest paid 44 32
Income taxes paid 3 33
Accounts payable associated with capital expenditures 28 22
Dividends payable 84 80
Fair value of assets acquired 155 31
Fair value of liabilities assumed 7 0
Fair value of net assets acquired 148 31
Merger consideration payable (6) 0
Cash paid for business acquisitions 142 31
Less: Cash acquired 0 0
Business acquisitions, net of cash acquired 142 31
Leases:    
Leased assets obtained in exchange for new operating lease liabilities 35 44
Changes in bank overdrafts $ (51) $ 33
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES (Details)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Oct. 31, 2023
USD ($)
Oct. 31, 2022
USD ($)
Nov. 30, 2021
USD ($)
Dec. 31, 2020
claim
Oct. 31, 2020
claim
Loss Contingencies [Line Items]              
Self-insurance reserves $ 166,000,000 $ 173,000,000          
Excludes general and professional liability claims              
Loss Contingencies [Line Items]              
Litigation reserves 1,000,000 $ 6,000,000          
Secured Receivables Credit Facility              
Debt Instrument [Line Items]              
Credit facility capacity     $ 525,000,000 $ 525,000,000      
Letters of credit outstanding, amount $ 73,000,000            
Senior Unsecured Revolving Credit Facility              
Debt Instrument [Line Items]              
Credit facility capacity         $ 750,000,000    
401(k) Plan Lawsuit | Pending Litigation              
Loss Contingencies [Line Items]              
Class action lawsuits | claim           2 2
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS SEGMENT INFORMATION (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Percentage of net revenues 100.00% 100.00%
Total net revenues $ 2,366 $ 2,331
Total operating income 300 305
Non-operating expense, net (34) (28)
Income before income taxes and equity in earnings of equity method investees 266 277
Income tax expense (66) (65)
Equity in earnings of equity method investees, net of taxes 8 5
Net income 208 217
Less: Net income attributable to noncontrolling interests 14 15
Net income attributable to Quest Diagnostics $ 194 $ 202
DIS business    
Segment Reporting Information [Line Items]    
Percentage of net revenues 97.00% 97.00%
Total net revenues $ 2,298 $ 2,259
Total operating income $ 373 $ 374
DIS business | Minimum    
Segment Reporting Information [Line Items]    
Percentage of net revenues 95.00% 95.00%
All other operating segments    
Segment Reporting Information [Line Items]    
Total net revenues $ 68 $ 72
Total operating income 9 8
General corporate activities    
Segment Reporting Information [Line Items]    
Total operating income $ (82) $ (77)
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE RECOGNITION (Details)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Percentage of net revenues 100.00% 100.00%  
Net accounts receivable 100.00%   100.00%
DIS business      
Segment Reporting Information [Line Items]      
Percentage of net revenues 97.00% 97.00%  
Net accounts receivable 96.00%   96.00%
DIS business | Healthcare Insurers      
Segment Reporting Information [Line Items]      
Percentage of net revenues 40.00% 40.00%  
Net accounts receivable 28.00%   24.00%
DIS business | Healthcare Insurers | Fee-for-service      
Segment Reporting Information [Line Items]      
Percentage of net revenues 37.00% 37.00%  
DIS business | Healthcare Insurers | Capitated      
Segment Reporting Information [Line Items]      
Percentage of net revenues 3.00% 3.00%  
DIS business | Government Payers      
Segment Reporting Information [Line Items]      
Percentage of net revenues 12.00% 12.00%  
Net accounts receivable 7.00%   7.00%
DIS business | Client Payers      
Segment Reporting Information [Line Items]      
Percentage of net revenues 33.00% 33.00%  
Net accounts receivable 40.00%   45.00%
DIS business | Patients (including coinsurance and deductible responsibilities)      
Segment Reporting Information [Line Items]      
Percentage of net revenues 12.00% 12.00%  
Net accounts receivable 21.00%   20.00%
DIS business | Minimum      
Segment Reporting Information [Line Items]      
Percentage of net revenues 95.00% 95.00%  
All other operating segments | DS Businesses      
Segment Reporting Information [Line Items]      
Percentage of net revenues 3.00% 3.00%  
Net accounts receivable 4.00%   4.00%
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUBSEQUENT EVENTS (Details) - Subsequent Event - Senior Notes - Four point two five percent Senior Notes Due 2024
 1 Months Ended
Apr. 24, 2024
USD ($)
Subsequent Event [Line Items]  
Debt instrument, interest rate 4.25%
Amount outstanding $ 300,000,000
Extinguishment of debt $ 300,000,000
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 130 219 1 false 49 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://questdiagnostics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 2 false false R3.htm 0000003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 7 false false R8.htm 0000008 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS DESCRIPTION OF BUSINESS Notes 8 false false R9.htm 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 0000010 - Disclosure - EARNINGS PER SHARE Sheet http://questdiagnostics.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 10 false false R11.htm 0000011 - Disclosure - RESTRUCTURING ACTIVITIES Sheet http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES RESTRUCTURING ACTIVITIES Notes 11 false false R12.htm 0000012 - Disclosure - BUSINESS ACQUISITIONS Sheet http://questdiagnostics.com/role/BUSINESSACQUISITIONS BUSINESS ACQUISITIONS Notes 12 false false R13.htm 0000013 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 13 false false R14.htm 0000014 - Disclosure - DEBT Sheet http://questdiagnostics.com/role/DEBT DEBT Notes 14 false false R15.htm 0000015 - Disclosure - FINANCIAL INSTRUMENTS Sheet http://questdiagnostics.com/role/FINANCIALINSTRUMENTS FINANCIAL INSTRUMENTS Notes 15 false false R16.htm 0000016 - Disclosure - STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Sheet http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Notes 16 false false R17.htm 0000017 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA Sheet http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATA SUPPLEMENTAL CASH FLOW & OTHER DATA Notes 17 false false R18.htm 0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 0000019 - Disclosure - BUSINESS SEGMENT INFORMATION Sheet http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION BUSINESS SEGMENT INFORMATION Notes 19 false false R20.htm 0000020 - Disclosure - REVENUE RECOGNITION Sheet http://questdiagnostics.com/role/REVENUERECOGNITION REVENUE RECOGNITION Notes 20 false false R21.htm 0000021 - Disclosure - SUBSEQUENT EVENTS Sheet http://questdiagnostics.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 24 false false R25.htm 9954472 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://questdiagnostics.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://questdiagnostics.com/role/EARNINGSPERSHARE 25 false false R26.htm 9954473 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS 26 false false R27.htm 9954474 - Disclosure - FINANCIAL INSTRUMENTS (Tables) Sheet http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables FINANCIAL INSTRUMENTS (Tables) Tables http://questdiagnostics.com/role/FINANCIALINSTRUMENTS 27 false false R28.htm 9954475 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables) Sheet http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATATables SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables) Tables http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATA 28 false false R29.htm 9954476 - Disclosure - BUSINESS SEGMENT INFORMATION (Tables) Sheet http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables BUSINESS SEGMENT INFORMATION (Tables) Tables http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION 29 false false R30.htm 9954477 - Disclosure - REVENUE RECOGNITION (Tables) Sheet http://questdiagnostics.com/role/REVENUERECOGNITIONTables REVENUE RECOGNITION (Tables) Tables http://questdiagnostics.com/role/REVENUERECOGNITION 30 false false R31.htm 9954478 - Disclosure - EARNINGS PER SHARE (Details) Sheet http://questdiagnostics.com/role/EARNINGSPERSHAREDetails EARNINGS PER SHARE (Details) Details http://questdiagnostics.com/role/EARNINGSPERSHARETables 31 false false R32.htm 9954479 - Disclosure - RESTRUCTURING ACTIVITIES (Details) Sheet http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails RESTRUCTURING ACTIVITIES (Details) Details http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES 32 false false R33.htm 9954480 - Disclosure - BUSINESS ACQUISITIONS (Details) Sheet http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails BUSINESS ACQUISITIONS (Details) Details http://questdiagnostics.com/role/BUSINESSACQUISITIONS 33 false false R34.htm 9954481 - Disclosure - FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details) Sheet http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details) Details http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables 34 false false R35.htm 9954482 - Disclosure - FAIR VALUE MEASUREMENTS (Narrative) (Details) Sheet http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails FAIR VALUE MEASUREMENTS (Narrative) (Details) Details http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables 35 false false R36.htm 9954483 - Disclosure - FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Assets and Liabilities Unobservable Inputs) (Details) Sheet http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Assets and Liabilities Unobservable Inputs) (Details) Details http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables 36 false false R37.htm 9954484 - Disclosure - DEBT (Details) Sheet http://questdiagnostics.com/role/DEBTDetails DEBT (Details) Details http://questdiagnostics.com/role/DEBT 37 false false R38.htm 9954485 - Disclosure - FINANCIAL INSTRUMENTS (Balance Sheets) (Details) Sheet http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails FINANCIAL INSTRUMENTS (Balance Sheets) (Details) Details http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables 38 false false R39.htm 9954486 - Disclosure - STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details) Sheet http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details) Details http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST 39 false false R40.htm 9954487 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Details) Sheet http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails SUPPLEMENTAL CASH FLOW & OTHER DATA (Details) Details http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATATables 40 false false R41.htm 9954488 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES 41 false false R42.htm 9954489 - Disclosure - BUSINESS SEGMENT INFORMATION (Details) Sheet http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails BUSINESS SEGMENT INFORMATION (Details) Details http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables 42 false false R43.htm 9954490 - Disclosure - REVENUE RECOGNITION (Details) Sheet http://questdiagnostics.com/role/REVENUERECOGNITIONDetails REVENUE RECOGNITION (Details) Details http://questdiagnostics.com/role/REVENUERECOGNITIONTables 43 false false R44.htm 9954491 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://questdiagnostics.com/role/SUBSEQUENTEVENTS 44 false false All Reports Book All Reports dgx-20240331.htm dgx-20240331.xsd dgx-20240331_cal.xml dgx-20240331_def.xml dgx-20240331_lab.xml dgx-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dgx-20240331.htm": { "nsprefix": "dgx", "nsuri": "http://questdiagnostics.com/20240331", "dts": { "inline": { "local": [ "dgx-20240331.htm" ] }, "schema": { "local": [ "dgx-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "dgx-20240331_cal.xml" ] }, "definitionLink": { "local": [ "dgx-20240331_def.xml" ] }, "labelLink": { "local": [ "dgx-20240331_lab.xml" ] }, "presentationLink": { "local": [ "dgx-20240331_pre.xml" ] } }, "keyStandard": 206, "keyCustom": 13, "axisStandard": 21, "axisCustom": 1, "memberStandard": 25, "memberCustom": 24, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 130, "entityCount": 1, "segmentCount": 49, "elementCount": 458, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 479, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://questdiagnostics.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000002 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "unique": true } }, "R3": { "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "0000003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "unique": true } }, "R4": { "role": "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetCreditLossExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "unique": true } }, "R7": { "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-25", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-25", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS", "longName": "0000008 - Disclosure - DESCRIPTION OF BUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://questdiagnostics.com/role/EARNINGSPERSHARE", "longName": "0000010 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES", "longName": "0000011 - Disclosure - RESTRUCTURING ACTIVITIES", "shortName": "RESTRUCTURING ACTIVITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://questdiagnostics.com/role/BUSINESSACQUISITIONS", "longName": "0000012 - Disclosure - BUSINESS ACQUISITIONS", "shortName": "BUSINESS ACQUISITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS", "longName": "0000013 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://questdiagnostics.com/role/DEBT", "longName": "0000014 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTS", "longName": "0000015 - Disclosure - FINANCIAL INSTRUMENTS", "shortName": "FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST", "longName": "0000016 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST", "shortName": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATA", "longName": "0000017 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA", "shortName": "SUPPLEMENTAL CASH FLOW & OTHER DATA", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION", "longName": "0000019 - Disclosure - BUSINESS SEGMENT INFORMATION", "shortName": "BUSINESS SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://questdiagnostics.com/role/REVENUERECOGNITION", "longName": "0000020 - Disclosure - REVENUE RECOGNITION", "shortName": "REVENUE RECOGNITION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://questdiagnostics.com/role/SUBSEQUENTEVENTS", "longName": "0000021 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://questdiagnostics.com/role/EARNINGSPERSHARETables", "longName": "9954472 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "9954473 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables", "longName": "9954474 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "dgx:ScheduleofDebtInstrumentFairValueBasisAdjustmentAttributabletoHedgedDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dgx:ScheduleofDebtInstrumentFairValueBasisAdjustmentAttributabletoHedgedDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATATables", "longName": "9954475 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables)", "shortName": "SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables", "longName": "9954476 - Disclosure - BUSINESS SEGMENT INFORMATION (Tables)", "shortName": "BUSINESS SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://questdiagnostics.com/role/REVENUERECOGNITIONTables", "longName": "9954477 - Disclosure - REVENUE RECOGNITION (Tables)", "shortName": "REVENUE RECOGNITION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails", "longName": "9954478 - Disclosure - EARNINGS PER SHARE (Details)", "shortName": "EARNINGS PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "unique": true } }, "R32": { "role": "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails", "longName": "9954479 - Disclosure - RESTRUCTURING ACTIVITIES (Details)", "shortName": "RESTRUCTURING ACTIVITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-42", "name": "dgx:RestructuringAndRelatedActivitiesTargetPercentForAnnualProductivitySavings", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-42", "name": "dgx:RestructuringAndRelatedActivitiesTargetPercentForAnnualProductivitySavings", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails", "longName": "9954480 - Disclosure - BUSINESS ACQUISITIONS (Details)", "shortName": "BUSINESS ACQUISITIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails", "longName": "9954481 - Disclosure - FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details)", "shortName": "FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-56", "name": "us-gaap:TradingSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "unique": true } }, "R35": { "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "longName": "9954482 - Disclosure - FAIR VALUE MEASUREMENTS (Narrative) (Details)", "shortName": "FAIR VALUE MEASUREMENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails", "longName": "9954483 - Disclosure - FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Assets and Liabilities Unobservable Inputs) (Details)", "shortName": "FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Assets and Liabilities Unobservable Inputs) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-73", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-74", "name": "dgx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesAdditionsAndIssuances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "unique": true } }, "R37": { "role": "http://questdiagnostics.com/role/DEBTDetails", "longName": "9954484 - Disclosure - DEBT (Details)", "shortName": "DEBT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-81", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-81", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "longName": "9954485 - Disclosure - FINANCIAL INSTRUMENTS (Balance Sheets) (Details)", "shortName": "FINANCIAL INSTRUMENTS (Balance Sheets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-82", "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-82", "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails", "longName": "9954486 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details)", "shortName": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails", "longName": "9954487 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Details)", "shortName": "SUPPLEMENTAL CASH FLOW & OTHER DATA (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954488 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:MalpracticeLossContingencyAccrualUndiscounted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:MalpracticeLossContingencyAccrualUndiscounted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "longName": "9954489 - Disclosure - BUSINESS SEGMENT INFORMATION (Details)", "shortName": "BUSINESS SEGMENT INFORMATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "dgx:PercentageofNetRevenues", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "unique": true } }, "R43": { "role": "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails", "longName": "9954490 - Disclosure - REVENUE RECOGNITION (Details)", "shortName": "REVENUE RECOGNITION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "dgx:PercentageofNetRevenues", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "dgx:PercentageofNetAccountsReceivable", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "unique": true } }, "R44": { "role": "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails", "longName": "9954491 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-130", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-130", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dgx-20240331.htm", "first": true, "unique": true } } }, "tag": { "dgx_A401kPlanLawsuitMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "A401kPlanLawsuitMember", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "401(k) Plan Lawsuit", "label": "401(k) Plan Lawsuit [Member]", "documentation": "401(k) Plan Lawsuit" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Expenses", "verboseLabel": "Accounts Payable and Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities [Member]", "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "dgx_AccountsReceivableDisaggregationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "AccountsReceivableDisaggregationTableTextBlock", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable Disaggregation", "label": "Accounts Receivable Disaggregation [Table Text Block]", "documentation": "Accounts Receivable Disaggregation [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowance for credit losses of $28 and $27 as of March\u00a031, 2024 and December\u00a031, 2023, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r280", "r281" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r31", "r32", "r120", "r181", "r507", "r545", "r546" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r12", "r32", "r449", "r452", "r482", "r541", "r542", "r736", "r737", "r738", "r747", "r748", "r749" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r692" ] }, "dgx_AdditionalBasedOnRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "AdditionalBasedOnRevenueMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional, Based on Revenue", "label": "Additional, Based on Revenue [Member]", "documentation": "Additional, Based on Revenue" } } }, "auth_ref": [] }, "dgx_AdditionalImpactMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "AdditionalImpactMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Impact", "label": "Additional Impact [Member]", "documentation": "Additional Impact" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r115" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r425", "r426", "r427", "r551", "r747", "r748", "r749", "r769", "r784" ] }, "dgx_AdditionalReimbursementCoverageMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "AdditionalReimbursementCoverageMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional, Reimbursement Coverage", "label": "Additional, Reimbursement Coverage [Member]", "documentation": "Additional, Reimbursement Coverage" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r698" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r698" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r698" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r698" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r69", "r70", "r397" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r663", "r674", "r684", "r709" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r666", "r677", "r687", "r712" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r698" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r705" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r670", "r678", "r688", "r705", "r713", "r717", "r725" ] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllOtherSegmentsMember", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All other operating segments", "label": "Other Segments [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r248", "r264", "r265", "r266", "r267", "r268" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r723" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r182", "r282", "r288" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 }, "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "parentTag": "us-gaap_DepreciationDepletionAndAmortization", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of intangible assets", "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r53", "r57" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options and performance share units (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r242" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r148", "r178", "r210", "r251", "r266", "r272", "r285", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r440", "r444", "r468", "r503", "r574", "r640", "r654", "r765", "r766", "r772" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r173", "r184", "r210", "r285", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r440", "r444", "r468", "r640", "r765", "r766", "r772" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r99" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Available-for-sale debt securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r283", "r290", "r495", "r752" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r720" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r721" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r716" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r716" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r716" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r716" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r716" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r716" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r719" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r717" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r717" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r90", "r93" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r434", "r634", "r635" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r71", "r72", "r434", "r634", "r635" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r434" ] }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, expected tax deductible amount", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Consideration", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r0", "r1", "r11" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in contingent consideration liability", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r438", "r743" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum contingent consideration payment", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r77" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r2", "r76", "r437" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement input", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r464" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONS" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS ACQUISITIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r142", "r435" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r73", "r74" ] }, "dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations [Abstract]", "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable associated with capital expenditures", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "dgx_CapitatedMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "CapitatedMember", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitated", "label": "Capitated [Member]", "documentation": "Capitated [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAcquiredFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: Cash acquired", "label": "Cash Acquired from Acquisition", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)." } } }, "auth_ref": [ "r34" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r38", "r175", "r616" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r130", "r206" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r130" ] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATA" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL CASH FLOW & OTHER DATA", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r128" ] }, "us-gaap_CashSurrenderValueFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashSurrenderValueFairValueDisclosure", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash surrender value of life insurance policies", "label": "Cash Surrender Value, Fair Value Disclosure", "documentation": "Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI)." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r696" ] }, "dgx_ChangingComparableCompanyRevenueVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "ChangingComparableCompanyRevenueVolatilityMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changing Comparable Company Revenue Volatility", "label": "Changing Comparable Company Revenue Volatility [Member]", "documentation": "Changing Comparable Company Revenue Volatility" } } }, "auth_ref": [] }, "dgx_ChangingDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "ChangingDiscountRateMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changing Discount Rate", "label": "Changing Discount Rate [Member]", "documentation": "Changing Discount Rate" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dgx_ClientPayersMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "ClientPayersMember", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Client Payers", "label": "Client Payers [Member]", "documentation": "Client Payers [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r697" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r697" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r26", "r107", "r505", "r561" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r135", "r319", "r320", "r612", "r759" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends per common share", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r140" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r643", "r644", "r645", "r647", "r648", "r649", "r650", "r747", "r748", "r769", "r782", "r784" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r114" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r114", "r562" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r114" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r114", "r562", "r580", "r784", "r785" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value $0.01 per share; 600 shares authorized as of both March\u00a031, 2024 and December\u00a031, 2023; 162 shares issued as of both March\u00a031, 2024 and December\u00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r114", "r506", "r640" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r702" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r701" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r703" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r700" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to Quest Diagnostics", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r33", "r187", "r189", "r197", "r499", "r519" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Comprehensive income attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r7", "r81", "r84", "r187", "r189", "r196", "r498", "r518" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r84", "r143", "r187", "r189", "r195", "r497", "r517" ] }, "dgx_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "ContingentConsiderationMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Contingent Consideration [Member]", "documentation": "Contingent Consideration [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetCreditLossExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetCreditLossExpense", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision (credit) for credit losses", "label": "Contract with Customer, Asset, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r289", "r386", "r629" ] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateMember", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General corporate activities", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r751" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of services", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r124", "r210", "r285", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r468", "r765" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenueAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating costs and expenses and other operating income:", "label": "Cost of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of services", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating costs and expenses, net", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r123" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r75" ] }, "dgx_DSBusinessesMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "DSBusinessesMember", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DS Businesses", "label": "DS Businesses [Member]", "documentation": "DS Businesses [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://questdiagnostics.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r136", "r208", "r336", "r342", "r343", "r344", "r345", "r346", "r347", "r352", "r359", "r360", "r362" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://questdiagnostics.com/role/DEBTDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r19", "r110", "r111", "r149", "r151", "r212", "r337", "r338", "r339", "r340", "r341", "r343", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r478", "r623", "r624", "r625", "r626", "r627", "r744" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount outstanding", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r19", "r151", "r363" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r104", "r106", "r337", "r478", "r624", "r625" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of debt", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r350", "r467", "r624", "r625" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://questdiagnostics.com/role/DEBTDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r23", "r338" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://questdiagnostics.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r212", "r337", "r338", "r339", "r340", "r341", "r343", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r361", "r478", "r623", "r624", "r625", "r626", "r627", "r744" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://questdiagnostics.com/role/DEBTDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r24", "r212", "r337", "r338", "r339", "r340", "r341", "r343", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r478", "r623", "r624", "r625", "r626", "r627", "r744" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://questdiagnostics.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r24", "r64", "r65", "r103", "r104", "r106", "r109", "r138", "r139", "r212", "r337", "r338", "r339", "r340", "r341", "r343", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r361", "r478", "r623", "r624", "r625", "r626", "r627", "r744" ] }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation liabilities", "label": "Deferred Compensation Liability, Classified, Noncurrent", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax benefit", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r141", "r165", "r432", "r433", "r746" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "parentTag": "us-gaap_DepreciationDepletionAndAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r58" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r256" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL INSTRUMENTS", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r145", "r447", "r454" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r14", "r91", "r94" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r454" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r14", "r85", "r86", "r87", "r89", "r92", "r94", "r95", "r97", "r98", "r454" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Financial Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r14", "r85", "r86", "r89", "r96", "r211" ] }, "dgx_DescriptionOfBusinessAbstract": { "xbrltype": "stringItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "DescriptionOfBusinessAbstract", "lang": { "en-us": { "role": { "terseLabel": "Description of Business (Abstract)", "label": "Description of Business (Abstract)", "documentation": "Description of Business (Abstract)" } } }, "auth_ref": [] }, "dgx_DiagnosticInformationServicesBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "DiagnosticInformationServicesBusinessMember", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DIS business", "label": "Diagnostic Information Services Business [Member]", "documentation": "Diagnostic Information Services Business [Member]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r768" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends declared", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r140" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable", "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r111", "r112", "r150", "r651", "r780" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r658" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r691" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share attributable to Quest Diagnostics\u2019 common stockholders:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r198", "r218", "r219", "r220", "r221", "r222", "r227", "r229", "r239", "r240", "r241", "r245", "r457", "r458", "r500", "r520", "r619" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r198", "r218", "r219", "r220", "r221", "r222", "r229", "r239", "r240", "r241", "r245", "r457", "r458", "r500", "r520", "r619" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r43", "r44" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS (LOSS) PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r226", "r242", "r243", "r244" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r656" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r656" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r656" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r730" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r656" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r656" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r656" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r656" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r169", "r190", "r191", "r192", "r213", "r214", "r215", "r217", "r223", "r225", "r246", "r286", "r287", "r376", "r425", "r426", "r427", "r429", "r430", "r448", "r449", "r450", "r451", "r452", "r453", "r456", "r469", "r471", "r472", "r473", "r474", "r475", "r482", "r541", "r542", "r543", "r551", "r600" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in equity method investees", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r261", "r284", "r734", "r753" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r699" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r663", "r674", "r684", "r709" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r660", "r671", "r681", "r706" ] }, "dgx_ExcludesgeneralandprofessionalliabilityclaimsMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "ExcludesgeneralandprofessionalliabilityclaimsMember", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excludes general and professional liability claims", "label": "Excludes general and professional liability claims [Member]", "documentation": "Excludes general and professional liability claims [Member]" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r705" ] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extinguishment of debt", "label": "Extinguishment of Debt, Amount", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r99", "r101", "r102" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r350", "r390", "r391", "r392", "r393", "r394", "r395", "r461", "r486", "r487", "r488", "r624", "r625", "r631", "r632", "r633" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r100", "r147" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r460", "r461", "r463", "r464", "r466" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r459" ] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueHedgingMember", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedging", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r88" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets / Liabilities, Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r350", "r390", "r395", "r461", "r486", "r631", "r632", "r633" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs, Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r350", "r390", "r395", "r461", "r487", "r624", "r625", "r631", "r632", "r633" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Significant Unobservable Inputs, Level 3", "terseLabel": "Fair Value, Inputs, Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r350", "r390", "r391", "r392", "r393", "r394", "r395", "r461", "r488", "r624", "r625", "r631", "r632", "r633" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r15", "r100" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement Inputs", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r146" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total fair value adjustments included in earnings - realized/unrealized", "negatedTerseLabel": "Total fair value adjustments included in earnings - realized/unrealized", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r465" ] }, "dgx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesAdditionsAndIssuances": { "xbrltype": "monetaryItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesAdditionsAndIssuances", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases, additions and issuances", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Additions and Issuances", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Additions and Issuances" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability", "periodStartLabel": "Balance, December 31, 2023", "periodEndLabel": "Balance, March 31, 2024", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r350", "r390", "r391", "r392", "r393", "r394", "r395", "r486", "r487", "r488", "r624", "r625", "r631", "r632", "r633" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring Basis", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r459", "r466" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofAssetsandLiabilitiesUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r15", "r17" ] }, "us-gaap_FairValueOfAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfAssetsAcquired", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "parentTag": "dgx_FairValueOfNetAssetsAcquired", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of assets acquired", "label": "Fair Value of Assets Acquired", "documentation": "The fair value of assets acquired in noncash investing or financing activities." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "dgx_FairValueOfNetAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "FairValueOfNetAssetsAcquired", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "totalLabel": "Fair value of net assets acquired", "label": "Fair value of net assets acquired", "documentation": "Fair value of net assets acquired" } } }, "auth_ref": [] }, "dgx_FeeforserviceMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "FeeforserviceMember", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fee-for-service", "label": "Fee-for-service [Member]", "documentation": "Fee-for-service [Member]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r492", "r493" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r54", "r56" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r667", "r678", "r688", "r713" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r667", "r678", "r688", "r713" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r667", "r678", "r688", "r713" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r667", "r678", "r688", "r713" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r667", "r678", "r688", "r713" ] }, "dgx_FourpointtwofivepercentSeniorNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "FourpointtwofivepercentSeniorNotesDue2024Member", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Four point two five percent Senior Notes Due 2024", "label": "Four point two five percent Senior Notes Due 2024 [Member]", "documentation": "Four point two five percent Senior Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails", "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r176", "r291", "r494", "r622", "r640", "r755", "r756" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill acquired during the period", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r294", "r622" ] }, "dgx_GovernmentPayersMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "GovernmentPayersMember", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government Payers", "label": "Government Payers [Member]", "documentation": "Government Payers [Member]" } } }, "auth_ref": [] }, "dgx_HaystackOncologyIncMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "HaystackOncologyIncMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Haystack Oncology, Inc.", "label": "Haystack Oncology, Inc. [Member]", "documentation": "Haystack Oncology, Inc." } } }, "auth_ref": [] }, "dgx_HealthcareInsurersMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "HealthcareInsurersMember", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Healthcare Insurers", "label": "Healthcare Insurers [Member]", "documentation": "Healthcare Insurers [Member]" } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedge Accounting Basis Adjustment", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": [ "r446" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts attributable to Quest Diagnostics\u2019 common stockholders:", "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes and equity in earnings of equity method investees", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r251", "r265", "r271", "r274", "r521", "r620" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in earnings of equity method investees, net of taxes", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r9", "r121", "r154", "r258", "r284", "r512" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r159", "r166", "r224", "r225", "r259", "r428", "r431", "r522" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r37", "r39" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r8" ] }, "dgx_IncreaseDecreaseInBankOverdrafts": { "xbrltype": "monetaryItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "IncreaseDecreaseInBankOverdrafts", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in bank overdrafts", "label": "Increase (Decrease) in Bank Overdrafts", "documentation": "Increase (Decrease) in Bank Overdrafts" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets and liabilities, net", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Non-controlling Interest [Abstract]", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options and performance share units", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r230", "r231", "r232", "r241", "r398" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r670", "r678", "r688", "r705", "r713", "r717", "r725" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r723" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r659", "r729" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r659", "r729" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r659", "r729" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r52", "r55" ] }, "us-gaap_InterestAndDividendIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndDividendIncomeOperating", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest and Dividend Income, Operating", "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein." } } }, "auth_ref": [ "r156", "r786" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r105", "r158", "r193", "r255", "r477", "r585", "r652", "r783" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "totalLabel": "Interest expense, net", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r157" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r201", "r204", "r205" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r183", "r617", "r640" ] }, "dgx_InvigorateProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "InvigorateProgramMember", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Invigorate Program", "label": "Invigorate Program [Member]", "documentation": "Invigorate Program [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Leases:", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "dgx_LencoDiagnosticsLaboratoriesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "LencoDiagnosticsLaboratoriesIncMember", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lenco Diagnostics Laboratories, Inc.", "label": "Lenco Diagnostics Laboratories, Inc. [Member]", "documentation": "Lenco Diagnostics Laboratories, Inc." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding, amount", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r119", "r153", "r510", "r640", "r745", "r754", "r771" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAssumed1", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "parentTag": "dgx_FairValueOfNetAssetsAcquired", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of liabilities assumed", "label": "Liabilities Assumed", "documentation": "The fair value of liabilities assumed in noncash investing or financing activities." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r22", "r174", "r210", "r285", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r441", "r444", "r445", "r468", "r640", "r765", "r772", "r773" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r99" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r20" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserve", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation reserves", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": [ "r26", "r760" ] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusAxis", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r760" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusDomain", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r760" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r19", "r504" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r180" ] }, "us-gaap_LongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMember", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Long-Term Debt [Member]", "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://questdiagnostics.com/role/DEBTDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r24" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://questdiagnostics.com/role/DEBTDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r24", "r59" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r321", "r322", "r323", "r326", "r761", "r762" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r321", "r322", "r323", "r326", "r761", "r762" ] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class action lawsuits", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r761", "r762" ] }, "us-gaap_MalpracticeLossContingencyAccrualUndiscounted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MalpracticeLossContingencyAccrualUndiscounted", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Self-insurance reserves", "label": "Malpractice Loss Contingency, Accrual, Undiscounted", "documentation": "Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period." } } }, "auth_ref": [ "r760" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r697" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r697" ] }, "dgx_MeasurementInputComparableCompanyRevenueVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "MeasurementInputComparableCompanyRevenueVolatilityMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Comparable Company Revenue Volatility", "label": "Measurement Input, Comparable Company Revenue Volatility [Member]", "documentation": "Measurement Input, Comparable Company Revenue Volatility [Member]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r770" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r462" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "dgx_MergerConsiderationPaidPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "MergerConsiderationPaidPayableNet", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Merger consideration payable", "label": "Merger Consideration Paid (Payable), Net", "documentation": "Merger Consideration Paid (Payable), Net" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r322", "r323", "r324", "r325", "r396", "r490", "r540", "r553", "r554", "r605", "r606", "r607", "r608", "r609", "r613", "r614", "r621", "r628", "r636", "r642", "r767", "r774", "r775", "r776", "r777", "r778", "r779" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r30", "r152", "r210", "r285", "r327", "r329", "r330", "r331", "r334", "r335", "r468", "r509", "r564" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Distributions to noncontrolling interest partners", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r140" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage by noncontrolling owners", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r716" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r724" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r698" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS" ], "lang": { "en-us": { "role": { "terseLabel": "DESCRIPTION OF BUSINESS", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r160", "r167" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r203" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r203" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r130", "r131", "r132" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 }, "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Quest Diagnostics", "terseLabel": "Net income attributable to Quest Diagnostics", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r122", "r132", "r155", "r172", "r185", "r188", "r192", "r210", "r216", "r218", "r219", "r220", "r221", "r224", "r225", "r237", "r251", "r265", "r271", "r274", "r285", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r458", "r468", "r515", "r582", "r598", "r599", "r620", "r652", "r765" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r83", "r144", "r185", "r188", "r224", "r225", "r514", "r738" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings available to Quest Diagnostics\u2019 common stockholders \u2013 basic and diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r199", "r228", "r233", "r234", "r235", "r236", "r238", "r241" ] }, "dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "NetIncomeLossExcludingRedeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Net income", "label": "Net Income (Loss), Excluding Redeemable Noncontrolling Interest", "documentation": "Net Income (Loss), Excluding Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Standards to be Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r697" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r667", "r678", "r688", "r705", "r713" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r695" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r694" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r705" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r724" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r724" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r79", "r376", "r747", "r748", "r749", "r784" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-operating expense, net", "terseLabel": "Non-operating expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r126" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "verboseLabel": "Total operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r251", "r265", "r271", "r274", "r620" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r480" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r480" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r479" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r177" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive (loss) income", "verboseLabel": "Other comprehensive income (loss), net of taxes", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r13", "r18", "r186", "r189", "r194", "r469", "r470", "r475", "r496", "r516", "r736", "r737" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r132" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r127" ] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other operating expense, net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r697" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r665", "r676", "r686", "r711" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r668", "r679", "r689", "r714" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r668", "r679", "r689", "r714" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Earnings allocated to participating securities", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted", "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": [ "r238" ] }, "dgx_PatientsMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "PatientsMember", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patients (including coinsurance and deductible responsibilities)", "label": "Patients [Member]", "documentation": "Patients [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r693" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other investing activities", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r731", "r739" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r36" ] }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsMinorityInterest", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Distributions to noncontrolling interest partners", "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests." } } }, "auth_ref": [ "r36" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Employee payroll tax withholdings on stock issued under stock-based compensation plans", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r200" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails", "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for business acquisitions", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r35", "r436" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Business acquisitions, net of cash acquired", "terseLabel": "Business acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r35" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r129" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r696" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r696" ] }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PendingLitigationMember", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pending Litigation", "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": [ "r760" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r695" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r705" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r698" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r694" ] }, "dgx_PercentageofNetAccountsReceivable": { "xbrltype": "percentItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "PercentageofNetAccountsReceivable", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net accounts receivable", "label": "Percentage of Net Accounts Receivable", "documentation": "Percentage of Net Accounts Receivable" } } }, "auth_ref": [] }, "dgx_PercentageofNetRevenues": { "xbrltype": "percentItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "PercentageofNetRevenues", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of net revenues", "label": "Percentage of Net Revenues", "documentation": "Percentage of Net Revenues" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r735" ] }, "dgx_PrepaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "PrepaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments to acquire businesses", "label": "Prepayments to Acquire Businesses, Net of Cash Acquired", "documentation": "Prepayments to Acquire Businesses, Net of Cash Acquired" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowings", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r741" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r732", "r740" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r16" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r276", "r491", "r534", "r535", "r536", "r537", "r538", "r539", "r615", "r630", "r641", "r733", "r763", "r764", "r768", "r781" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r276", "r491", "r534", "r535", "r536", "r537", "r538", "r539", "r615", "r630", "r641", "r733", "r763", "r764", "r768", "r781" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r172", "r185", "r188", "r202", "r210", "r216", "r224", "r225", "r251", "r265", "r271", "r274", "r285", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r439", "r442", "r443", "r458", "r468", "r501", "r513", "r550", "r582", "r598", "r599", "r620", "r637", "r638", "r653", "r738", "r765" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r502", "r511", "r640" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r693" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r693" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r322", "r323", "r324", "r325", "r389", "r396", "r421", "r422", "r423", "r489", "r490", "r540", "r553", "r554", "r605", "r606", "r607", "r608", "r609", "r613", "r614", "r621", "r628", "r636", "r642", "r645", "r757", "r767", "r775", "r776", "r777", "r778", "r779" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r322", "r323", "r324", "r325", "r389", "r396", "r421", "r422", "r423", "r489", "r490", "r540", "r553", "r554", "r605", "r606", "r607", "r608", "r609", "r613", "r614", "r621", "r628", "r636", "r642", "r645", "r757", "r767", "r775", "r776", "r777", "r778", "r779" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r660", "r671", "r681", "r706" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interest", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r60", "r61", "r62", "r63" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityFairValue", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interest", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value", "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r60", "r61", "r62", "r63" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r742" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r661", "r672", "r682", "r707" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r662", "r673", "r683", "r708" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r669", "r680", "r690", "r715" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES" ], "lang": { "en-us": { "role": { "terseLabel": "RESTRUCTURING ACTIVITIES", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r306", "r307", "r309", "r312", "r318" ] }, "dgx_RestructuringAndRelatedActivitiesTargetPercentForAnnualProductivitySavings": { "xbrltype": "percentItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "RestructuringAndRelatedActivitiesTargetPercentForAnnualProductivitySavings", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target percent for annual productivity savings", "label": "Restructuring and Related Activities, Target Percent For Annual Productivity Savings", "documentation": "Restructuring and Related Activities, Target Percent For Annual Productivity Savings" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total restructuring charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9", "r313", "r315", "r758" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r308", "r309", "r315", "r316" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r308", "r309", "r310", "r311", "r315", "r316", "r317" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring reserve", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r309", "r314" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r116", "r140", "r508", "r544", "r546", "r548", "r563", "r640" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r169", "r213", "r214", "r215", "r217", "r223", "r225", "r286", "r287", "r425", "r426", "r427", "r429", "r430", "r448", "r450", "r451", "r453", "r456", "r541", "r543", "r551", "r784" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Net revenues", "verboseLabel": "Total net revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r252", "r253", "r264", "r269", "r270", "r276", "r278", "r279", "r385", "r387", "r491" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITION" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE RECOGITION", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r168", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r388" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r481", "r639" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r724" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r724" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r71", "r72", "r434" ] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATATables" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow and Other Data", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r750" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r308", "r309", "r310", "r311", "r315", "r316", "r317" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r48", "r49", "r50", "r51" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Segment Reporting Information by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r48", "r49", "r50", "r51" ] }, "dgx_ScheduleofDebtInstrumentFairValueBasisAdjustmentAttributabletoHedgedDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "ScheduleofDebtInstrumentFairValueBasisAdjustmentAttributabletoHedgedDebtTableTextBlock", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt", "label": "Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt [Table Text Block]", "documentation": "Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt [Table Text Block]" } } }, "auth_ref": [] }, "dgx_ScheduleofStockholdersEquityandRedeemableNoncontrollingInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "ScheduleofStockholdersEquityandRedeemableNoncontrollingInterestLineItems", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items]", "label": "Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items]", "documentation": "[Line Items] for Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table]" } } }, "auth_ref": [] }, "dgx_ScheduleofStockholdersEquityandRedeemableNoncontrollingInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "ScheduleofStockholdersEquityandRedeemableNoncontrollingInterestTable", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table]", "label": "Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table]", "documentation": "Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table]" } } }, "auth_ref": [] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Receivables Credit Facility", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r655" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r657" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r248", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r274", "r279", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r311", "r317", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r622", "r733", "r781" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS SEGMENT INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r247", "r248", "r249", "r250", "r251", "r263", "r268", "r272", "r273", "r274", "r275", "r276", "r277", "r279" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r125" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://questdiagnostics.com/role/DEBTDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "dgx_SeniorunsecuredrevolvingcreditfacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "SeniorunsecuredrevolvingcreditfacilityMember", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Revolving Credit Facility", "label": "Senior unsecured revolving credit facility [Member]", "documentation": "Senior unsecured revolving credit facility [Member]" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax restructuring charges", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r133", "r207" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r171", "r248", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r274", "r279", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r305", "r311", "r317", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r622", "r733", "r781" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r29", "r169", "r190", "r191", "r192", "r213", "r214", "r215", "r217", "r223", "r225", "r246", "r286", "r287", "r376", "r425", "r426", "r427", "r429", "r430", "r448", "r449", "r450", "r451", "r452", "r453", "r456", "r469", "r471", "r472", "r473", "r474", "r475", "r482", "r541", "r542", "r543", "r551", "r600" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r213", "r214", "r215", "r246", "r491", "r547", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r562", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r575", "r576", "r577", "r578", "r579", "r581", "r583", "r584", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r600", "r646" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r213", "r214", "r215", "r246", "r491", "r547", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r562", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r575", "r576", "r577", "r578", "r579", "r581", "r583", "r584", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r600", "r646" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r664", "r675", "r685", "r710" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under benefit plans, shares", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r13", "r113", "r114", "r140" ] }, "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reissuance of shares for employee benefit plan", "label": "Stock Issued During Period, Shares, Treasury Stock Reissued", "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement." } } }, "auth_ref": [ "r13", "r114", "r140" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under benefit plans", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r68", "r113", "r114", "r140" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r13", "r29", "r140" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share repurchase authorization remaining available", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total Quest Diagnostics stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r114", "r117", "r118", "r134", "r564", "r580", "r601", "r602", "r640", "r654", "r745", "r754", "r771", "r784" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Quest Diagnostics stockholders\u2019 equity:", "terseLabel": "Stockholders' Equity Attributable to Parent [Abstract]", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance, value", "periodEndLabel": "Balance, value", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r79", "r80", "r82", "r169", "r170", "r191", "r213", "r214", "r215", "r217", "r223", "r286", "r287", "r376", "r425", "r426", "r427", "r429", "r430", "r448", "r449", "r450", "r451", "r452", "r453", "r456", "r469", "r471", "r475", "r482", "r542", "r543", "r549", "r564", "r580", "r601", "r602", "r610", "r653", "r745", "r754", "r771", "r784" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r137", "r209", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r455", "r603", "r604", "r611" ] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsAxis", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsDomain", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Domain]", "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r476", "r484" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r476", "r484" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r476", "r484" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r476", "r484" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r476", "r484" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r483", "r485" ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Elements [Abstract]", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r704" ] }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, Value", "periodEndLabel": "Balance, Value", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r27", "r210", "r285", "r468" ] }, "us-gaap_TemporaryEquityNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityNetIncome", "crdr": "credit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Net income", "label": "Temporary Equity, Net Income", "documentation": "The portion of net income or loss attributable to temporary equity interest." } } }, "auth_ref": [] }, "dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to noncontrolling interest partners", "label": "Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders" } } }, "auth_ref": [] }, "dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member", "presentation": [ "http://questdiagnostics.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.50% Senior Notes due March 2025", "label": "Three Point Five Zero Percent Senior Notes due March 2025 [Member]", "documentation": "Three Point Five Zero Percent Senior Notes due March 2025 [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r696" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r703" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r723" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r725" ] }, "us-gaap_TradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradingSecurities", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation trading securities", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r108", "r179", "r618" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r726" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r727" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r725" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r725" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r728" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r726" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, at Cost", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of treasury stock- shares", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r13", "r114", "r140" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost; 51 shares as of both March\u00a031, 2024 and December\u00a031, 2023", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r28", "r66", "r67" ] }, "dgx_TriggeringEventAxis": { "xbrltype": "stringItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "TriggeringEventAxis", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Triggering Event [Axis]", "label": "Triggering Event [Axis]", "documentation": "Triggering Event" } } }, "auth_ref": [] }, "dgx_TriggeringEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "TriggeringEventDomain", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Triggering Event [Domain]", "label": "Triggering Event [Domain]", "documentation": "Triggering Event" } } }, "auth_ref": [] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r308", "r309", "r315", "r316" ] }, "dgx_UMassJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://questdiagnostics.com/20240331", "localname": "UMassJointVentureMember", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UMass Joint Venture", "label": "UMass Joint Venture [Member]", "documentation": "UMass Joint Venture [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r722" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use Of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r45", "r46", "r47", "r161", "r162", "r163", "r164" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Shares)", "totalLabel": "Weighted average common shares outstanding - diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r228", "r241" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Shares)", "verboseLabel": "Weighted average common shares outstanding - basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r227", "r241" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.27(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "14", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "15", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//230/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//820/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.1-5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EE" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39" } } } ZIP 65 0001022079-24-000099-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001022079-24-000099-xbrl.zip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

* MRDP970@ II-VV,&J.03,D89VDIE448? 'NOKX/.6[F_E2\\XR^*,Y!('?DHP M82G#J>UM/(JK/HT 7MD9MZ*N"L0"=TGX M<+_S@%]7#F:]Z+2>Y &0$Y?Q\%_A,9'KO^B*ES=SY7H]+K\L7@H]+ADXW;AO MC9$W)-BPXUZPPP$15SB!FE%11159?BK^V:_H2F0IB)V&Q'="XXF%DXZ!%7YU0U8JR90"TN7"9< D [ MR[DTH3EQVB5 #*>9EY"7;<=9M=L%%*+\7"S$W5H\ES,2>LJI]23.\TPJ+Y?% M. ]T99KZ6Y$RGPH&&L[>36IDJW'4ZD)11O_0M%%%'#S>JE-@AK=#3L0 O":R ME(#%N*LA<,Z&7G42FGCTU1#@TP%8@V_ QV#=Z(J-W35E%@H_RHB'F>]EF'BI M'O/C$QR*V">)B,/8-ZK)/5EY9$6M:)G<8P[@[U?$BU#!],X8$&@4UEGFK49A M':XTV2BLLP#:H[#./V"WPWW?Y*7R$-5>>?M:90[N\N'S0,J44A\'D:ZU%KF/ M:1)%.)(B#%*113D!E:YW4AI9;;[_^>'[[;__>?OU$>E2@L?OL!VM6T!F&YH3 MV#"]VI-$-#M/B;?1#V^1'P7J]>"B0>Q*I9).(<2Y+$ZG <)#@G MB<2AS'F:I<13!V18IL*X#(]M0:J^5A5ONB7#OBM,TV87FO(P\MZF:;6%/U0?I4E[1]>KE7I0Z)^K%N^Z&Y1 1 M^B/W_4CF-,]9!(JEFQ =V5#OJ"%E%PK@I::1T,QLJVM1P.SC/LGT"NTE,N)< M5 .4KA-.^TB^3^ZI@1 ZTU!-WK6M'E>GQ U;;_2*UPME:.:Z=G(_>FEW*Q!Y M7I[3D.'0BPDF:1ACJOX&BY22C =^$&4@72;T.*C*F5L.&G-GP)?JL#% M:V8X1A$:S'JXDI=%=3D0N[/R7 \5Q6F .7<"=LW&W>-FLRWU4?7]I MPCP_CRA/<4*(Q(2F!.>,^#J-SX_5:5-&,>A6"41]9%/3WGA;[*":G\N]D6ZI MVKLE3F1EZY\<2$F;FE.IM5T8_<37Y6*U]VE&N=:R$M.(#DXW[7?W= ;%8N+R M#"]B9YBJ_J^?B[HEE[)W>NJ6^L71#1JR/(UU8RR@)GGQ2*D M2<2S!&*%NDF-;'+J+L3S/668E>D1D9E)<0,<9C]JS"VB5VA/UIT9&(;F2.=[ M"$VJX,. C[79X UX*J5:Y*M8ELV!VS!W\N"ED75.T<)?;^\-5>T44K]F780& MIDA;( [O!CJYM\IM/%QILF3&LP#:V8OG'[ ,P+(?@F_FHIZ=_6F^_.O[YN5E M7NV,=-Y*3'VL9D?N7#[BY430/,)Q*O0PD33&>9(SS&*1A$'D*S\:%*.QY&/L MT$N+AWI8O.:L\@3K;> C75-@0-=2X(;AWO'%" P&-PSI5,^= *_0@6!;;"F? MNIJ .T[ ^#+AN HG6W(Q;;#Y,E&=A*(O7,[2MHDG3>";>-%3LU!1SO*ZLB@'%:2V(N0A. MK 7@53O+H*V0_H].VWZE\SKP4:Y7A>ZNI?^ANK!L_T7KR3IFNHWO?Q3U_^Y& M;M_^9#]T&L WNA:W4@JVGGE4IG'NA3CQD@"3F')UWI<)3C.=[)FQG*:@^<[3 ML@^R5_#2QZ]BC6J2J&K%I7P$[5]5/X@]V]5?KG:@JG^'F;.)/[J99?QU/R7, MR&K.KFH/K\6@OC[=?;'ZD3JD<_"7AV_4H/;Y,[]M)=74T- 6&]+@4(W. MG?U^GZ_B:"N8F/E)=Y7W^3#'&]0[<6&WURG[JCEX6"UU?WC^X>W/4BCRGXH% M73 =FSN-%L=)%(8\))@D+-;%10Q3*CW,>,9%&$899:##/9R%D7WDRNI(=0PI MZYH[N>4$T1TKP'XT%F(VVR'&%1[PRD[MU97LMMR@_ W]IAE2>_?O:,?3V,%Z M>YDXLK$6#$QJ)^T%=&SK+EC)10%U78RU482:B1;+1?E!R.5*U,\]ZO+A+\5B MN2K6;ZUI&&8UPED2!DP9.2Q]ID[_-$MPEA**_8Q)P;G'/<$ACOF$O(_LE3>% MR7G%;C,+IZ[5KCPX :GUOJ2Z>]SO;V:!?]&O"C/=9RK-]TC0'LKVDW>6H5\U MHX!0!;0.?NH)$LOY7*^T13Q6M?HDXA^EYGUS!6_K^+X1#"C 4U#06,L4ET&Y7LY3D5*<)CR($Y( M&',:0KQP2SY&=L4KZLI?9'H^P"YW'NU+'&"[AZVPS7:""40(L^HU0[MLE+IXLY.7R@<1S;7EHM)[>>%HCJVA98YN5X!]%OFY2 M2X+$DQ')0DQI'F(2\!33S,]Q$ LOE#$1<49AP;0C"F.'^VMZ.N=3%*\Z%%FB M&_47Q5JI%0-,G>T6D6F\[ +@T.A8C5G3&J%*IQ.)L[C7\?H31[DZX)W&M+H> MM$I1>Q#+KV()3E)KOS9!FMK#[3WZ>GL/RE0[0-:O+1>" EY][?&X3U@[!\$V M9>U@K2F3ULZ!.$I;._N(W>Y3^^JZMG6Y4%[BQ^4S+18S[@=<1+'$/.'ZYIKG M.!-YBCTI14 ]QKS$J"%F+Y61-:>^(HG_49('%8><%9+;_7 P;IEMPQ.!] MJ!>1H[WH/(U)]Z->F,=[4O_#%EUH^3\?EWJYJ@.X:=O9]DLC:];^4*E;K[;K MX@V#/:K&YJRY>2<:N\ZQ!RM-URKV'("#WK!G'[#RTOY06M94 M>4)5L5+_I[[)/GS!VW@94F\.7^N+Y^V$US;/$ [ 5M5[OD9.9L.D /TV,KX&"/ M?N@. Z]B19_$UXT^9-[+J@]2>;]9 MEVNZT E6.K[ 9@%-*8G]!$=$1CJXPG">YA0KM991'F4RX*#^R2#J(RMV10/] M5BSJ+F5E]QV_ T$2GV5*E +S( R4+10^3F-U]J:Q%^6!3X),QK !9*.)TFHX MV98;1&MV= L^/1:WK-A!RST_"*-@:/E#-B,X4J5E! M+5ZNJL!?M_# ]M=*"(ZL,HSVI+;:2BS'%MQN$7CG[-O%6M]0U$7=NWJ0[VNZ MWI0SDLLPBB)E>:1,M>7Q<";"'.<\2F@8,>K'1J5;0X3&ONZK2*.&=JM*J:9N MWF:[5UC]AL.E"(!7?Y;H03VY3:!9M>CN77BRCMTF\-H-O(V>MVQZ4F??+)[V MB36SA"=2Z@EL-*(ZC\67F&8TU&X"85$F C^AD"3+,S1 *@I/AMQ1;!(A@5U. MSL@D\/S8DU&$A:0Y)EF8 M7GTH!S--LT8'T[$ML(:0PW*^<_R[JK8[6'O:8KASL$YJU2UTT*I>KYVJT[[YVE-FPMI OLD+]+HI0M5>!=BF#$F$R]1>AM*7]\991331%(A;Z>WGB8)V.X(7A.O.R 6HJ%9H@=H) VJOI"=87&OFY_<)RG4#[-3! M_U?RV#0/1>[Y"M^80 J)$;9< :8L"!6HC!]\#BJ02H;'E>FF3OR^IQ95B M2^+(I'H)LI$S\PP.AK,\GO_G%=2WJH5F)U[$9E^-'M37N*60X>B*OEVF03C- MQF/LIP0+C$(7AXA$B8<2GW.4I4%$DB"DD0<:?KI>)5 M:@#R$1CX##33,+,B"\S:E*!VE.OF;^Z<9?4,M532"E.!.71,TOU>I]#\M,!& M +Q('VQF9_AU^IO$H]@(]?+2;[%[_WH4JT)>\GX=Z6N>Y:QLW"PU^"PV(LME M/+0^Z%Z]I^QMV;O5*CF-3@X_"M6G^E&MYB@VFMTY#VLU&*I_DY\$[/BMWS:F M,+]F#4Y0\N :3"8E&B8)G"TI<0T<[03&5?M,Z-K_0W=\_T7&&%+.8K/-5:X) ME.KKW\&R5ZD$.Z5DQ46RRM?E,5@L'[^W684!S?W]8(S["#,XP#R!+@1FTX;C MEDX;">C?=K[Y@%'3.L,"X_\]L5QUW!]D++(KGTU2;!8O^;9A\.?4I8*D GE> M(!")"48QCC@2V*.^G[HDX:#DXX LVZ6L6K+3$0TL: T@I5G>,F,_L-AUT70+ M$]@:UIDJA0U(FKMID "#^7S+$67\O%$I]?4#5P_"T00$A3[-$,$JR(KXS%B/*"NEQ), M".B15;/J62_0_E/V4\V("BS=&/XX]-S*_P,9YHLJW=I/ =3J.6W]5 JDAYC4 M2IG'#GK&*M%&E9NYBFT#V/,*N!4I$PG[+VY>9S08(6Z&0P^YON4M$I7#J@P/S/(%QZOL\4"#!/UNN?C*> =.PS18P_ M)&I>"GP-H\_([G76])WJ]N?U0WYW?]/\1GY)Z5[=VK98X0'M'1GP9&1$9PS__C^_75[]\2Y/I<#SZE[_0?R1_^26-PC@. M1Y?_\I?/%Q_ _.5__.L__,,__U\ __/=V<=?WH_#S74:S7XYG"0W2_&7/X>S M+[_,OJ1?_C:>_.?PF_OETY6;Y?'D&N!?Y__L3 M?V(>?\YU D^"!<&8!1NT!9WP%T9RJGC\?R[_25/#I941HG$!A,!/&&_?)G-OO[3K[_^^>>?__C=3Z[^ M<3RY_)41PG^]^_1?;C_^_<7G_^3S3U-K[:_SW]Y_=#I<]D%\+/WU?_[Q\3Q\ M2=<.AJ/IS(U"><%T^$_3^0\_CH.;S;G^)EV_K/Q$^0[N/@;E1T 9SX_I7_=9.FLSATEZ/Q=#8,TW\,X^M?RX=^ M/1PC*#ZYRT+R_!&S'U_3O_QE.KS^>G7_LR^3E/_E+_'R.Q31$KYX[__]\&]_ M?2#AZR1-$3?S)7_$']P^HKQL>W+2]UD:Q;18ZMV;KL;AR8>N"J/'D[M_>>5\ MNIK_=!#3<#!_\H&?SB8NS 9&ANRI5N!HEB!,,F"R0+PY2;@QRADKGJZ^D#Y% MVN=RF:;PCY?C;[_B@W\MJ"Y?%-[P.5]>O&[!G^WHOMN(%_C9@: VR*@O;H(/@O!E>!7O_G6>C*]KR&HVKL"YA5B0W+_\@JO.:3))\>-"*BL7-U_9 M#/5KFG^RAL3__<9-\(E7/\[2U_%D5I9 DLL"@BA\$)Z <]D #=9JSAGQUE81 M_K,7KX4#UCX.=N%G(Y#XE";#<3P:Q?=X)N-O?$[9$#"<(!NR)F"I=R SDUE) M$I6250#QY+5KP8&W#X?M>=D(&"XF;C0=%L;? CHI:53(%IQD!/"_-:D!#M0V(GCO:,BJ/1;#C[\6%XE4YNKGV:#+QU(D6AP&NT MF 4S GR8F]_&.^),8D;MA(;G;UP+!;)=%.S$P2:D?Y8NAX4)H]F)NTX#)9G* M/&? U3,0U$GPT6I@PE/FE,'S+59 P-.WKH4"U3H*=N!D$T@X1%Y-W-4Q.DW? M_RW]&!"1.!4I 9%HYHAH/!A+!;!@%^U:6-"M8V$77O8,AL.; M2>'4A^$TN*O_2&YR;^YD*4O !9T@;4%(;\ 1:8'*Q#T/EEK/=\+#JC>O!0G3 M+B2J<+01 _)A$1_P)],!(<+-F6"5]&@#.XI''75@LPT^&2:H=%7LQV $O EF6>&Q +UFZ ,GR3)PFE*?=-,7*5Z\7?R(_ M"RZV96K/R#C %<3Y*J[L_P<.9\.QS=H#/TX',Y0E M!Q>8AZ"#HIE&3^ENX:U?'X>C M1 ?>BF(B.8A>(]ZU5,@:7)/E(5,9*&.R1M!JR:O70T?#0GD M8OSG:$!DYI'E#$X07()"SJ *M&A*)VT<(]G(&J&L%R]>#Q7-!S5W8VA+F)@? MCJ>33Y/QM^$HI$'.3K.$)Z(VPH!@Z%XYSRE8&[37BDO.*P+CV=O70T?SP MS<<_=V9KWT'0LH9),9I%V2'<08'2(D+4VS&4=LV<[P>'QV]8# M0,O1SFU9U[/(2\[=U:SE3#L%:<\<5A&P8".L\>,DD M,.5CUHZ;P/).LG_RNO4$WW#(4%59(%M!@H6:WVXME;UT/ PT')7=F91/NP.U5[2*5JT :97 S'0B*'"%. ME *#L@YKP"8E@40?5 C*3'P-J@SS:A<\M+U<-!\ MM'%[1C:!@Z/K-+G$(^^WR?C/V9?#\?57-T(X4URTU1$85;B,R"A82@(8$[,/ M'@UE4N,N?.G+U\-%\V'&W1G;!#[.OZ2KJSOJO3>*YA(;=>@J"^0"&)[1A[+, M$:6U<*3&A??C=ZZ'AH9CCCNRL0D0(.'7)9%C'/[S_ OR;7IZ,RN5P<6S'JC@ M(W$Y [5Z;B5K<.5.UMGH"%'$H.JKX8"\0L-Z(&DX.EF9S=5 \\^_ON#H1_S! M3A7:IR?GIQ^/WQ]<'+T_O\ __S@ZN3@__7#ZZ>CLX.(8?_MT%>N5;K_]T'HU MW1LN8,=B[YLI7#KW=5!RJJ[3_%*S9.#=0TXJDNV\[-.@'A')HEH148)4P;KH M113LM1OC[*9^#H+;]RSV8+J:3>]^\K 9WR!E6SUS]]BS]"V-;M('W%^'X]'\ MD7\;XM%Y,YWAZR9'W\/53=D*!],IFEHI7KCO Q)RBKBS@%."=G<.&<]3&T$+ MZM'L#E:D4'GU6Y#93^EY3>3<*:M]R:K'8^]NB8>X\4_S[4+OF:;0QS>E5L S>)0*$^1PC$4K2UTZ[;0"WE)!^JMB[A-3N_&X-- ,3@]$Y)S BHK5O MM 23L@.JC/:**6G#:\D:.X.E7[U30:"O060C[C8 C7/T (H_F$9IXJX.1O$@ M7@]'\[+,$E4\^OXUC:9ID)7RP=( +LD$PDJ#7Y$,"7<04>6>@KP6DML&,^M1 MUJ_&J0^F#N31 ,H.KLL5QG_/Y7*:CU%"H\NAOTKE()Y-!REDE2-#!R)HBEP3 M&JPP%HP/I-Q_\LA?RQ?:!EVO4]1/^XWN4%61_UNC"3U2/ZZ$I]/9ES0Y_9K* MIAA=+L[]VZUQDF8#=#J-S(D!"1)UL","694UZ! ,)2HI&E^+"&V#I]V]-9*F*O&=0X%I'IQ.X MF.;W]+)X#1KYY26A/&O/7\N2V08\;Q+53X.A+J%45PX-6-/SK(\TG;TX=Y-2 M@BHFR^UN1"ZE!!8Y!+AK\"DJ!AU?2\3;+NJZG)9^G?S*(A]WP/\&<#2WXE:R M:J H4U)37(V-N./J4H_^ZP5__D69?QOB; M;_B18FQ,!X'@ A*W0!*QZ(\$!DY*"FAS4*=,(,J^EI*Z_:WE7I;73]/ +BV[ M5K'1S+;!)=]N^W=IE/(0=4K*PFN9P1HC +_T8"@:*YXJZ5C.-(K:@?P5I/33 MM[![..[&\UW#81<5O8RUMH7'G<"2 .G+140.)=4\,SQ-'+7:&^]E?9>CEK*K MGJ"W/V570QX-&(J?)F/<(?/HCG#%_J!HWJ142E\5!S1S%!AOF!+1TZAK7TL_ MO+V?[HA=PF5+SC9P=*$G_8#U@]EL,O0W,^>OTL48K=I0$GO&\TO2NS-\H)+0 MR92R62E*[QWO2]6< QH"(IYD2=AK/=FWQ M7*IG%7#SE,([[? $SS& YL'D' *5NK;I](2 GAHU[@U!&S&X 3UUY"8C!/?T M4YK,$Z/O.4(%$3+:",3K@.NP"2QC$:RC+#-+LE&U V>K:.FI=6.7F*G"]@:4 MR_-UO'/381APY9Q53D$.*8+@PN$>L!RLT%11(;C1M>WII83T&[^O(^,W@+,Y MPYO(?7F^C/?#JQMT_ ;6V$1(H*"S+%YFQ#UE6,GGT(PFP3@SM2\35Y#2;YQ^ M+]C9ANE-H.=OJ4R/3/$ '^HN;]L.G>87E3WW7/,R$ZM4!*E%!B&)!4N#!YXB M\3[+F%\MQMX&5IO2V%//V2X/N4[%U,#AM^[Z%CHZ.NZ%% &X5JX8AA)<0L.0 M$*FCUIQ[5;N\82,"^STLN\7*EL#<7'#MHO)6V;^L?F2,.LV$*L.*2.D&C68# M80)("HPQ[7-*M;,$-R2QWZ.X!616$=[/6+IZ>/K'I[.CWX].SH__>G1\@M\> M/5W.3C6LRY[>>3'KFTNJ5-5Z?Y:77/ERN!^,8BF3GZ0O:30=?KN]4+R';5*2 MF$ <4%V2Z,ML(A.B E1OB@G)H\VU\\TW)+%BG%Y9[K4@'@Q1N0S8T&!XR7G2 M5B1):2 /G??ZB=-W=M)VB8M7XO>;<+R!4W2>RK2$+64M)PEY=^&^+^;TX,\G MR4W3^[3X^YYQ3B9G!2TM"DKC8\UQL48J4#I&$ZV2TKW6Z67KU+.=J.[WK-TG M-OU0$'\WS>+:]H['@TX"31; MRT &C3O;2 ?&2PI$*2X(_/" M#:KOLJBT$R"98HIFIPBO[_JKMA^&XEN ;NYI8LYVXI^-VB"\BG4A.+ M$E[GXCHFS9S1'!1QZ#$JIL%ZAXS(5ELJD,.N=A2T\A+Z37;>IW72I^S;AOY: MRQ7,1*UB B-9Z4:N(ABC'1#/A;-9:6)J)T'O2'*_U8^-0+NZ;!LP*5Y9[L & MK[3/!'+,Q2D.$:QP'&R@Z"TGFI7?HT;NMVJR$0AN))-JFK+CD.J[@X\')X=' MY[\?'5WLV@3PZ;,Z"9>^0F[]X.B'X7("9&)G7I(RL1 M"3& ISF!5X[$D$TV#Z,9ZD=$5]*U;^4AXP":2E/C(";)UL;ANHTF D MBDR5T\KZVJ'0IQ0T$PZM@X07;6NV9W<+IY>;?BF*&/\JV?K?W%7)T#^8';K) MY >>RG]U5S=I$,O,6*(%<-3#($1TX(E#Q9FR2"HE;F/MW.6U".L76KM(_OF! M55T,#6#K((0RNWIZED+"):'-AX?PW?@'W&V.R4C QI+2QKP!SVT9,:EB]-%+ MQ6KG$+Y&3[_!E8I(JL;T!@!4:H9&^)$?I6\!U8HI+B1H=&C1'B0>G# 9K.." MV(@^KJL=E7O\_GY#$Q4!LC53&P#$ITGZZH9WO9E08<[#@@OFW&'<)"XM=Q;4 MG#>>4!;-V9-B>6\=F+[&F3UZ_Y7A$]M$32 JJ?$!Z(B<

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end XML 67 dgx-20240331_htm.xml IDEA: XBRL DOCUMENT 0001022079 2024-01-01 2024-03-31 0001022079 2024-04-15 0001022079 2023-01-01 2023-03-31 0001022079 2024-03-31 0001022079 2023-12-31 0001022079 2022-12-31 0001022079 2023-03-31 0001022079 us-gaap:CommonStockMember 2023-12-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001022079 us-gaap:RetainedEarningsMember 2023-12-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001022079 us-gaap:TreasuryStockCommonMember 2023-12-31 0001022079 us-gaap:NoncontrollingInterestMember 2023-12-31 0001022079 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001022079 us-gaap:CommonStockMember 2024-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001022079 us-gaap:RetainedEarningsMember 2024-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2024-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2024-03-31 0001022079 us-gaap:CommonStockMember 2022-12-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001022079 us-gaap:RetainedEarningsMember 2022-12-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001022079 us-gaap:TreasuryStockCommonMember 2022-12-31 0001022079 us-gaap:NoncontrollingInterestMember 2022-12-31 0001022079 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001022079 us-gaap:CommonStockMember 2023-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001022079 us-gaap:RetainedEarningsMember 2023-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2023-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2023-03-31 0001022079 dgx:InvigorateProgramMember 2024-03-31 0001022079 dgx:InvigorateProgramMember 2024-01-01 2024-03-31 0001022079 dgx:InvigorateProgramMember 2023-01-01 2023-03-31 0001022079 us-gaap:CostOfSalesMember dgx:InvigorateProgramMember 2024-01-01 2024-03-31 0001022079 us-gaap:SellingGeneralAndAdministrativeExpensesMember dgx:InvigorateProgramMember 2024-01-01 2024-03-31 0001022079 us-gaap:CostOfSalesMember dgx:InvigorateProgramMember 2023-01-01 2023-03-31 0001022079 us-gaap:SellingGeneralAndAdministrativeExpensesMember dgx:InvigorateProgramMember 2023-01-01 2023-03-31 0001022079 us-gaap:AccountsPayableAndAccruedLiabilitiesMember dgx:InvigorateProgramMember 2024-03-31 0001022079 us-gaap:AccountsPayableAndAccruedLiabilitiesMember dgx:InvigorateProgramMember 2023-12-31 0001022079 2023-01-01 2023-12-31 0001022079 us-gaap:CustomerRelationshipsMember 2024-03-31 0001022079 dgx:LencoDiagnosticsLaboratoriesIncMember 2024-02-12 2024-02-12 0001022079 dgx:LencoDiagnosticsLaboratoriesIncMember 2024-02-12 0001022079 dgx:LencoDiagnosticsLaboratoriesIncMember us-gaap:CustomerRelationshipsMember 2024-02-12 0001022079 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001022079 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001022079 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001022079 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001022079 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001022079 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001022079 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001022079 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001022079 dgx:HaystackOncologyIncMember dgx:AdditionalBasedOnRevenueMember 2023-06-30 0001022079 dgx:HaystackOncologyIncMember dgx:AdditionalReimbursementCoverageMember 2023-06-30 0001022079 dgx:HaystackOncologyIncMember dgx:MeasurementInputComparableCompanyRevenueVolatilityMember 2024-03-31 0001022079 dgx:HaystackOncologyIncMember us-gaap:MeasurementInputDiscountRateMember 2024-03-31 0001022079 dgx:HaystackOncologyIncMember us-gaap:MeasurementInputDiscountRateMember dgx:AdditionalImpactMember 2024-03-31 0001022079 dgx:HaystackOncologyIncMember dgx:MeasurementInputComparableCompanyRevenueVolatilityMember dgx:ChangingComparableCompanyRevenueVolatilityMember 2024-03-31 0001022079 dgx:HaystackOncologyIncMember dgx:MeasurementInputComparableCompanyRevenueVolatilityMember dgx:ChangingComparableCompanyRevenueVolatilityMember 2024-01-01 2024-03-31 0001022079 dgx:HaystackOncologyIncMember us-gaap:MeasurementInputDiscountRateMember dgx:ChangingDiscountRateMember 2024-03-31 0001022079 dgx:HaystackOncologyIncMember dgx:MeasurementInputComparableCompanyRevenueVolatilityMember dgx:ChangingDiscountRateMember 2024-01-01 2024-03-31 0001022079 us-gaap:FairValueInputsLevel3Member dgx:ContingentConsiderationMember 2023-12-31 0001022079 us-gaap:FairValueInputsLevel3Member dgx:ContingentConsiderationMember 2024-01-01 2024-03-31 0001022079 us-gaap:FairValueInputsLevel3Member dgx:ContingentConsiderationMember 2024-03-31 0001022079 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member dgx:ContingentConsiderationMember 2024-03-31 0001022079 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel3Member dgx:ContingentConsiderationMember 2024-03-31 0001022079 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member dgx:ContingentConsiderationMember 2023-12-31 0001022079 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel3Member dgx:ContingentConsiderationMember 2023-12-31 0001022079 dgx:UMassJointVentureMember 2015-07-01 0001022079 dgx:ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member us-gaap:SeniorNotesMember 2024-03-31 0001022079 us-gaap:LongTermDebtMember us-gaap:FairValueHedgingMember 2024-03-31 0001022079 us-gaap:LongTermDebtMember us-gaap:FairValueHedgingMember 2023-12-31 0001022079 2023-10-01 2023-12-31 0001022079 2023-04-01 2023-06-30 0001022079 2023-07-01 2023-09-30 0001022079 us-gaap:SecuredDebtMember 2023-10-31 0001022079 dgx:SeniorunsecuredrevolvingcreditfacilityMember 2021-11-30 0001022079 us-gaap:SecuredDebtMember 2024-03-31 0001022079 us-gaap:SecuredDebtMember 2022-10-31 0001022079 dgx:A401kPlanLawsuitMember us-gaap:PendingLitigationMember 2020-12-31 0001022079 dgx:A401kPlanLawsuitMember us-gaap:PendingLitigationMember 2020-10-31 0001022079 dgx:ExcludesgeneralandprofessionalliabilityclaimsMember 2024-03-31 0001022079 dgx:ExcludesgeneralandprofessionalliabilityclaimsMember 2023-12-31 0001022079 srt:MinimumMember dgx:DiagnosticInformationServicesBusinessMember 2024-01-01 2024-03-31 0001022079 srt:MinimumMember dgx:DiagnosticInformationServicesBusinessMember 2023-01-01 2023-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2024-01-01 2024-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2023-01-01 2023-03-31 0001022079 us-gaap:AllOtherSegmentsMember 2024-01-01 2024-03-31 0001022079 us-gaap:AllOtherSegmentsMember 2023-01-01 2023-03-31 0001022079 us-gaap:CorporateMember 2024-01-01 2024-03-31 0001022079 us-gaap:CorporateMember 2023-01-01 2023-03-31 0001022079 dgx:FeeforserviceMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2024-01-01 2024-03-31 0001022079 dgx:FeeforserviceMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2023-01-01 2023-03-31 0001022079 dgx:CapitatedMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2024-01-01 2024-03-31 0001022079 dgx:CapitatedMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2023-01-01 2023-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2024-01-01 2024-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2023-01-01 2023-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:GovernmentPayersMember 2024-01-01 2024-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:GovernmentPayersMember 2023-01-01 2023-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2024-01-01 2024-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2023-01-01 2023-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:PatientsMember 2024-01-01 2024-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:PatientsMember 2023-01-01 2023-03-31 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2024-01-01 2024-03-31 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2023-01-01 2023-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2024-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2023-12-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:GovernmentPayersMember 2024-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:GovernmentPayersMember 2023-12-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2024-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2023-12-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:PatientsMember 2024-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:PatientsMember 2023-12-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2024-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2023-12-31 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2024-03-31 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2023-12-31 0001022079 dgx:FourpointtwofivepercentSeniorNotesDue2024Member us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2024-04-01 2024-04-24 0001022079 dgx:FourpointtwofivepercentSeniorNotesDue2024Member us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2024-04-24 shares iso4217:USD iso4217:USD shares pure dgx:claim 0001022079 --12-31 2024 Q1 false 10-Q true 2024-03-31 false 001-12215 Quest Diagnostics Inc DE 16-1387862 500 Plaza Drive Secaucus, NJ 07094 (973) 520-2700 Common Stock, $0.01 Par Value DGX NYSE Yes Yes Large Accelerated Filer false false false 111091574 2366000000 2331000000 1595000000 1560000000 440000000 439000000 29000000 26000000 -2000000 -1000000 2066000000 2026000000 300000000 305000000 -43000000 -35000000 9000000 7000000 -34000000 -28000000 266000000 277000000 66000000 65000000 8000000 5000000 208000000 217000000 14000000 15000000 194000000 202000000 1.74 1.80 1.72 1.78 111000000 112000000 112000000 113000000 208000000 217000000 -2000000 3000000 -2000000 3000000 206000000 220000000 14000000 15000000 192000000 205000000 474000000 686000000 28000000 27000000 1322000000 1210000000 181000000 190000000 251000000 286000000 2228000000 2372000000 1810000000 1816000000 579000000 602000000 7830000000 7733000000 1192000000 1166000000 133000000 135000000 182000000 198000000 13954000000 14022000000 1239000000 1359000000 906000000 303000000 153000000 153000000 2298000000 1815000000 3804000000 4410000000 489000000 503000000 817000000 876000000 77000000 76000000 0.01 0.01 600000000 600000000 162000000 162000000 2000000 2000000 2292000000 2320000000 8935000000 8825000000 -16000000 -14000000 51000000 51000000 4781000000 4826000000 6432000000 6307000000 37000000 35000000 6469000000 6342000000 13954000000 14022000000 208000000 217000000 116000000 107000000 1000000 -1000000 -18000000 -4000000 22000000 24000000 -11000000 -3000000 114000000 58000000 -152000000 -211000000 42000000 11000000 -38000000 -6000000 154000000 94000000 142000000 31000000 104000000 127000000 -33000000 0 -213000000 -158000000 0 140000000 0 140000000 12000000 25000000 23000000 28000000 79000000 74000000 11000000 14000000 -52000000 15000000 -153000000 -76000000 -212000000 -140000000 686000000 315000000 474000000 175000000 111000000 2000000 2320000000 8825000000 -14000000 -4826000000 35000000 6342000000 76000000 194000000 13000000 207000000 1000000 -2000000 -2000000 84000000 84000000 11000000 11000000 -42000000 48000000 6000000 22000000 22000000 -2000000 14000000 12000000 6000000 17000000 23000000 111000000 2000000 2292000000 8935000000 -16000000 -4781000000 37000000 6469000000 77000000 111000000 2000000 2295000000 8290000000 -21000000 -4673000000 37000000 5930000000 77000000 202000000 14000000 216000000 1000000 3000000 3000000 80000000 80000000 13000000 13000000 1000000 1000000 -42000000 48000000 6000000 24000000 24000000 -1000000 31000000 30000000 10000000 18000000 28000000 112000000 2000000 2266000000 8412000000 -18000000 -4612000000 38000000 6088000000 77000000 DESCRIPTION OF BUSINESS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">    </span></div>    Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") work across the healthcare ecosystem to create a healthier world, one life at a time. The Company's diagnostic information services ("DIS") business provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, the diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. In the right hands and with the right context, the diagnostic insights can inspire actions that transform lives and create a healthier world. The Company provides services to a broad range of customers within its primary customer channels - physicians (including those associated with accountable care organizations and Federally Qualified Health Centers), hospitals, and patients and consumers. Other customers include health plans, employers, emerging retail healthcare providers, government agencies, pharmaceutical companies and other commercial clinical laboratories. The Company offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The Company's large in-house staff of medical and scientific experts, including medical directors, scientific directors, genetic counselors and board-certified geneticists, provide medical and scientific consultation to healthcare providers and patients regarding the Company's tests and test results, and help them best utilize Quest Diagnostics' services to improve outcomes and enhance satisfaction. The Company's Diagnostic Solutions ("DS") group, which represents the balance of the Company's consolidated net revenues, includes the Company's risk assessment services business, which offers solutions for insurers, and the Company's healthcare information technology businesses, which offer solutions for healthcare providers and payers. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2023 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023 but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The accounting policies of the Company are the same as those set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2023 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    Earnings Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan (“ELTIP”) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan (“DLTIP”), as well as the dilutive effect of accelerated share repurchase agreements ("ASRs"), if applicable. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    New Accounting Standards to be Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In November 2023, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which will require companies to disclose significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"). The pronouncement is effective for annual filings for the year ended December 31, 2024 and for interim periods within the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In December 2023, the FASB issued a new accounting standard which will require companies to make additional income tax disclosures. The pronouncement is effective for annual filings for the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In March 2024, the Securities and Exchange Commission issued a rule which will require companies to make certain climate-related disclosures in periodic filings. The rule includes certain disclosures in the footnotes of the financial statements: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capitalized costs, expenditures expensed, and losses incurred as a result of severe weather events and other natural conditions, such as hurricanes, tornadoes, flooding, drought, wildfires, extreme temperatures, and sea level rise;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capitalized costs, expenditures expensed, and losses related to carbon offsets and renewable energy credits or certificates if they are used as a material component of a registrant’s plans to achieve its disclosed climate-related targets or goals; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether estimates and assumptions used to produce the financial statements were materially impacted by risks and uncertainties associated with severe weather events and other natural conditions or any disclosed climate-related targets or transition plans. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The footnote disclosures are effective for annual filings for the year ended December 31, 2025. The Company is currently evaluating the impact of the adoption of the rule.</span></div> The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2023 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023 but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan (“ELTIP”) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan (“DLTIP”), as well as the dilutive effect of accelerated share repurchase agreements ("ASRs"), if applicable. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.</span></div> In November 2023, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which will require companies to disclose significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"). The pronouncement is effective for annual filings for the year ended December 31, 2024 and for interim periods within the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In December 2023, the FASB issued a new accounting standard which will require companies to make additional income tax disclosures. The pronouncement is effective for annual filings for the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In March 2024, the Securities and Exchange Commission issued a rule which will require companies to make certain climate-related disclosures in periodic filings. The rule includes certain disclosures in the footnotes of the financial statements: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capitalized costs, expenditures expensed, and losses incurred as a result of severe weather events and other natural conditions, such as hurricanes, tornadoes, flooding, drought, wildfires, extreme temperatures, and sea level rise;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capitalized costs, expenditures expensed, and losses related to carbon offsets and renewable energy credits or certificates if they are used as a material component of a registrant’s plans to achieve its disclosed climate-related targets or goals; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether estimates and assumptions used to produce the financial statements were materially impacted by risks and uncertainties associated with severe weather events and other natural conditions or any disclosed climate-related targets or transition plans. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The footnote disclosures are effective for annual filings for the year ended December 31, 2025. The Company is currently evaluating the impact of the adoption of the rule.</span></div> EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:75.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.030%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Quest Diagnostics’ common stockholders:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Earnings allocated to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to Quest Diagnostics’ common stockholders – basic and diluted</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding – basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding – diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to Quest Diagnostics’ common stockholders:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72 </span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78 </span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:75.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.030%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:75.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.030%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Quest Diagnostics’ common stockholders:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Earnings allocated to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to Quest Diagnostics’ common stockholders – basic and diluted</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding – basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding – diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to Quest Diagnostics’ common stockholders:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72 </span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78 </span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 194000000 202000000 1000000 1000000 193000000 201000000 111000000 112000000 1000000 1000000 112000000 113000000 1.74 1.80 1.72 1.78 The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:75.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.030%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1000000 0 RESTRUCTURING ACTIVITIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Invigorate Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company is engaged in a multi-year program called Invigorate, which includes structured plans to drive savings and improve productivity across the value chain, including in such areas as patient services, logistics and laboratory operations, revenue services, information technology and procurement. The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to partially offset pressures from the current inflationary environment, including labor and benefit cost increases and reimbursement pressures. The Company is leveraging automation and artificial intelligence to improve productivity and also improve quality across the entire value chain, not just in the laboratory. Other areas of focus include reducing denials and patient concessions, enhancing the digital experience, and selecting and retaining talent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    Restructuring Charges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's pre-tax restructuring charges for the three months ended March 31, 2024 and 2023 were $6 million and $15 million, respectively, entirely related to employee separation costs associated with various workforce reduction initiatives as the Company continued to restructure its organization. Of the total restructuring charges incurred during the three months ended March 31, 2024, $4 million and $2 million were recorded in cost of services and selling, general and administrative expenses, respectively. Of the total restructuring charges incurred during the three months ended March 31, 2023, $9 million and $6 million were recorded in cost of services and selling, general and administrative expenses, respectively. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Charges for all periods presented were primarily recorded in the Company's DIS business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restructuring liability as of March 31, 2024 and December 31, 2023, which is included in accounts payable and accrued expenses, was $13 million and $12 million, respectively.</span></div> 0.03 6000000 15000000 4000000 2000000 9000000 6000000 13000000 12000000 BUSINESS ACQUISITIONS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the three months ended March 31, 2024, the Company completed acquisitions for an aggregate purchase price of $148 million (including contingent consideration initially estimated at $6 million), net of cash acquired, including the acquisitions discussed below. Of such amount, $30 million was prepaid during the twelve months ended December 31, 2023. In the Company's consolidated statement of cash flows for the three months ended March 31, 2024, such $30 million is included in business acquisitions, net of cash acquired, with a corresponding offset in other investing activities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The acquisitions preliminarily resulted in goodwill of $99 million, all of which is deductible for tax purposes. The acquisitions also preliminarily resulted in $56 million of customer-related intangible assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of select assets of Lenco Diagnostic Laboratories, Inc. ("Lenco")</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On February 12, 2024, the Company acquired select assets of Lenco, an independent clinical diagnostic laboratory provider serving physicians in New York, in an all-cash transaction for $111 million. Based on the preliminary purchase price allocation, which may be revised as additional information becomes available during the measurement period, the assets acquired and liabilities assumed primarily consist of $75 million of tax-deductible goodwill, $43 million of customer-related intangible assets and $7 million of operating lease liabilities. The intangible assets are being amortized over a useful life of 15 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The acquisitions were accounted for under the acquisition method of accounting. As such, the assets acquired and liabilities assumed were recorded based on their estimated fair values as of the closing dates. Supplemental pro forma combined financial information has not been presented as the impact of the acquisitions is not material to the Company's consolidated financial statements. The goodwill recorded primarily includes the expected synergies resulting from combining the operations of the acquired entity with those of the Company and the value associated with an assembled workforce and other intangible assets that do not qualify for separate recognition. All of the goodwill acquired in connection with the acquisitions has been allocated to the Company's DIS business. For further details regarding business segment information, see Note 12.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For details regarding the Company's 2023 acquisitions, see Note 6 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.</span> 148000000 6000000 30000000 30000000 99000000 99000000 56000000 111000000 75000000 75000000 43000000 7000000 P15Y FAIR VALUE MEASUREMENTS <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets/Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">March 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    A detailed description regarding the Company's fair value measurements is contained in Note 8 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company offers certain employees the opportunity to participate in a non-qualified supplemental deferred compensation plan. A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities. The trading securities are classified within Level 1 of the fair value hierarchy because the changes in the fair value of these securities are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held, exclusive of any transaction costs. A </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation. The deferred compensation liabilities are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the trading securities.</span></div><div style="padding-right:72pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program. A participant's deferrals, together with Company matching credits, are “invested” at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments. Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the deferred compensation obligation are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Deferrals under the plan currently may only be made by participants who made deferrals under the plan in 2017. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's available-for-sale debt securities are measured at fair value using discounted cash flows. These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable. Significant inputs include cash flows projections and a discount rate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     During June 2023, the Company acquired Haystack Oncology, Inc. ("Haystack"), an early-stage oncology company focused on minimal residual disease testing to aid in the detection of residual or recurring cancer and better inform therapy decisions. In connection with the acquisition there is a contingent consideration obligation under which the seller can receive up to $100 million of additional consideration dependent upon the achievement of certain revenue benchmarks through 2028 and up to an additional $50 million of consideration dependent upon the Company receiving reimbursement coverage from the Centers for Medicare and Medicaid Services ("CMS"). The portion of the contingent consideration obligation which is dependent upon the achievement of certain revenue benchmarks was measured at fair value using a Monte Carlo method and is classified within Level 3 of the fair value hierarchy as the fair value is determined based on significant inputs that are not observable. Significant inputs include management’s estimate of revenue and other market inputs, including comparable company revenue volatility (40%) and a discount rate (10.5%). The portion of the contingent consideration obligation which is dependent upon the Company receiving reimbursement coverage from the CMS is also classified within Level 3 of the fair value hierarchy as the fair value is principally determined based on management's estimate, which is a significant input that is not observable. Additionally, the fair value of the entire contingent consideration obligation is also impacted by a market discount rate (5%) which adjusts the estimated payments to present value. The fair value of the contingent consideration obligation is not overly sensitive to movements in the comparable company revenue volatility or the discount rate used for the portion of the obligation that is dependent upon the achievement of certain revenue benchmarks. For example, changing the comparable company revenue volatility from 40% to 30% impacts the fair value by $8 million (assuming no other inputs are modified) and changing the discount rate from 10.5% to 7.0% impacts the fair value by $5 million (assuming no other inputs are modified).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has additional contingent consideration obligations in connection with other acquisitions. The liabilities related to such obligations are included in the amounts below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2023</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, additions and issuances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value adjustments included in earnings - realized/unrealized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, March 31, 2024</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     The $3 million net loss included in earnings associated with the change in the fair value of contingent consideration for the three months ended March 31, 2024 is reported in other operating expense, net.    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Of the aggregate $113 million contingent consideration obligation as of March 31, 2024, $79 million and $34 million were included in other liabilities and accounts payable and accrued expenses, respectively, in the Company's consolidated balance sheet. Of the aggregate $104 million contingent consideration obligation as of December 31, 2023, $99 million and $5 million were included in other liabilities and accounts payable and accrued expenses, respectively, in the Company's consolidated balance sheet.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. As of March 31, 2024, the redeemable noncontrolling interest was presented at its fair value. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy because the fair value is based on a discounted cash flow analysis that takes into account, among other items, the joint venture's expected future cash flows, long term growth rates, and a discount rate commensurate with economic risk.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. As of both March 31, 2024 and December 31, 2023, the fair value of the Company’s debt was estimated at $4.6 billion. Principally all of the Company's debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates currently offered to the Company with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments.</span></div> The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets/Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">March 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 74000000 74000000 0 0 59000000 0 59000000 0 133000000 74000000 59000000 0 138000000 0 138000000 0 113000000 0 0 113000000 251000000 0 138000000 113000000 77000000 0 77000000 70000000 70000000 0 0 55000000 0 55000000 0 2000000 0 0 2000000 127000000 70000000 55000000 2000000 131000000 0 131000000 0 104000000 0 0 104000000 235000000 0 131000000 104000000 76000000 0 76000000 100000000 50000000 0.40 0.105 0.05 0.40 0.30 8000000 0.105 0.070 5000000 The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2023</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, additions and issuances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value adjustments included in earnings - realized/unrealized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, March 31, 2024</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 104000000 6000000 -3000000 113000000 -3000000 113000000 79000000 34000000 104000000 99000000 5000000 0.189 4600000000 4600000000 DEBT<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has $600 million of 3.50% senior notes due March 2025. The senior notes are included in current portion of long-term debt in the Company's March 31, 2024 consolidated balance sheet. Such notes were included in long-term debt in the Company's December 31, 2023 consolidated balance sheet. For further details, see Note 14 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.</span></div> 600000000 0.0350 FINANCIAL INSTRUMENTS <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Derivatives – Cash Flow Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    From time to time, the Company has entered into various interest rate lock agreements and forward-starting interest rate swap agreements to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in interest rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Derivatives – Fair Value Hedges </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Historically, the Company has entered into various fixed-to-variable interest rate swap agreements in order to convert a portion of the Company's long-term debt into variable interest rate debt. All such fixed-to-variable interest rate swap agreements have been terminated and proceeds from the terminations have been reflected as basis adjustments to the hedged debt instruments and are being amortized as a reduction of interest expense, net over the remaining terms of such debt instruments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of March 31, 2024 and December 31, 2023, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:18.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hedge Accounting Basis Adjustment (a)</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) As of both March 31, 2024 and December 31, 2023, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span>A detailed description regarding the Company's use of derivative financial instruments is contained in Note 16 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K. The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.</span></div> As of March 31, 2024 and December 31, 2023, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:18.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hedge Accounting Basis Adjustment (a)</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) As of both March 31, 2024 and December 31, 2023, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.</span></div> 10000000 13000000 STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST<div style="text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Accumulated Other Comprehensive Loss by Component</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) includes: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign currency translation adjustments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 8); and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For the three months ended March 31, 2024 and 2023, the tax effects related to the deferred gains (losses) on cash flow hedges and net changes in available-for-sale debt securities were not material. Foreign currency translation adjustments related to indefinite investments in non-U.S. subsidiaries are not adjusted for income taxes. </span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Program</span></div><div style="text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the first quarter of 2024, the Company's Board of Directors declared a quarterly cash dividend of $0.75 per common share. During each of the four quarters of 2023, the Company's Board of Directors declared a quarterly cash dividend of $0.71 per common share. </span></div><div style="text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of March 31, 2024, $1.0 billion remained available under the Company’s share repurchase authorization. The share repurchase authorization has no set expiration or termination date.</span></div><div style="text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchases</span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For both the three months ended March 31, 2024 and 2023, the Company repurchased no shares of its common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shares Reissued from Treasury Stock</span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For the three months ended March 31, 2024 and 2023, the Company reissued 0.5 million shares and 0.7 million shares, respectively, from treasury stock under its Employee Stock Purchase Plan and its stock-based compensation program. For details regarding the Company's stock ownership and compensation plans, see Note 18 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    Redeemable Noncontrolling Interest</span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. The subsidiary performs diagnostic information services in a defined territory within the state of Massachusetts. Since the redemption of the noncontrolling interest is outside of the Company's control, it has been presented outside of stockholders' equity at the greater of its carrying amount or its fair value. As of March 31, 2024 and December 31, 2023, the redeemable noncontrolling interest was presented at its fair value. For further details regarding the fair value of the redeemable noncontrolling interest, see Note 6.</span></div> 0.75 0.71 0.71 0.71 0.71 1000000000 0 0 500000 700000 0.189 SUPPLEMENTAL CASH FLOW AND OTHER DATA<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Supplemental cash flow and other data for the three months ended March 31, 2024 and 2023 was as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.844%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable associated with capital expenditures</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Businesses acquired:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of net assets acquired</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for business acquisitions</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Leases:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for new operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>    During the three months ended March 31, 2024 and 2023, other financing activities, net in the Company's consolidated statement of cash flows included changes in bank overdrafts, which are generally settled in cash in the short term, of $(51) million and $33 million, respectively. Supplemental cash flow and other data for the three months ended March 31, 2024 and 2023 was as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.844%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable associated with capital expenditures</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Businesses acquired:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of net assets acquired</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for business acquisitions</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Leases:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for new operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 87000000 81000000 29000000 26000000 116000000 107000000 49000000 37000000 6000000 2000000 -43000000 -35000000 44000000 32000000 3000000 33000000 28000000 22000000 84000000 80000000 155000000 31000000 7000000 0 148000000 31000000 -6000000 0 142000000 31000000 0 0 142000000 31000000 35000000 44000000 -51000000 33000000 COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Letters of Credit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company can issue letters of credit under its $525 million secured receivables credit facility and its $750 million senior unsecured revolving credit facility. For further discussion regarding the facilities, see Note 14 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In support of its risk management program, $73 million in letters of credit under the $525 million secured receivables credit facility were outstanding as of March 31, 2024, providing collateral for current and future automobile liability and workers’ compensation loss payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Lease Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company remains subject to contingent obligations under certain real estate leases for which no liability has been recorded. For further details, see Note 19 to the audited consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Legal Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues. The Company has insurance coverage rights in place (limited in amount; subject to deductible) for certain potential costs and liabilities related to these proceedings and investigations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Company’s 401(k) plan. The complaint alleges, among other things, that the fiduciaries of the 401(k) plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments. In October 2020, the court consolidated the two lawsuits under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Quest Diagnostics ERISA Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and plaintiffs filed a consolidated amended complaint. In May 2021, the court denied the Company's motion to dismiss the complaint. Discovery has been completed. Plaintiffs' motion for class certification and the Company's motion for summary judgment are pending.</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On June 3, 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (“AMCA”) had informed the Company and Optum360 LLC that an unauthorized user had access to AMCA’s system between August 1, 2018 and March 30, 2019 (the “AMCA Data Security Incident”). Optum360 provides revenue management services to the Company, and AMCA provided debt collection services to Optum360. AMCA first informed the Company of the AMCA Data Security Incident on May 14, 2019. AMCA’s affected system included financial information (e.g., credit card numbers and bank account information), medical information and other personal information (e.g., social security numbers). Test results were not included. Neither Optum360’s nor the Company’s systems or databases were involved in the incident. AMCA also informed the Company that information pertaining to other laboratories’ customers was also affected. Following announcement of the AMCA Data Security Incident, AMCA sought protection under the U.S. bankruptcy laws. The bankruptcy proceeding has been dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident. The U.S. Judicial Panel on Multidistrict Litigation transferred the cases that were then still pending to, and consolidated them for pre-trial proceedings in, the U.S. District Court for New Jersey. In November 2019, the plaintiffs in the multidistrict proceeding filed a consolidated putative class action complaint against the Company and Optum360 that named additional individuals as plaintiffs and that asserted a variety of common law and statutory claims in connection with the AMCA Data Security Incident. In January 2020, the Company moved to dismiss the consolidated complaint; the motion to dismiss was granted in part and denied in part. Plaintiffs filed an amended complaint, which the Company also moved to dismiss. The motion was granted in part and denied in part. Discovery is proceeding.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In addition, a group of state attorney general offices are investigating the Company in connection with the AMCA Data Security Incident. The Company is cooperating with the investigation. </span></div><div style="text-indent:72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    ReproSource Fertility Diagnostics, Inc. (“ReproSource”), a subsidiary of the Company, is subject to two putative class action lawsuits related to a data security incident that occurred in August 2021 in which plaintiffs allege that an unauthorized party accessed or acquired protected health information and personally identifiable information of ReproSource patients. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bickham v. ReproSource Fertility Diagnostics, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is pending in the U.S. District Court for the District of Massachusetts (the "Massachusetts District Court"), and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trouville v. ReproSource Fertility Diagnostics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was originally filed in the U.S. District Court for the Eastern District of California, has now been transferred to the Massachusetts District Court. A third case filed in the Massachusetts District Court, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gordon v. ReproSource Fertility Diagnostics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was consolidated into the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bickham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bickham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trouville </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complaints seek to represent a class of all individuals potentially impacted by the August 2021 data security incident, and generally allege that ReproSource, among other claims, failed to adequately safeguard patients’ private information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">    On January 10, 2024, ReproSource agreed to settle the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Bickham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">case on a class-wide basis. The settlement is pending approval by the District Court. If approved, ReproSource will receive a full release for all claims that the settlement class might possess arising out of the August 2021 data security incident. The Company’s motion to stay the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Trouville</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case was granted. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company is subject to a putative class action entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cole, et al. v Quest Diagnostics Incorporated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in the U. S. District Court for the Eastern District of California, for allegedly conspiring with Facebook to track customers’ internet communications on Company web platforms without authorization, in violation of the California Invasion of Privacy Act and the California Confidentiality of Medical Information Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The complaint alleged that the Company’s actions were an invasion of privacy and contributed to a loss of value in plaintiffs’ personally identifiable information. The Company moved to dismiss the case or, in the alternative, transfer venue to the U.S. District Court for New Jersey. Subsequently, plaintiffs filed an amended complaint, which the Company also moved to dismiss. The Company's motion to transfer the case was granted. The Company has refiled its motion to dismiss with the New Jersey District Court.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As previously disclosed, in August 2011, the Company had received a subpoena from the U.S. Attorney for the Northern District of Georgia seeking various business records, including records related to the Company's compliance program, certain marketing materials, certain product offerings, and certain test ordering and other policies. The Company cooperated with the request. In 2021, a third amended complaint in a qui tam action filed in the U.S. District Court for the Northern District of Georgia was unsealed, which is related to the matter underlying the August 2011 subpoena. Both the U.S. Department of Justice and the State of Georgia declined to intervene in the action. The Company moved to dismiss the complaint and the complaint was dismissed without prejudice in August 2022. The relator subsequently filed a fourth amended complaint. The Company has moved to dismiss the fourth amended complaint. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company also received subpoenas from the U.S. Attorney for the District of New Jersey. The subpoenas seek various records relating to the Company’s relationship with the New York Giants and adherence to certain company policies and federal laws. The Company is cooperating with the investigation. </span></div><div style="text-indent:72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Legal Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In the normal course of business, the Company has been named, from time to time, as a defendant in various legal actions, including arbitrations, class actions and other litigation, arising in connection with the Company's activities as a provider of diagnostic testing, information and services. These actions could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on the Company's client base and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company is also involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The federal or state governments may bring claims based on the Company's current practices, which it believes are lawful. In addition, certain federal and state statutes, including the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of government or private payers. The Company is aware of lawsuits, and from time to time has received subpoenas, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws. The Company understands that there may be other pending qui tam claims brought by former employees or other "whistleblowers" as to which the Company cannot determine the extent of any potential liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the Company's consolidated results of operations or cash flows in the period in which the impact of such matters is determined or paid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    These matters are in different stages. Some of these matters are in their early stages. Matters may involve responding to and cooperating with various government investigations and related subpoenas. As of March 31, 2024, the Company does not believe that material losses related to legal matters are probable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Reserves for legal matters totaled $1 million and $6 million as of March 31, 2024 and December 31, 2023, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for General and Professional Liability Claims</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims. These suits could involve claims for substantial damages. Any professional liability litigation could also have an adverse impact on the Company's client base and reputation. The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures. The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company is subject to a series of individual claims brought by persons in Ireland related to allegations stemming from pap smear screening services performed by the Company. In general, claimants have alleged that the results of certain pap smear screening tests performed by the Company and other providers, pursuant to a program coordinated by the Irish government, were incorrect for individuals who were later diagnosed with cervical cancer. The Irish government and an independent scoping inquiry commissioned by the Irish government found that the Company’s performance of its screening services for the Irish cervical cancer screening program were in accordance with both Ireland’s requirements and international standards. The Company has settled claims made by certain individuals, is a party in multiple lawsuits and may be served as a party in additional lawsuits. The Company does not believe that the resolution of existing or future claims will have a material adverse effect on its financial position or liquidity, but the ultimate outcomes of these claims are unpredictable and subject to significant uncertainties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Reserves for general and professional liability claims matters, including those associated with both asserted and incurred but not reported claims, are established on an undiscounted basis by considering actuarially determined losses based upon the Company's historical and projected loss experience. Such reserves totaled $166 million and $173 million as of March 31, 2024 and December 31, 2023, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    While the basis for claims reserves is actuarially determined losses based upon the Company's historical and projected loss experience, the process of analyzing, assessing and establishing reserve estimates relative to these types of claims involves a high degree of judgment. Although the Company believes that its present reserves and insurance coverage are sufficient to cover currently estimated exposures, it is possible that the Company may incur liabilities in excess of its recorded reserves or insurance coverage. Changes in the facts and circumstances associated with claims could have a material impact on the Company’s results of operations (principally costs of services), cash flows and financial condition in the period that reserve estimates are adjusted or paid.</span></div> 525000000 750000000 73000000 525000000 2 2 1000000 6000000 166000000 173000000 BUSINESS SEGMENT INFORMATION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's CODM, assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers within its primary customer channels - physicians, hospitals, and patients and consumers. The DIS business accounted for greater than 95% of net revenues in 2024 and 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses offer solutions for insurers and offer solutions for healthcare providers and payers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of March 31, 2024, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table is a summary of segment information for the three months ended March 31, 2024 and 2023. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2023 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.011%"><tr><td style="width:1.0%"></td><td style="width:75.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.197%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,298 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues </span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating earnings (loss):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-operating expense, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes and equity in earnings of equity method investees</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of equity method investees, net of taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.95 0.95 The following table is a summary of segment information for the three months ended March 31, 2024 and 2023. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2023 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.011%"><tr><td style="width:1.0%"></td><td style="width:75.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.197%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,298 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues </span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating earnings (loss):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-operating expense, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes and equity in earnings of equity method investees</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of equity method investees, net of taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2298000000 2259000000 68000000 72000000 2366000000 2331000000 373000000 374000000 9000000 8000000 -82000000 -77000000 300000000 305000000 -34000000 -28000000 266000000 277000000 66000000 65000000 8000000 5000000 208000000 217000000 14000000 15000000 194000000 202000000 REVENUE RECOGNITION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DIS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Net revenues in the Company’s DIS business accounted for over 95% of the Company’s total net revenues for the three months ended March 31, 2024 and 2023 and are primarily comprised of a high volume of relatively low-dollar transactions. The DIS business, which provides clinical testing services and other services, satisfies its performance obligations and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered. The Company estimates the amount of consideration it expects to be entitled to receive from payer customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials), and patient price concessions. The portfolios determined using the portfolio approach consist of the following groups of payer customers: healthcare insurers, government payers (Medicare and Medicaid programs), client payers and patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For further details regarding revenue recognition in the Company's DIS business, see Note 3 to the audited consolidated financial statements in the Company's 2023 Annual Report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s DS businesses primarily satisfy their performance obligations and recognize revenues when delivery has occurred or services have been rendered. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Revenue and Net Accounts Receivable by Payer Customer Type</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The approximate percentage of net revenue by type of payer customer was as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitated</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total healthcare insurers</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The approximate percentage of net accounts receivable by type of payer customer was as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Insurers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client Payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net accounts receivable</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.95 0.95 The approximate percentage of net revenue by type of payer customer was as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitated</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total healthcare insurers</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.37 0.37 0.03 0.03 0.40 0.40 0.12 0.12 0.33 0.33 0.12 0.12 0.97 0.97 0.03 0.03 1 1 The approximate percentage of net accounts receivable by type of payer customer was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Insurers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client Payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net accounts receivable</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.28 0.24 0.07 0.07 0.40 0.45 0.21 0.20 0.96 0.96 0.04 0.04 1 1 SUBSEQUENT EVENTS    During April 2024, the Company repaid in full the outstanding indebtedness under the Company's $300 million of 4.25% senior notes which matured on April 1, 2024. 300000000 300000000 0.0425 false false false false

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�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